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ABSTRACT OF DISSERTATION

LYMPHOCYTE-MEDIATED INFLAMM-AGING IN THE HORSE
Senior horses (≥20 years) exhibit inflamm-aging, or chronic, low-grade
inflammation that occurs systemically with aging, similarly to humans. Inflamm-aging has
previously been characterized in the horse in circulation as well as specifically being
mediated by lymphocytes and monocytes. In humans, inflamm-aging has been associated
with increased morbidity and mortality. However, in the horse, relatively little about
inflamm-aging is known regarding clinical effects or factors influencing severity. The
contribution of lymphocytes to inflamm-aging of senior horses was examined, specifically
through determining the relationships of inflamm-aging with various other health
parameters, effects of seasonality, and the extent to which inflamm-aging can be modulated
by anti-inflammatory phytonutrient curcumin. The overall hypothesis of this research is
that lymphocyte-mediated inflamm-aging of the senior horse is associated with various
factors including season, endocrine function, body composition, and nutritional status, and
may be modulated by polyphenol curcumin. The effect of season on lymphocyte-mediated
inflamm-aging was examined, and senior horses exhibited elevated inflammation
compared to adult horse as expected, while also exhibiting changes in inflammatory
cytokine production and gene expression throughout the year. In addition to season,
pituitary pars intermedia dysfunction (PPID), a common endocrinopathy in senior horses
that is associated with immunosuppression, was examined in a group of senior horses to
determine any effects on degree of inflamm-aging. Results indicated no significant
differences between age-matched PPID and non-PPID horses for lymphocyte-mediated
inflammatory cytokine production or gene expression. The immunosuppressive aspect of
PPID does not appear to be associated with the degree of lymphocyte-mediated
inflammation of the aged horse. Additionally, an expansive correlative study was
undertaken to determine relationships between inflamm-aging and basal nutritional status,
body composition, age, and PPID within a similarly-managed senior horse population.
Results showed various relationships between inflammatory markers and nutritional status,
particularly yielding positive associations with serum folate and with serum fatty acids
C22:2n6c and C22:5n3c. Inflammation was also associated with age itself but was not
associated with body composition parameters and showed mild association with PPID (and
serum inflammatory C-reactive protein). As a whole, this study demonstrates that
nutritional status can be associated with inflammatory markers. Similarly, many
phytonutrients have exhibited anti-inflammatory properties, which may be beneficial to the
senior horse exhibiting inflamm-aging. Specifically, the effects of polyphenols including
curcuminoids, resveratrol, quercetin, pterostilbene, and hydroxypterostilbene on
lymphocyte production of inflammatory cytokines by senior horses were examined in vitro
and found to significantly reduce inflammation similarly to common non-steroidal antiinflammatory drugs. This study led to the in vivo investigation of the effectiveness of
curcumin in modulating chronic inflammation of the senior horse. No significant
differences were seen between groups receiving curcumin and placebo for the various

inflammatory parameters, which may be due to the dose or low bioavailability of curcumin.
As a whole, this research provides further understanding of factors associated with
inflamm-aging of the senior horse.
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CHAPTER 1
LITERATURE REVIEW
Senior horses generally refer to those ≥ 20 years old, which similar to the senior
human population, is a demographic of increasing importance as numbers continue to rise.
Senior horses (≥20 years) comprise approximately 11.4% of the equine population in the
United States (USDA, 2016), while those ≥15 years compose approximately 29% of the
horses in the United Kingdom (≥15 years) (Ireland et al., 2011a). This USDA estimate of
senior horses (≥20 years) comprising 11.4% of the US equine population (USDA, 2016) is
increased from the 7.6% estimated only ten years prior (USDA, 2006), indicating the
growth of the senior demographic among equids. Furthermore, among equine facilities in
the United States, 44.6% possessed one or more senior horse (≥20 years) (USDA, 2016).
These senior horses are frequently ridden for pleasure or kept as companion animals, while
some continue engaging in athletic competitions and breeding into their late teens and
twenties (Ireland et al., 2011a). Causes of mortality among horses aged 20 or older in the
United States include: other (26.6%, with old age as the most common specified cause),
colic (13.4%), cancer (13.2%), neurologic problems (12.1%), and chronic weight loss
(11.7%) (USDA, 2016).
An Overview of Inflamm-aging
The onset of old age is associated with multiple physiological changes, particularly
those associated with the immune system. Horses, like humans, exhibit the phenomenon
of inflamm-aging (chronic, systemic, low-grade inflammation that is associated with
advanced age), in addition to exhibiting immunosenescence (decreased immune response
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associated with old age). Initially the occurrence of inflamm-aging appears somewhat
paradoxical in the face of the existence of immunosenescence; however, this phenomenon
of inflamm-aging has traditionally been thought to occur as an overload response of the
immune system being subjected to countless mitogens over the course of a lifetime.
(Adams et al., 2008; Franceschi et al., 2000; Vasto et al., 2007). More recently, inflammaging has specifically been thought to derive from at least some of the following factors:
1) increased cell debris due to potential accumulation time and/or deficient elimination, 2)
senescent cells and their secretory pro-inflammatory cytokines, 3) immunosenescence,
which is likely exacerbated by persistent infections, 4) endogenous microbiota of the
digestive tract potentially leaking into the surrounding tissues with age, causing chronic
inflammation, or a shift toward more pro-inflammatory types of microbiota with age, and
5) increased coagulation with aging (Franceschi and Campisi, 2014).
Given the variety of stimuli thought to trigger inflamm-aging, it is not surprising
that quite a few mechanisms may be involved in this phenomenon. The classic
inflammatory cascade is regulated by nuclear factor(NF)-κβ and is thought to be the
primary pathway by which inflamm-aging is mediated (Salminen et al., 2008; Xia et al.,
2016). However, the target of rapamycin (TOR) pathway has also been researched in
regards to inflamm-aging, as it regulates longevity through a variety of means (Stanfel et
al., 2009) and also is associated with NF-κB activation, suggesting a regulatory role in
inflamm-aging (Temiz-Resitoglu et al., 2017; Xia et al., 2016). Other pathways that may
be involved in inflamm-aging either due to their effects on aging as a whole or due to their
effects specifically on inflammation (whether pro- or anti-inflammatory) include: Retinoic-
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acid-inducible gene-I (RIG-I), Notch, Sirtuin, Transforming growth factor(TGF)-β, and
Ras pathways (Xia et al., 2016).
Inflamm-aging manifests itself by increased gene expression and protein
production of various inflammatory cytokines, both systemically and specifically mediated
by peripheral blood mononuclear cells (PBMC) (Adams et al., 2008; Adams et al., 2009;
Fagiolo et al., 1993). In humans, old age has been linked to increases in pro-inflammatory
interleukin(IL)-1, IL-6, tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP),
and serum amyloid A (SAA) (Franceschi et al., 2000; Ostan et al., 2015). Similarly, in the
horse, inflamm-aging has been characterized by increased production of IFN-γ and TNFα mediated by lymphocytes and monocytes as well as increased serum TNF-α protein
levels and increased whole blood gene expression of IL-1β, IL-15, IL-18, and TNF-α
(Adams et al., 2008; Adams et al., 2009). More recently, inflamm-aging in the horse has
also been characterized by increased PBMC-mediated IFN-γ gene expression (Adams et
al., 2015).
In humans, inflamm-aging is associated with morbidity and mortality (Franceschi
and Campisi, 2014). Furthermore, inflamm-aging underlies various maladies including
Alzheimer’s

disease,

Parkinson’s

disease,

macular

degeneration,

osteoporosis,

cardiovascular diseases such as atherosclerosis, and various others (Xia et al., 2016).
Chronic inflammation even appears to be associated with cancer and diabetes (Freund et
al., 2010; Vasto et al., 2009; Xia et al., 2016), two maladies particularly rampant in the
United States currently. Given the association of inflamm-aging with numerous diseases
in aged humans, it is anticipated that inflamm-aging has negative implications on equine
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health; however, specific clinical conditions associated with inflamm-aging in the horse
have not yet been identified.
Inflamm-aging and Season
It is unknown whether external conditions, such as season, exacerbate inflammaging. Seasonal immune changes in other species have been demonstrated (Bilbo et al.,
2002; Bowden et al., 2007; McFarlane et al., 2012). Seasonality in cytokine levels both
circulating in serum and mediated by PBMC have been demonstrated in baboons
(McFarlane et al., 2012). Particularly, pro-inflammatory serum C-reactive protein and
mitogen-stimulated PBMC production of TNF-α and IL-6 have exhibited lowest levels in
December, while serum IL-6 levels for baboons housed outdoors were actually highest in
December, indicating that different types of cells may be producing cytokines quite
differentially at a given time of year (McFarlane et al., 2012). Siberian hamsters subjected
to lipopolysaccharide injection also exhibited decreased inflammatory response (IL-6 and
IL-1β) in addition to decreased fever and anorexia duration, when exposed to photoperiods
reflecting winter in comparison to summer (Bilbo et al., 2002).
In the horse specifically, a few studies have been performed regarding seasonal
changes in immune parameters; however, several of these studies primarily examined
horses in diseased states known to have seasonal elements. For example, in a study
examining summer pasture-associated obstructive pulmonary disease (SPAOPD), PBMCmediated gene expression of IFN-γ was higher in summer compared to winter in both
diseased (p<0.05) and control (p<0.10) horses (Beadle et al., 2002). In a large-scale
retrospective study examining lower airway inflammation of racehorses, bronchoalveolar
lavage (BAL) revealed influences of season on cell profiles; specifically, lower airway
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inflammation was associated with an increase in mast cell percentage, which occurred most
commonly in spring (Secombe et al., 2015). Another study examining stable air quality
seasonally found that BAL samples from trotting horses in training had elevated levels of
IL-6 expression in winter compared to summer, however the horses were stabled all but 47 hours of the day during winter, while only around 12 hours during summer which may
have also affected the immune system aside from season alone (Riihimaki et al., 2008).
Additionally, serum IL-4 has been shown to be elevated in winter compared to late spring
in ponies (Wray et al., 2013). Thus, the horse has demonstrated some seasonal variations
in immune parameters, but specifically examining inflamm-aging seasonally has not yet
been investigated.
Several inflammatory diseases in humans have demonstrated seasonal fluctuations
(Araki et al., 2017; Feldthusen et al., 2016; Vinnik et al., 2016). Inflamm-aging itself has
not been examined seasonally to determine whether it appears exacerbated at certain times
of year. However, given the prevalence of seasonality in inflammatory human diseases,
seasonal fluctuations associated with inflamm-aging are likely.
Additionally, although little is known regarding seasonal changes in inflammation
in the horse, seasonal rhythms in various hormones are known to occur in horses. In healthy
horses, α-melanocyte stimulating hormone (α-MSH) and adrenocorticotropin hormone
(ACTH) both display rather marked seasonal patterns, with levels of both these hormones
peaking in fall as horses prepare for winter (McFarlane et al., 2011). These seasonal
hormonal patterns appear to derive from both the hypothalamus and the pituitary, as
demonstrated by a sheep model in which the neural tissue connecting the two organs was
surgically removed (Lincoln and Richardson, 1998). Although ACTH does not have a
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clearly defined relationship with either pro- or anti-inflammatory cytokines, α-MSH has
demonstrated numerous anti-inflammatory, antioxidant effects (Bhardwaj et al., 1996;
Catania et al., 1999; Luger and Brzoska, 2007; Oktar et al., 2004). Specifically, α-MSH
increases anti-inflammatory IL-10 production by monocytes (Bhardwaj et al., 1996) and
also downregulates LPS-activated NF-κB (Luger et al., 2000). Thus, the seasonal rhythm
of anti-inflammatory α-MSH in the horse may influence inflammatory cytokine production
over the course of the year.
Inflamm-aging and Pituitary Pars Intermedia Dysfunction (PPID)
ACTH and α-MSH hormones are elevated in horses with the endocrinopathy
known as pituitary pars intermedia dysfunction (PPID) or equine Cushing’s disease
(McFarlane et al., 2011). PPID is prevalent among aged horses, affecting 15-30% of this
demographic, and is characterized by the presence of hypertrichosis (McFarlane et al.,
2011). Other clinical signs of PPID include polydipsia, polyuria, hyperhidrosis, muscle
atrophy, laminitis, regionalized adiposity, immunosuppression and increased susceptibility
to disease, behavioral abnormalities (such as lethargy), reproductive infertility, and
neurologic impairment (McFarlane, 2011). PPID is thought to be caused by dopaminergic
neurodegeneration of the pituitary pars intermedia, compromising the natural negative
feedback loop such that the PPID horse produces elevated levels of pro-opiomelanocortin
(POMC)-derived hormones ACTH and α-MSH (McFarlane, 2011). These elevated levels
of ACTH and/or α-MSH are likely the mediators of the clinical signs that characterize
PPID. Although exact mechanisms are not clear (Hart et al., 2016), these POMC-derived
hormones have demonstrated preliminary effects on hair pigmentation in humans (Bohm
et al., 2006; Tobin, 2008), and may affect hair growth in the horse, leading to the
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characteristic hypertrichosis. As previously discussed, α-MSH also has many antiinflammatory properties (Bhardwaj et al., 1996; Catania et al., 1999; Luger and Brzoska,
2007; Oktar et al., 2004), which when produced at the elevated levels seen in PPID, may
lead to the clinical symptoms of immunosuppression and increased susceptibility to disease
characterizing PPID. Specifically, PPID horses have been reported to exhibit increased
bacterial infections causing dermatophilosis, pneumonia, and abscesses (McFarlane,
2011). This decreased ability of the PPID horse to respond to pathogens may be
exacerbated by the fact that the senior horse is already immune-compromised, exhibiting
the age-related phenomena of inflamm-aging and immunosenescence.
A few studies have been performed to determine immune changes associated with
PPID. PPID horses have demonstrated decreased neutrophil function, evidence by
decreased oxidative burst activity as well as decreased adhesion (McFarlane et al., 2015).
In examining oxidative burst activity, a positive association was shown for the ratio of
insulin:α-MSH, indicating a potential role for hormones in immune function of the PPID
horse (McFarlane et al., 2015). Another study reported that PPID horses exhibit total
leukocyte cytokine dysregulation, in which cytokines varied as to whether they reflected
age-matched non-PPID (IL-8) or adult non-PPID horses (IFN-γ, IL-6) depending on the
cytokine, although the spread of much of the data for each cytokine was quite large
(McFarlane and Holbrook, 2008). Still, this differential expression of cytokines in the PPID
horse suggests that the aged, PPID horse may exhibit inflamm-aging differently from the
non-PPID, aged horse.
Although some research regarding PPID has been performed, studies to better
understand the pathogenesis of this endocrine disease, particularly as it relates to
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immunosuppression and susceptibility to opportunistic infections, need to be undertaken.
Furthermore, inflamm-aging of the senior horse has been established both in whole blood
as well as being mediated by PBMC. Thus, it would be of interest to determine if PPID
specifically affects PBMC function of the senior horse exhibiting inflamm-aging.
Inflamm-aging and General Health
In addition to the effects of PPID on the immune system of the senior horse, little
is known regarding the implications of inflamm-aging of the horse in relation to overall
health, specifically regarding nutritional status and muscle composition. Given the
prevalence of senior horses, with nearly half of the equine operations in the US having a
least one senior horse (USDA, 2016), promoting healthspan in addition to lifespan is key.
And, given that inflamm-aging appears to underlie most age-associated diseases in humans
(Freund et al., 2010; Vasto et al., 2009; Xia et al., 2016), understanding physiological
relationships of other health parameters with inflamm-aging will likely help promote better
quality of life through improved management of the senior horse.
Loss of muscle mass is associated not only with the occurrence of PPID, as
previously mentioned, but is also associated with advanced aging. This old age-associated
loss of muscle mass is termed sarcopenia. In humans, sarcopenia occurs at a rate of
approximately 6% per decade starting mid-life (Janssen, 2010; Janssen and Ross, 2005).
Although longitudinal studies examining rates of sarcopenia have not been performed in
the horse, the occurrence of sarcopenia in the horse is a known phenomenon (Lehnhard et
al., 2004; Reed et al., 2015). In fact, an owner-reported survey of over 900 horses in the
United Kingdom found that 23.9% of horses aged 15 years or older have exhibited loss of
muscle tone (Ireland et al., 2011b).
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Some studies have found an inverse relationship between inflammation and mass
and strength of skeletal muscle. Various human studies have found increased proinflammatory cytokines (TNF-α, IL-6, and CRP) associated with decreased muscle mass
and strength, including in the elderly (Schaap et al., 2009; Schaap et al., 2006; Visser et
al., 2002). Additionally, sarcopenia in cattle appears to be associated with lymphocyte
(primarily CD8+) inflammation (Costagliola et al., 2016).
In the horse, specific muscle changes associated with age include: shifts in muscle
fiber types (increased percentage of myosin heavy chain types I and IIA) (Li et al., 2016),
decreased density of mitochondria (Li et al., 2016), and decreased satellite cell activity in
response to exercise (Reed et al., 2015). This decreased satellite cell activity in response to
exercise is thought to be associated with the increased inflammatory state of the senior
horse experiencing inflamm-aging. It is thought that inflamm-aging may diminish the
ability of the senior horse to experience hypertrophy and acute exercise-associated
inflammation similarly to their younger counterparts during strenuous exercise (Reed et
al., 2015), making the maintenance of physical fitness more difficult in the senior horse.
As exercise is key for prevention and treatment of sarcopenia and considering regular
exercise in humans and mice tends to be anti-inflammatory, including in regards to
inflamm-aging (Lesniewski et al., 2011; Montero-Fernandez and Serra-Rexach, 2013;
Sallam and Laher, 2016; Woods et al., 2012), further research should be performed to better
understand any connections between sarcopenia and inflamm-aging in the horse in order
to better manage the senior horse.
In relation to nutritional status of the senior horse and potential relationships with
inflamm-aging, various vitamins, minerals, and fatty acids have demonstrated biological
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effects on immunity and specifically inflammation. Vitamin D has well-established antiinflammatory properties (Abbas, 2016; Capri et al., 2006; Moore et al., 2005). Vitamin C
has been shown to downregulate IL-6 in bone marrow mononuclear cells of adults aged 67
± 6.8 years, another population of cells where inflamm-aging has been demonstrated
(Pangrazzi et al., 2017). Vitamin E has also been shown to mitigate inflamm-aging,
downregulating the elevated levels of pro-inflammatory prostaglandin E2 (PGE2) in aged
mice (Wu et al., 2001). In the aged horse, supplementation with Vitamin E has improved
bacterial killing capacity of monocytes and neutrophils (Petersson et al., 2010). The
immunity of the horse also appears to be affected by some minerals, such as deficiencies
in selenium (Brummer et al., 2013).
Poly-unsaturated fatty acids (PUFA) have been associated with anti-inflammatory
activity as well. Independent of age, PUFA, especially n-3 fatty acids, exhibited positive
correlations with anti-inflammatory cytokines (IL-10, transforming growth factor[TGF]-β)
and negative correlations with pro-inflammatory cytokines (IL-6, TNF-α) in a large-scale
human population study primarily focused on the aged population (78.9% ≥65 yrs; age
range = 20-98 yrs) (Ferrucci et al., 2006). This suggests that increased levels of dietary
PUFA may decrease the degree of inflamm-aging (Ferrucci et al., 2006). Another shortterm study found that an infusion of fish oil-based n-3 fatty acids decreased endotoxinstimulated production of TNF-α, IL-1, IL-6, and IL-8 by monocytes, again indicating an
anti-inflammatory capacity of n-3 fatty acids (Mayer et al., 2003). Furthermore, in horses
with chronic lower airway inflammatory disease, supplementation with n-3 fatty acids has
also demonstrated clinical benefits (Nogradi et al., 2015). Clearly nutrition has
demonstrated clinical effects on inflammation and specifically inflamm-aging (Dasilva et
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al., 2016; Dato et al., 2016) and should therefore be explored specifically in the senior
horse experiencing inflamm-aging.
Inflamm-aging and Mitigation by Polyphenols, Particularly Curcumin
In addition to vitamins, minerals, and fatty acids, various plant-derived bioactive
polyphenols have anti-inflammatory, antioxidant effects that may benefit the senior horse
exhibiting inflamm-aging. Some polyphenols of interest include resveratrol, quercetin,
pterostilbene, hydroxypterostilbene, and curcumin.
Resveratrol, a phytoalexin and sirtuin-1 activator found in red wine, has
demonstrated anti-inflammatory effects both in vitro and in vivo (Kelly, 2010; Knutson and
Leeuwenburgh, 2008). Resveratrol mediates anti-inflammatory effects through both the
NF-κB and MAPK pathways, decreasing expression of TNF-α and IL-1β while also
decreasing activity of myeloperoxidase, a marker of oxidative stress (Zhang et al., 2017).
Furthermore, resveratrol has exhibited various anti-inflammatory and anti-oxidant effects
in an aged mouse model, including decreasing age-related inflammatory profiles (Gines et
al., 2017; Wong et al., 2011), indicating that resveratrol is able to modulate the degree of
inflamm-aging. In the horse, in vitro work has demonstrated the ability of resveratrol to
decrease neutrophil-mediated oxidative stress (Kohnen et al., 2007). Additionally, oral
supplementation of horses with resveratrol has reportedly decreased some measures of
lameness (Watts et al., 2016) and also increased antioxidant capacity of older horses
(Ememe et al., 2015), indicating that resveratrol is biologically active in the horse and may
be able to decrease inflamm-aging.
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Quercetin, a flavonoid commonly found in various fruits, vegetables and tea, has
exhibited anti-inflammatory and antioxidant effects both in vitro and in vivo, as well.
Quercetin has particularly been successful in mitigating inflammation induced by high-fat
and high-fructose diets in rodents (Das et al., 2013; Vazquez Prieto et al., 2015). Quercetin
has been shown to exert anti-inflammatory effects by downregulating the NF- κβ and p38
MAPK signaling pathways (Wang et al., 2017). In a model of age-associated macular
degeneration, which has an underlying inflammatory component, quercetin was shown to
decrease inflammation (IL-6, IL-8) (Hytti et al., 2015), showing potential for the capability
of quercetin to decrease age-associated inflammation.
Pterostilbene,

an

analog

of

resveratrol

found

in

blueberries,

and

hydroxypterostilbene, an analog of pterostilbene found in the plant Sphaerophysa salsula,
have likewise demonstrated anti-inflammatory and antioxidant effects. Pterostilbene acts
as a nuclear factor erythroid 2-related factor-2 (Nrf2) activator, decreasing inflammatory
cytokines in a mouse model of diabetes (Sireesh et al., 2017). Pterostilbene as well as
resveratrol and quercetin have been shown to decrease pro-inflammatory expression of
TNF-α, IL-1β, IL-6, and iNOS, while also decreasing NF-κB activation in macrophage
and kidney cell lines, respectively. Hydroxypterostilbene has demonstrated antiinflammatory activity as well by decreasing pro-inflammatory COX-2 protein levels
(Cheng et al., 2014; Takemoto et al., 2015). Hydroxypterostilbene mediated these effects
through the PI3K/Akt, MAPK, and mTOR signaling pathways (Cheng et al., 2014).
Curcumin, the primary anti-inflammatory component of the turmeric spice derived
from the rhizomes of Curcuma longa (Kumar et al., 2010), is of particular interest
regarding anti-inflammatory capacity. In addition to the extensive evidence of its various
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anti-inflammatory, anti-oxidant, anti-tumor, and various other health-promoting effects
(Franck et al., 2008; Schaaf et al., 2009; Venkatesan and Chandrakasan, 1995), curcumin
has specifically demonstrated effects in the horse. Several equine studies in vivo and ex
vivo have shown the potential of curcumin as an anti-inflammatory, antioxidant agent
(Clutterbuck et al., 2009; Derochette et al., 2013; Franck et al., 2006; Franck et al., 2008;
Siard et al., 2016). In a preliminary study, horses supplemented orally with curcumin
demonstrated anti-inflammatory effects, showing decreased levels of whole blood IL-1β
and IL-1RN expression (Farinacci et al., 2009b). Taken together, curcumin in particular
appears a prime candidate to mitigate inflamm-aging of the senior horse.
Curcumin is a pleiotropic agent, exerting various biological effects by a vast
number of mechanisms, with even anti-inflammatory effects being mediated through quite
a variety of different ways (Di Pierro et al., 2013). Primary signaling pathways through
which curcumin suppresses inflammation include NF-κB and COX. Specifically, curcumin
inhibits IκB kinase (IKK) activity, decreasing phosphorylation of IκBα, thereby
sequestering more NF-κB outside of the nucleus and keeping NF-κB from acting as a
transcription factor, leading to decreased production of inflammatory cytokines, such as
IL-6, IL-12, and TNF-α (Bharti et al., 2003; Nanji et al., 2003). Curcumin modulates the
COX pathway, which may actually be a caveat of the NF-κB pathway (Kim et al., 2006),
by selectively inhibiting COX-2 activity (Goel et al., 2001), such that it cannot convert
arachidonic acid into pro-inflammatory PGE2 (Chizzolini and Brembilla, 2009; Park and
Conteas, 2010), thereby suppressing inflammation.
Curcumin has mediated these anti-inflammatory effects extensively in vitro
(Derochette et al., 2013; Lin et al., 2014) while also having numerous biological effects in
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vivo, including decreased inflammation (Venkatesan and Chandrakasan, 1995). In addition
to the previously mentioned small-scale study in horses examining curcumin
supplementation on inflammation (Farinacci et al., 2009b), several other studies in vivo
and ex vivo have demonstrated the potential of curcumin as an anti-inflammatory,
antioxidant agent in the horse (Clutterbuck et al., 2009; Derochette et al., 2013; Franck et
al., 2006; Franck et al., 2008; Siard et al., 2016).
Although free curcumin is readily metabolized following oral administration
(Kumar et al., 2010) and therefore not biologically active, many formulations have been
engineered to enable curcumin to remain bioavailable and bioactive. Some of the most
researched formulations that have been shown to increase bioavailability include solid lipid
curcumin particle™ technology (Longvida®) (Gota et al., 2010) and phosphatidylcholine
curcumin phytosomes (Meriva®) (Cuomo et al., 2011). In older humans, Longvida®
administered orally has demonstrated biological effects by improving mood and working
memory (Cox et al., 2015) as well as improving vascular endothelial function (SantosParker et al., 2017). Additionally, Longivda® has decreased pathology associated with
Alzheimer’s disease in an aged mouse model (Ma et al., 2013). Furthermore, Longvida has
recently demonstrated anti-inflammatory effects, reducing serum TNF-α and IL-8, as well
as decreasing circulating marker of muscle damage creatine kinase following exercise
(McFarlin et al., 2016). Oral administration of Meriva® has also resulted in various antiinflammatory effects, ranging from improvements in inflammatory ocular conditions
(Mazzolani and Togni, 2013) to decreased levels of pain, similarly to acetaminophen (Di
Pierro et al., 2013). In a study of osteoarthritic patients, all markers of inflammation
[interleukin(IL)-1β, IL-6, soluble CD40 ligand, soluble vascular adhesion molecule-1
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(sVCAM-1), and erythrocyte sedimentation rate (ESR)] were significantly reduced in the
treatment group (n=50) but not the control group (n=50) over the course of the 8 month
study (Belcaro et al., 2010a). A previous study from the same group had also shown a
decrease in elevated levels of CRP when treated with curcumin phytosomes over the course
of 3 months (Belcaro et al., 2010b). Thus, these studies show that curcumin can certainly
mediate biological effects, including decreasing inflammation, when administered orally
using an enhanced bioavailability formulation.
Given the bioavailability and bioactivity of various curcumin formulations and the
fact that polyphenols including curcumin have been shown to decrease PBMC- and
specifically lymphocyte-mediated inflammation (Afman et al., 2014; Ford et al., 2016;
Literat et al., 2001; Siard et al., 2016), it is therefore likely that curcumin may be able to
modulate lymphocyte-mediated inflamm-aging of the senior horse.
Furthermore, inflamm-aging of the senior horse would provide a good model in
which to test the anti-inflammatory nature of these phytonutrients, like curcumin, not only
for potential benefits to the senior horse experiencing inflamm-aging but also for the many
chronic inflammatory conditions common in the horse. Chronic inflammation is frequently
treated with nonsteroidal anti-inflammatory drugs (NSAIDs), despite the fact that many
NSAIDs have adverse side effects and/or are not indicated for chronic treatment of
inflammation (Bessone, 2010; Ingrasciotta et al., 2015; Martinez Aranzales et al., 2015;
McConnico et al., 2008; Monreal et al., 2004; Reed et al., 2006). Thus, the potential of
polyphenols, such as curcumin, to attenuate inflammation in the senior horse may provide
an alternative to the use of NSAIDs in treating chronic inflammation, while also benefiting
the health of the senior horse as a whole by decreasing the degree of inflamm-aging.
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Hypothesis and Specific Aims
The overall hypothesis of this research is that lymphocyte-mediated inflamm-aging
of the senior horse is associated with various factors including season, endocrine function,
body composition, and nutritional status, and may be modulated by curcumin, a plantderived polyphenol.
Specific aims are as follows:
1. To determine the effects of season on lymphocyte-mediated inflamm-aging of
the senior horse.
2. To determine the relationship between lymphocyte-mediated inflamm-aging of
the

senior

horse

and

nutrient

status,

body

composition,

hematology/biochemistry, and pituitary pars intermedia dysfunction (PPID).
3. To determine the relationship between lymphocyte-mediated inflamm-aging
and the age-associated endocrinopathy PPID in the senior horse.
4. To determine effects of polyphenols curcumin, resveratrol, pterostilbene,
hydroxypterostilbene, and quercetin on lymphocyte-mediated inflamm-aging
of the senior horse in vitro.
5. To determine the effectiveness of curcumin as an anti-inflammatory
supplement to modulate inflamm-aging of the senior horse.
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CHAPTER 2
EFFECT OF SEASON ON LYMPHOCYTE-MEDIATED INFLAMM-AGING
AND IMMUNOSENESCENCE IN THE HORSE
Abstract
Senior horses (≥20 years) exhibit changes in the immune system associated with
advanced age, similarly to those evidenced in humans. Specifically, senior horses
experience inflamm-aging or systemic,

chronic,

low-grade inflammation

and

immunosenescence or decreased immune response, particularly evidenced by decreased
response to vaccination and decreased lymphocytes proliferation. While age is a factor
known to impact immune responses, season has also been shown to influence immune
responses of many species including fish, rodents, and primates. Although a few studies
examining diseased horses have explored seasonal relationships with immune function,
healthy horses have not yet been examined to determine if they display seasonal variations.
Furthermore, the senior horse is of interest to gain a better understanding of when these
immunosuppressed horses may be more prone to disease.
In this study, peripheral blood mononuclear cells (PBMC) were collected from n=8
senior (mean age = 23.38±1.66 yr) and n=8 adult horses (mean age = 10.75 ± 0.83 yr)
monthly for one year. PBMC to be used for lymphocyte proliferation assay using
carboxyfluorescein succinimidyl ester (CFSE) staining were stimulated with concanavalin
A for 96 hours prior to flow cytometry analysis. PBMC for all other assays were stimulated
with phorbol 12-myristate 13-acetate (PMA) for 4 hours. PBMC were then intracellularly
stained for inflammatory cytokines interferon(IFN)-γ and tumor necrosis factor(TNF)-α
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and analyzed using flow cytometry to determine the percent of lymphocytes producing
each cytokine (%) as well as the mean fluorescence intensity (MFI). PBMC were also
analyzed seasonally (January, April, July, and October) using RNA isolation, reverse
transcription, and real-time polymerase chain reaction (RT-PCR) to determine gene
expression

of

IFN-γ,

TNF-α,

interleukin(IL)-4,

IL-6,

and

IL-10.

Cortisol,

adrenocorticotropin hormone (ACTH), and body weights were analyzed seasonally
(January, April, July, and October) as well. Statistical analyses were performed using SAS
9.4 software mixed procedures with repeated measures, and significance was set at p<0.05.
Results showed significant differences between senior and adult horses for all flow
cytometry measures of inflammation and for lymphocyte proliferation (p<0.05), as
expected. Seasonal differences were identified for IFN-γ MFI, %TNF-α, and TNF-α MFI
(p<0.05). Gene expression of IL-6 varied seasonally, being significantly decreased in July
(p<0.05), while TNF-α gene expression was highest in July compared to January and April
(p<0.05). Gene expression of IFN-γ and TNF-α was also significantly greater for senior
horses than adult horses (p<0.05). Body weight appeared to have some effects on immune
parameters, but these seasonal changes are likely due to a wide and complex variety of
mechanisms. In general, inflammation was decreased during winter and elevated in spring
and summer. Furthermore, senior horses exhibited overall increased inflammation and
decreased lymphocyte proliferation in comparison to adult horses, demonstrating the
immune-compromising effects of aging. Thus, the senior horse exhibiting inflamm-aging
and immunosenescence appears to be affected by seasonal immune changes, which may
have management implications to best promote health.
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Introduction
In multiple species, old age is associated with various alterations in immune
function, which can have negative implications on health. The horse is no exception,
experiencing both inflamm-aging (systemic, chronic low-grade inflammation) and
immunosenescence (decreased immune response) similar to elderly humans (Adams et al.,
2008; Franceschi et al., 2000). Inflamm-aging in the horse has been characterized as
increased circulating pro-inflammatory cytokines, whole blood gene expression of
inflammatory cytokines, and peripheral blood mononuclear cell (PBMC)-mediated
production of inflammatory cytokines (Adams et al., 2008; Adams et al., 2009).
Immunosenescence has also been characterized in the horse, encompassing both decreased
response to vaccination and decreased lymphocyte proliferation of old horses in relation to
young horses (Adams et al., 2008; Goto et al., 1993; Horohov et al., 1999). The occurrence
of these age-associated changes in immune function have been well-established; however,
the potential effect of season on the aged immune system merits investigation in the horse.
Many species are known to exhibit seasonal changes in various parameters
including immune response, body weight, adipose tissue content, voluntary food intake,
metabolic rate, heat production, reproductive activity, length and color of hair coat, and
hormone levels (McFarlane et al., 2012). Some of the species exhibiting seasonal changes,
particularly in immune response, include various types of fish, rodents, and primates (Bilbo
et al., 2002; Bowden et al., 2007; Mann et al., 2000; McFarlane et al., 2012). In a baboon
study specifically examining seasonal changes in inflammation in the northern hemisphere,
serum C-reactive protein (CRP), an acute phase protein, was decreased in December
compared to June (p<0.05), and serum interleukin(IL)-6 also showed an effect of season
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(p<0.001) (McFarlane et al., 2012). In another study, Siberian hamsters injected with
lipopolysaccharide and subjected to short vs. long day length (to mimic winter and summer,
respectively) experienced decreased inflammatory cytokine production (IL-6 and IL-1β)
as well as decreased duration of fever and anorexia during short day length, indicating that
immune response may be diminished during winter (Bilbo et al., 2002).
A few studies have also demonstrated effects of season on immune parameters in
the horse (Riihimaki et al., 2008; Secombe et al., 2015; Wray et al., 2013). Peripheral blood
mononuclear cells have been examined in equids to determine the effects on seasonal
allergy-related changes in cytokine production (Beadle et al., 2002; Hamza et al., 2007).
For example, a study examining equine insect bite hypersensitivity in Icelandic horses
showed increased PBMC-mediated interferon(IFN)-γ and decreased IL-4 production and
mRNA expression in winter compared to summer (Hamza et al., 2007). A study examining
summer pasture-associated obstructive pulmonary disease (SPAOPD), another malady
thought to have an allergic component, showed seasonal changes in PBMC-mediated IFNγ expression as well; however, in this study, IFN-γ expression was lower in the winter
compared to summer, for both control and diseased horses (Beadle et al., 2002).
The present study was performed to determine seasonal changes in lymphocytemediated inflammatory cytokine production of senior horses (which are known to
experience inflamm-aging and immunosenescence) compared to adult horses. We
hypothesized that season will affect immune function in both senior and adult horses, with
senior horses experiencing elevated inflammation and diminished lymphocyte proliferation
relative to adult horses overall. Determining seasonal effects on immunity will provide a
better understanding of when senior horses, which are already immunocompromised, may
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be more prone to disease. Furthermore, determining whether season may be a potential
confounding factor may aid in improving experimental design of future studies.
Methods and Materials
2.1. Animals
Eight senior horses (mean age ± SD = 23.38 ± 1.77 yr) and eight adult horses (mean
age ± SD = 10.75 ± 0.89) were housed at the University of Kentucky, Department of
Veterinary Science Maine Chance Farm. Horses were maintained on pasture throughout
the year, receiving mixed grass hay ad libitum during winter months. The horses also had
access to salt and mineral blocks. All horses were free of clinical signs of infectious disease
and did not exhibit signs of lameness throughout the study, and all sixteen horses enrolled
completed the study. All procedures were in accordance with the University of Kentucky
Institute of Animal Care and Use Committee.
Due to the fact that the study duration was a year (April 2013 – March 2014), the
diets of horses varied, with some horses receiving concentrates during the study.
Specifically, all horses received the same isocaloric diet for the first 2 months of the study
(50% oats, 50% alfalfa pellets). However, since the adult horses were gaining weight, for
management purposes, the adult horses did not receive feed for the following 10 months
of the study. The senior horses continued to receive the 50% oats, 50% alfalfa pellets
mixture through September; however amounts changed in order to maintain body weight.
The senior horses then received a senior feed October through December, then were
returned to the maintenance diet of oats and alfalfa pellets, also receiving an additional
balancer pellet in February and March. Although diet could not be accounted for in the
model as a covariate because it was confounded with month, analysis was performed on
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the 2 months at the beginning of the study when all horses received the same diet, as well
as during the 10 months for the adult horses in which they received only forage, and similar
results were found for these subsets in relation to analyzing all the data. Thus, it is unlikely
that differences in feed afforded a significant role in the results of this study (see Section
2.8 & 3.4).
2.2. Data and Sample Collection
Over the course of one year, the body weights of the horses were recorded monthly
using a weight tape to determine any changes. Air temperatures were also collected using
the data reported by the UK Ag Weather Center for Spindletop Farm (adjacent to Maine
Chance Farm) at 1000 h on the days of blood collections, and hours of daylight were found
on the Weather Underground website for Lexington, Kentucky. Heparinized blood was
collected monthly in the morning (at approximately 1000 hours) via jugular venipuncture,
from which PBMC were then isolated. Gene expression from PBMC was then examined
seasonally (January, April, July, October). Serum and EDTA plasma was collected
seasonally

(January,

April,

July,

October)

to

measure

basal

cortisol

and

adrenocorticotropin hormone (ACTH), respectively.
2.3. PBMC Isolation and Freezing
PBMC were isolated using a Ficoll-Paque Plus™ (Amersham Biosciences,
Piscataway, NJ) density gradient and counted using a VICELLTM Counter-XR (Beckman
Coulter, Miami, FL), as previously described (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006; Siard et al., 2016). Each month over the course of the year-long
study, PBMCs were frozen in liquid nitrogen at a concentration of 2-5x107 in freeze media
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(50% RPMI 1640 [Gibco, Grand Island, NY], 40% fetal bovine serum [Sigma-Aldrich, St.
Louis, MO], and 10% dimethyl sulfoxide [Sigma]).
2.4. Culture Preparation
At the completion of the study, PBMC were thawed by horse for all months (n=12
samples per horse), washed in cRPMI media (RPMI 1640 [Gibco, Grand Island, NY]
supplemented with 2.5% fetal equine serum [FES; BioWest, Nuaillé, France], 55 μM 2mercaptoethanol [Gibco], and 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/mL
streptomycin [HyClone Pen/Strep/Glutamine solution; Thermo Scientific]), spun at 300g
x 10 minutes, and resuspended in cRPMI. PBMC were then counted using the VICELL to
attain desired plating concentrations.
Prior to intracellular staining and RNA isolation, PBMC were plated at a
concentration of 4x106 cells/mL in cRPMI media (in duplicate), stimulated with phorbol
12-myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 μM; Sigma) (single
well per sample), and incubated 4 hours at 37oC, 5% CO2 (Adams et al., 2008; Adams et
al., 2009; Breathnach et al., 2006; Siard et al., 2016). Brefeldin A (10 μg/mL; Sigma) was
also added to all wells (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006;
Siard et al., 2016).
Prior to proliferation analysis, PBMC were fluorescently tagged with
carboxyfluorescein succinimidyl ester (CFSE), as previously described (Adams et al.,
2008), with the exception that the reaction was quenched with FES and washed with 10%
FES, (instead of FBS). PBMC were then plated (in duplicate) at a concentration of 2x106
cells/mL in cRPMI media, stimulated with concanavalin A (2.5 µg/mL; Sigma) (single
well per sample), and incubated 96 hours at 37oC, 5% CO2 (Adams et al., 2008).
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2.5. IFN-γ and TNF-α Intracellular Staining and Flow Cytometry
Prior to intracellular staining, PBMC were transferred to duplicate 96-well Vbottom plates, fixed with 2% paraformaldehyde (Sigma), and incubated at 4oC overnight.
Intracellular staining for IFN-γ and TNF-α was performed as has previously been described
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016). Briefly,
PBMC were washed in saponin buffer [PBS supplemented with 1% fetal bovine serum
(FBS), 0.1% saponin (Sigma), and 0.1% sodium azide (Sigma)] and intracellularly stained
with IFN-γ FITC mouse anti-bovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg; 1:100
dilution) or TNF-α anti-equine monoclonal antibody (HL801; kindly provided by Dr. Rob
MacKay, University of Florida; 1:10 dilution) and secondary antibody FITC-conjugated
goat F(ab’)2 anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL; 1:1000 dilution) (Adams et al.,
2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016). PBMC from both
IFN-γ and TNF-α plates were resuspended in FACS Flow (Becton Dickinson, Franklin
Lakes, NJ) and transferred to 5-mL round-bottom tubes prior to analysis using a FACS
Calibur flow cytometer (Becton Dickinson) and Cell Quest® software (Becton Dickinson)
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016).
Lymphocyte populations were gated on cell size and granularity to determine the percent
of lymphocytes producing IFN-γ and TNF-α as well as mean fluorescence intensities (MFI)
of lymphocytes for each cytokine (Adams et al., 2008; Adams et al., 2009; Breathnach et
al., 2006).
2.6. RNA Isolation, Reverse Transcription, and Polymerase Chain Reaction
Following the incubation in 24-well plates, PBMC for all horses in each season
(January, April, July, October) were stored at -80oC in Trizol® solution, until RNA was
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isolated by phenol-chloroform extraction (Breathnach et al., 2006) and quantified using an
Epoch microplate spectrophotometer (BioTek, Winooski, VT). RNA was reverse
transcribed with master mix reagents (16 μL avian myeloblastosis virus [AMV] buffer 5X,
16 μL MgCl2, 4 μL dNTP, 1 μL RNasin, 1 μL oligo dT primer, and 0.5 μL AMV reverse
transciptase per sample; Promega, Madison, WI) and a thermocycler (Applied Biosystems,
Foster City, CA), incubating samples at 42oC for 15 minutes and 95oC for 5 minutes
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). cDNA samples were
then stored at -20oC until real time-polymerase chain reaction (RT-PCR) analysis. To
ensure accuracy and precision in aliquoting, an epMotion 5070 (Eppendorf) loaded plates
with cDNA samples and 5 equine specific intron-spanning primers and probes including
IFN-γ, IL-4, IL-6, IL-10, and TNF-α, (Applied Biosystems) in addition to Betaglucuronidase (β-GUS), the housekeeping gene (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006). The 7900HT Fast RT-PCR System (Applied Biosystems) was
used to perform RT-PCR, incubating samples at 95oC for 10 minutes, followed by 40
cycles of 95oC for 15s and 60oC for 60s (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006). Linear regression was used to determine cycle threshold (CT)
values, with relative changes in cytokine gene expression being quantified using the ΔΔCT
method (Livak and Schmittgen, 2001). The calibrator for each cytokine was the average
ΔCT of all media alone samples. Data are reported as relative quantity (RQ) values
according to the equation RQ = 2 -ΔΔCT (Livak and Schmittgen, 2001).
2.7. Endocrine Analysis.
Basal cortisol and basal ACTH were examined for all horses in each season
(January, April, July, October). Serum cortisol and EDTA plasma ACTH were analyzed
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by Cornell Animal Health Diagnostic Center, Endocrinology Laboratory using
chemiluminescence immunoassay (Immulite® 1000; Siemens, Berlin, Germany)(Place et
al., 2010).
2.8. Statistical Analysis.
Statistical analysis was performed using SAS 9.4 software (SAS Institute Inc.,
Cary, NC). Flow cytometry data from each month was grouped into seasons and averaged
according to the following: winter (December, January, February); spring (March, April,
May); summer (June, July, August); fall (September, October, November). Flow cytometry
data was analyzed using a mixed procedure with age category (senior or adult) and season
as well as the interaction between age category and season as the fixed effects, with season
as the repeated variable. Gene expression, hormone, and body weight data was analyzed
similarly but using month (January, April, July, and October) instead of seasonal averages.
Additionally, modeling was then performed with cortisol, ACTH, and body weight
data to determine whether these variables may be potential influencing factors on the
various immune parameters. Data was blocked by age category and analyzed individually
with each of the potential influencing factors (cortisol, ACTH, and body weight), month,
and the interaction of month and potential influencing factor as the fixed effects when
modeling for each of the immune parameters (%IFN-γ, IFN-γ MFI, %TNF-α, TNF-α MFI,
lymphocyte proliferation, IFN-γ RQ, TNF-α RQ, IL-4 RQ, IL-6 RQ, IL-10 RQ). Ambient
temperature was modeled over time (January, April, July, October) to determine
differences between months.
Due to some changes in diet over the course of the year-long study, additional
analysis was performed. Data from the first two months (April & May) in which all horses
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received the same isocaloric diet was modeled with age category, month, and age x month
to determine whether differences between adult and senior horses were similar to the results
of the entire dataset when diets were the same. Additionally, adult horses did not receive
feed (forage only) the last 10 months of the study, so those horses were analyzed by month
to determine if seasonal effects were similar for this subset as the entire dataset.
All data met skewness and kurtosis requirements, (although ACTH required logtransformation). Analyses with p<0.05 were considered statistically significant.
Results
3.1. Inflammatory cytokine production.
Senior horses exhibited elevated inflammation when compared to adult horses, as
expected. Specifically, senior horses exhibited a higher percentage of lymphocytes
producing IFN-γ (% IFN-γ) (Fig. 2.1A), as well as higher mean fluorescence intensity
(MFI) of lymphocytes intracellularly stained for IFN-γ (Fig. 2.1B) (p<0.001). Senior
horses also exhibited higher percentage of lymphocytes producing TNF-α (% TNF-α) (Fig.
2.2A), as well as higher TNF-α MFI (Fig. 2.2B) (p<0.001).
Some seasonal changes were observed in lymphocyte-mediated production of IFNγ. While the percent of lymphocytes producing IFN-γ did not significantly differ seasonally
(p>0.05) (Fig. 2.1A), IFN-γ MFI did vary seasonally (p<0.001) (Fig. 2.1B). Specifically,
IFN-γ MFI was lower in winter and fall than in spring and summer (p<0.05) (Fig. 2.1B).
Seasonal changes were also observed in lymphocyte-mediated production of TNFα. The percent of lymphocytes producing TNF-α and TNF-α MFI both significantly varied
with season (p<0.01). Specifically, %TNF- α was lower in winter than in spring and
summer (p<0.01), and %TNF-α was also lower in fall than spring (Fig. 2.2) (p<0.05). TNF-
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α MFI was lowest in winter compared to all seasons (p<0.01) (Fig. 2.2B). No significant
interactions of season and age category were present for any of the lymphocyte-mediated
inflammatory cytokine parameters (p>0.05).
3.2. Lymphocyte proliferation.
Lymphocyte proliferation also significantly differed between senior and adult
horses (p=0.023), with adult horses having higher proliferation than senior horses (Fig.
2.3). Lymphocyte proliferation did not differ significantly between seasons (p>0.05) (Fig.
2.3). No significant interaction of age category and season was present (p>0.05).
3.3. Cytokine gene expression.
Gene expression of various pro- and anti-inflammatory cytokines was examined
using PCR to examine any differences seasonally for senior and adult horses. January,
April, July, and October were analyzed to determine gene expression of IFN-γ, TNF-α, IL4, IL-6, and IL-10, as each of these months was considered the middle month for each
season (winter, spring, summer, and fall, respectively) (Fig. 2.4). For the cytokines
analyzed, significant differences between senior and adult horses were found for IFN-γ and
TNF-α (p<0.01) (Fig. 2.4).
A significant overall effect of month was found for IL-6 (p<0.05), while a trend for
an effect of month was determined for TNF-α (p=0.055) (Fig. 2.4B&C). Specifically, IL6 gene expression was lower in July than in all other months analyzed, showing diminished
levels in summer (p<0.05). Meanwhile, TNF-α was higher in July than in January or April
(p<0.05) but did not significantly differ from October, showing that gene expression of
TNF-α is greater in summer than in winter or spring. There were no other significant effects
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of month (p>0.05), and there were not significant interactions of age category and month
for any of the cytokines analyzed (p>0.05).
3.4. Potential influencing factors.
Serum cortisol, plasma ACTH, body weight, ambient air temperatures, and length
of daylight were examined seasonally (in January, April, July, and October) to determine
whether they may affect inflammatory and proliferative parameters. Serum cortisol
significantly differed between months, with an overall p-value of <0.0001, but did not
differ between age groups (Fig. 2.5A). Cortisol was lowest in January and October and
highest in April (Fig. 2.5A). Plasma ACTH was statistically significant for differences both
between age groups and months (p<0.01) (Fig. 2.5B). Senior horses exhibited elevated
plasma ACTH concentrations compared to adult horses (Fig. 2.5B). Overall, ACTH was
lowest in January and April and highest in October (Fig. 2.5B). Body weight did not vary
by month (p>0.05) and did not differ between senior and adult horses (p>0.05) (Fig. 2.6).
Ambient temperatures varied as expected with January (winter) being lowest and July
(summer) being highest (compared to all seasons) (p<0.05) (Table 2.1). Likewise, length
of daylight followed a similar pattern with January being shortest and July being longest
(Table 2.1).
For each of the immune parameters modeling with cortisol, ACTH, and body
weight for the months of January, April, July, and October was performed to determine
any influence on specific markers of the immune system. In a model incorporating month
and month interactions while also blocking for age category, it was found that IFN-γ MFI
and ACTH were positively associated (p=0.038). Weight was also individually associated
with %IFN-γ (p=0.018; negative), %TNF-α (p=0.003; negative), and lymphocyte
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proliferation (p=0.008; positive). No other relationships were found between cortisol,
ACTH, or body weight and immune parameters (%IFN-γ, IFN-γ MFI, %TNF-α, TNF-α
MFI, lymphocyte proliferation, IFN-γ RQ, TNF-α RQ, IL-4 RQ, IL-6 RQ, IL-10 RQ)
(p>0.05) in the aforementioned model.
Although diet was a confounding factor, the adult horses did not receive any feed
(only forage) for 10 months and still exhibited various seasonal changes in inflammatory
cytokine production. While the forage changed throughout the year, as horses were kept
on pasture and fed mixed-grass hay ad libitum during winter months, this is a common
management practice of equine facilities and arguably is part of a seasonal effect. In this
group of adult horses not receiving feed, seasonal changes were specifically seen for IFNγ MFI (p<0.0001), %TNF-α (p=0.003), and TNF-α MFI (p<0.001), quite similarly to the
results of the complete dataset (Fig. 2.1&2.2). Furthermore, although all horses were only
on the same diet for the first two months of the study due to differences in energy needs to
keep adult vs. senior horses at maintenance, differences in cytokine production were seen
between senior and adult horses. Specifically, differences between senior and adult horses
were seen for % IFN-γ (p=0.002), IFN-γ MFI (p=0.051), %TNF-α (p=0.002), and TNF-α
MFI (p=0.016), although lymphocyte proliferation did not demonstrate significant effects
of age (p=0.283). Additionally, for the full dataset, there were no interactions between age
category and month/season. Therefore, seasonal inflammatory changes likely are not due
to changes in feed.
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Discussion
Many species are known to undergo physiological changes seasonally as an
adaptation to varying conditions. These changes in physiology affect everything from
hormones to hair coat (McFarlane et al., 2012). Not surprisingly, immune function has also
demonstrated seasonal variations in many species as well (Bilbo et al., 2002; Bowden et
al., 2007; Mann et al., 2000; McFarlane et al., 2012). Few studies have been conducted in
the horse to determine seasonal effects, though some seasonal effects on immune response
of allergy-related conditions have been determined (Beadle et al., 2002; Hamza et al.,
2007). However, a longitudinal study to determine the effects of season on senior horses
in comparison to adult horses has not previously been performed.
Senior horses are known to experience inflamm-aging (chronic, low-grade
inflammation occurring systemically during old age) and immunosenescence (aging of the
immune system including decreased lymphocyte proliferation and decreased response to
vaccination) (Adams et al., 2008; Adams et al., 2009; Adams et al., 2011). The current
study determined the effects of season on function of PBMC in these already immunecompromised senior horses in comparison to adult horses.
As hypothesized, season affected lymphocyte-mediated inflammatory cytokine
production for multiple parameters examined. IFN-γ MFI, %TNF-α, and TNF-α MFI all
exhibited seasonal patterns. Specifically, IFN-γ MFI was lowest in winter and fall and
highest in spring and summer. Percent of lymphocytes producing TNF-α was lowest in
winter compared to spring and summer, and TNF-α MFI was lowest in winter compared
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to all seasons. As a whole, inflammation was diminished in the winter and elevated in the
spring and summer.
This general decrease in inflammation during winter is similar to what has been seen
in rhesus monkeys and baboons (Mann et al., 2000; McFarlane et al., 2012). Specifically,
Mann et al. (2000) showed a decrease in IFN-γ+ PBMC during winter compared to
summer (Mann et al., 2000). McFarlane et al. (2012) showed a decrease in proinflammatory serum CRP in December compared to June as well as a decrease of
inflammatory cytokine production in December following stimulation with both LPS and
CpG (deoxynucleotide found in viral, bacterial, fungal and parasitic DNA) (McFarlane et
al., 2012). However, the study also showed an increase in serum IL-6 in December
compared to June for baboons housed outdoors (McFarlane et al., 2012), showing that
various inflammatory cytokines can be expressed differentially from each other
dependent on the season.
Senior horses also exhibited elevated levels of inflammatory cytokine protein
production relative to adult horses in all measures, as expected. This was likewise seen in
the 2 month subset when horses were all receiving the same diet. Inflamm-aging in the
horse is a well-characterized phenomenon (Adams et al., 2008; Adams et al., 2009) that
was evidenced again in this study.
Senior horses had decreased lymphocyte proliferation compared to adult horses, as
expected. Functionally, these results indicate a decreased adaptive response of senior
horses to pathogen invasion in comparison to adult horses. Although the two month subset
when all horses received the same diet did not exhibit a significant difference between
senior and adult horses, previous studies examining lymphocyte proliferation of senior
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horses in comparison with adult horses have observed lower levels in senior horses as an
aspect of immunosenescence (Adams et al., 2008). It is expected that these differences in
lymphocyte proliferation between senior and adult horses would be more pronounced if
using a younger population of adult horses for comparison, similarly to previous studies
(in which the mean age was 4.5 years as compared to 10.8 years in the current study)
(Adams et al., 2008).
Lymphocyte proliferation did not significantly differ with seasonal. The lack of
seasonal differences was also seen in the 10 month subset of adult horses maintained on
forage. Lymphocyte proliferation has minimally been examined in regards to season, thus
the lack of seasonal differences is not entirely surprising. However, a study in rhesus
monkeys showed that lymphocyte proliferation was elevated in winter compared to
summer (Mann et al., 2000). Conversely, a study in humans had found that lymphocyte
proliferation was lower in patients with seasonal affective disorder (SAD) than in healthy
patients (Song et al., 2015a). This decreased lymphocyte proliferation in SAD patients was
corrected by light therapy, suggesting a potential role of photoperiod in lymphocyte
proliferation, although the effect of light therapy was only examined in SAD patients (Song
et al., 2015a). In the present study, equine lymphocyte proliferation did not appear to be
affected by season.
Gene expression of various cytokines including IFN-γ, TNF-α, IL-4, IL-6, and IL-10
mediated by PBMC was also examined to determine any differences seasonally as well as
between senior and adult horses. A significant effect of season was seen for IL-6, with July
being decreased relative to the other months examined (January, April, October). Despite
the deviation of these results compared to the other parameters in which inflammation was
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decreased most in winter, this decrease of IL-6 in summer is similar to the results seen by
McFarlane et al., 2012 in baboons (McFarlane et al., 2012), as previously mentioned.
However, gene expression of TNF-α was significantly increased in July compared to
January and April. Overall differences for senior and adult horses were also seen for gene
expression of IFN-γ and TNF-α, which are not surprising, given the differences in these
cytokine proteins determine by flow cytometry. Additionally, differences in PBMCmediated gene expression of IFN-γ between senior and adult horses have been found
previously, although differences in TNF-α were not significant (Adams et al., 2015).
No differences were seen seasonally or regarding age category for gene expression of
any other cytokines. Initially the lack of similarity in results between anti-inflammatory
IL-10 and the pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-6) may appear
unexpected. However, despite the fact that IL-10 is regulated in part by NF-κB (Cao et al.,
2006), which also regulates many of the pro-inflammatory cytokines including IFN-γ (Sica
et al., 1997), TNF-α (Collart et al., 1990), and IL-6 (Son et al., 2008), the IL-10 regulation
by NF-κB is primarily mediated by dendritic cells and macrophages (Cao et al., 2006;
Saraiva and O'Garra, 2010). In the present study, PBMC gene expression was analyzed,
where IL-10 is primarily regulated by the MAF/ERK pathway (in T-cells) (Saraiva and
O'Garra, 2010). Also, IL-10 gene expression of PBMC has previously been examined with
no differences between senior and adult horses being found (Adams et al., 2015).
Stress hormone levels of cortisol and ACTH were also analyzed to determine any
seasonal differences which may be potentially influencing factors on immune parameters.
Cortisol exhibited seasonal effects, being highest in April and lowest in January and
October. This aligns with the results of Cordero et al. (2012) in which cortisol was highest
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in spring for healthy horses (Cordero et al., 2012), although a study the following year
demonstrated no seasonal cortisol changes in ponies (Borer-Weir et al., 2013). ACTH was
most elevated in October and lowest in January and April, as expected. ACTH is known to
exhibit robust seasonal patterns, becoming quite elevated in the fall (McFarlane et al.,
2011). Additionally, ACTH was significantly higher in senior horses, which again was
expected, particularly since many senior horses develop pituitary pars intermedia
dysfunction (PPID), an endocrine disorder causing hypertrichosis and resulting in excess
production of ACTH (McFarlane, 2011). Since basal ACTH is used clinically to diagnose
PPID, it was included in the potential influencing factors model in order to determine
whether circulating levels of ACTH and potentially the presence of PPID are influencing
factors on immune function. Among the various immune parameters, ACTH appeared to
significantly affect only IFN-γ MFI, thus ACTH does not appear to have a significant role
in regulating immune function in general.
Body weight also appeared to have significant effects on each of the following: %IFNγ, %TNF-α, and lymphocyte proliferation. Specifically, body weight exhibited a negative
relationship with %IFN-γ and %TNF-α, which was unexpected, given that changes in body
weight and body fat in the old horse have been positively associated with PBMC-mediated
inflammation (Adams et al., 2009). In the present study however the negative relationships
were only slight (with every kg of increased body weight resulting in a decrease of %IFNγ and %TNF-α by 0.025 and 0.063, respectively), and body weights were determined using
a weight tape, which may not have been the most accurate measure of changes in weight.
The low temperatures in winter and/or short length of daylight also may contribute to
the decreased inflammation in winter. Short day length has been shown to decrease
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immune response in Siberian hamsters (Bilbo et al., 2002). However, these are not likely
to be primary contributing factors, as robust seasonal rhythms in other species have been
found for animals housed indoors at room temperature year-round (McFarlane et al., 2012).
Another potential factor that may affect the seasonal changes in inflammation is the
variation in forage the horses consumed throughout the year. Horses were maintained on
pasture but were fed mixed-grass hay in the winter months. Although forage was not tested
throughout the year, it is thought that perhaps the nonstructural carbohydrate (NSC) content
of the hay was lower than what the horses received from the grass pasture, yielding lower
levels of inflammation in winter, as horses fed higher levels of NSC were found to have
increased serum TNF-α (Suagee et al., 2011).
In conclusion, this study demonstrates seasonal patterns in pro-inflammatory cytokines
of both the adult horse and the senior horse exhibiting inflamm-aging and
immunosenescence. It appears that body weight may play a role, but the seasonal control
of the immune system appears quite complex and likely involves various aspects of the
immune-neuro-endocrine system (Weil et al. 2015; Haldar & Ahmad 2010) and may also
include forage type. The seasonal variations of inflammatory cytokine production,
particularly for the already immune-compromised senior horses, may yield understanding
of when horses may be more prone to infectious disease. For example, horses may be at
greater risk for disease in spring following the decreased inflammation in winter, as has
been shown in rhesus monkeys (Mann et al., 2000). These seasonal variations in
inflammatory cytokines may also have management implications, such as not vaccinating
during winter, as the immune system appears to be suppressed during those months and
would likely not elicit as strong of a protective response. However, more research needs to

36

be performed to determine what these seasonal inflammatory changes may specifically
mean for the health of the senior horse.
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Table 2.1. Ambient temperatures and length of daylight by representative month from
each season.
Season
January
April
July
October

Ambient Temperature (oC)
-10
17.5
25
4.2
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Length of Daylight (h)
10h 09m
13h 29m
14h 21m
10h 51m
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Page<0.0001
Pseason=0.336
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b
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b

a
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Figure 2.1. Lymphocyte production of pro-inflammatory cytokine interferon(IFN)-γ after
stimulation with PMA/ionomycin for n=8 senior (≥20 years) and n=8 adult (9-12 years)
horses for each season. Both (A) percent of lymphocytes producing IFN-γ (%IFN-γ) and
(B) IFN-γ mean fluorescence intensity (MFI) are shown, with significant differences
(p<0.05) between seasons being signified by different lettering (a, b). Page denotes the pvalue for overall differences between senior and adult horses for IFN-γ production, while
Pseason denotes the overall p-value for differences between seasons.
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Figure 2.2. Lymphocyte production of pro-inflammatory cytokine tumor necrosis
factor(TNF)-α after stimulation with PMA/ionomycin for n=8 senior (≥20 years) and n=8
adult (9-12 years) horses for each season. Both (A) percent of lymphocytes producing
TNF-α and (B) TNF-α mean fluorescence intensity (MFI) are shown, with significant
differences (p<0.05) between seasons being signified by different lettering (a, b, c). Page
denotes the p-value for overall differences between senior and adult horses for TNF-α
production, while Pseason denotes the overall p-value for differences between seasons.

40

Lymphocyte Proliferation Index

8

Page=0.023
Pseason=0.245

Senior
Adult

6

4

2

0
Winter

Spring Summer

Fall

Season

Figure 2.3. Lymphocyte proliferation of n=8 senior (≥20 years) and n=8 adult (9-12 years)
horses for each season. Peripheral blood mononuclear cells were stimulated with mitogen
concanavalin A and incubated 96 hours to determine lymphocyte proliferation index. Page
denotes the p-value for overall differences between senior and adult horses in lymphocyte
proliferation index, while Pseason denotes the overall p-value for differences between
seasons.
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Figure 2.4. Peripheral blood mononuclear
cell-mediated gene expression of 8 senior
(≥20 years) and 8 adult horses. Real-time
polymerase chain reaction was performed to
determine relative quantities (RQ) of (A)
interferon(IFN)-γ, (B) tumor necrosis
factor(TNF)-α, (C) interleukin(IL)-6, (D) IL4, and (E) IL-10 throughout the year (January,
April, July, and October). Page denotes the pvalue for overall differences between senior
and adult horses in gene expression, while
Pmonth denotes the overall p-value for
differences between months. Significant
differences (p<0.05) between months are
signified by different lettering (a, b).
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Figure 2.5. Potential hormone influences on seasonal inflammatory changes of n=8
senior (≥20 years) and n=8 adult (9-12 years) horses. Serum cortisol (A) and plasma
adrenocorticotropin hormone (ACTH) (B) were examined throughout the year (January,
April, July, and October) to determine whether these factors may influence any seasonal
inflammatory changes. Significant differences (p<0.05) between seasons are denoted by
different lettering (a, b, c). Page denotes the p-value for overall differences between
senior and adult horses in gene expression, while Pmonth denotes the overall p-value for
differences between months.
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Figure 2.6. Body weights of n=8 senior (≥20 years) and n=8 adult (9-12 years) horses
seasonally. Body weights were examined throughout the year (January, April, July, and
October) to determine whether it may influence any seasonal inflammatory changes. Any
significant differences (p<0.05) between seasons are denoted by different lettering. Page
denotes the p-value for overall differences between senior and adult horses in gene
expression, while Pmonth denotes the overall p-value for differences between months.
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CHAPTER 3
RELATIONSHIPS OF INFLAMM-AGING WITH NUTRITIONAL STATUS,
BODY COMPOSITION, AGE, AND PITUITARY PARS INTERMEDIA
DYSFUNCTION IN A SENIOR HORSE POPULATION.
Abstract
Similar to aged humans, senior horses (≥20 years) exhibit chronic low-grade
inflammation systemically, known as inflamm-aging. In addition to inflamm-aging, senior
horses present with sarcopenia and often the endocrinopathy pituitary pars intermedia
dysfunction (PPID). Despite the concurrence of these phenomena, the relationships
inflamm-aging may have with measures of nutritional status, body composition, age, and
pituitary function in the horse remain unknown. Thus, an exploratory study of a population
of n=42 similarly-managed senior horses was conducted. Serum was collected to determine
vitamin, mineral, and fatty acid content. Peripheral blood mononuclear cells were also
isolated to determine inflammatory cytokine production of interferon-γ (IFN-γ) and tumor
necrosis factor-α (TNF-α) following stimulation with a mitogen, as well as to determine
gene expression of interleukin(IL)-1β, IL-6, IL-10, IFN-γ, and TNF-α. Serum IL-6 and Creactive protein were determined by enzyme-linked immunosorbent assay. Whole blood
was collected for hematological and biochemical analysis. Body composition was
evaluated via ultrasound and muscle scoring for all 42 horses as well as by deuterium oxide
dilution for a subset of n=10 horses. Pituitary function was determined by measuring basal
adrenocorticotropin hormone concentrations as well as by thyrotropin releasing hormone
stimulation testing (to determine PPID status). Results showed various relationships
between inflammatory markers and the other variables measured. Most notably,
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docosadienoic acid (C22:2n6c), docosapentaenoic acid (C22:5n3c), and folate were
positively associated with numerous inflammatory parameters (P≤0.05). Being positive for
PPID was negatively associated with vitamin B12 and positively associated with
percentage of eosinophils (P≤0.05). No relationships between inflammation and body
composition were found, however age was associated with multiple parameters,
particularly with numerous inflammatory cytokines and fatty acids. In summary, inflammaging exhibited relationships with various other parameters examined, particularly with
certain fatty acids. This exploratory study provides insights into physiological changes
associated with inflamm-aging in the senior horse.
Introduction
Senior horses (≥20 years), like aged humans, exhibit chronic low-grade
inflammation that occurs systemically; this phenomenon is known as inflamm-aging
(Franceschi et al., 2000). In humans, the term inflamm-aging was coined (Franceschi et al.,
2000) after discovering that despite the generalized immunodepression previously known
to occur with aging, peripheral blood mononuclear cells (PBMC) produced elevated levels
of inflammatory cytokines in the elderly when compared to their younger counterparts
(Fagiolo et al., 1993). Various other systemic increases in markers of inflammation such
as interleukin(IL)-1, IL-6, tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP),
and serum amyloid A (SAA) have also been associated with old age in humans (Franceschi
et al., 2000; Ostan et al., 2015). These increases in pro-inflammatory cytokines and other
inflammatory markers in turn increase systemic inflammation. Inflamm-aging in the horse
is likewise characterized by increased pro-inflammatory cytokine production by
monocytes and lymphocytes of old horses when compared to young horses. Specifically,
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old horses have increased levels of circulating IL-1β, IL-15, IL-18, and TNF-α in whole
blood, as well as increased production of IFN-γ and TNF-α by lymphocytes and monocytes
after stimulation with a mitogen (Adams et al., 2008; Adams et al., 2009). A vast body of
human literature has shown systemic inflammation to be

an underlying condition

predisposing people to various diseases including Alzheimer’s disease, atherosclerosis,
macular degeneration, and degenerative arthritis (Franceschi and Campisi, 2014).
Inflamm-aging, therefore, is considered to be a key predictor of morbidity and mortality
(Franceschi and Campisi, 2014); however, what exactly inflamm-aging means for the
physiology of the horse remains unknown. Furthermore, the causes of inflamm-aging in
both humans and horses remain relatively unknown (Franceschi and Campisi, 2014).
In many species, various vitamins, minerals, and fatty acids have been associated
with inflammation, whether pro- or anti-inflammatory. Many studies have shown Vitamin
D to be anti-inflammatory in humans and rats (Abbas, 2016; Capri et al., 2006; Moore et
al., 2005). A recent human study in China showed folic acid, the synthetic form of folate,
to be anti-inflammatory as well, even improving cognition of patients with Alzheimer’s
disease (Chen et al., 2016). Mineral supplements including zinc (Zhu et al., 2016) and
selenium (Brummer et al., 2013) in piglets and horses, respectively, have also exhibited
various effects on immunity. In human patients experiencing a systemic inflammatory
response, most micronutrients decreased with the exception of iron, which was shown to
increase (Thurnham and Northrop-Clewes, 2016). In a human population study, many
polyunsaturated fatty acids (PUFAs) were associated with a lower inflammatory profile, in
that a negative correlation was found between PUFAs and pro-inflammatory cytokines,
while a positive correlation was found between PUFAs and anti-inflammatory cytokines
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(Ferrucci et al., 2006). Additionally, omega-3 supplementation in the horse has
demonstrated potential immunomodulatory effects at a clinical level (Nogradi et al., 2015).
Nutrition has implications for healthspan and life span; however, this relationship requires
further elucidation (Dato et al., 2016), particularly in the old horse, where much currently
remains unknown (Siciliano, 2002). Furthermore, the numerous associations between
inflammation and vitamins, minerals, and fatty acids in various species indicate that
nutritional intervention has the potential to alter inflammatory profiles (Dasilva et al., 2016;
Dato et al., 2016), which may extend to the senior horse.
In addition to inflamm-aging, old horses experience sarcopenia (age-associated
muscle wasting), similarly to other species including humans (Lehnhard et al., 2004; Reed
et al., 2015; Schaap et al., 2009; Schaap et al., 2006). In longitudinal human studies,
increased inflammatory markers, particularly TNF-α, IL-6, and CRP, were associated with
decreased muscle mass and strength (Schaap et al., 2009; Schaap et al., 2006). In a study
of over 3000 healthy, aged (70-79 yrs) adults, IL-6 and TNF-α were associated with
decreased muscle mass and strength (Visser et al., 2002). In aged cattle, lymphocytemediated (primarily CD8+) inflammation was also associated with sarcopenia (Costagliola
et al., 2016). In the old horse, decreased muscle mitochondrial density and shifted fiber
types (toward a higher percentage of myosin heavy chain types I and IIA) have been
associated with aging (Li et al., 2016). Furthermore, a recent study suggests that the proinflammatory status associated with inflamm-aging in old horses may decrease exerciseinduced satellite cell activity, thereby decreasing the normal process of hypertrophy
associated with exercise (Reed et al., 2015). This, in turn, may indicate why maintaining
physical fitness in senior horses is more challenging (Reed et al., 2015), a key issue in the
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equine industry due to the number of equine athletes competing into their senior years
(Malinowski et al., 1997; McKeever, 2016). The relationship between inflamm-aging and
sarcopenia therefore requires further study.
While there is little evidence that senior horses have different hematological or
biochemical reference ranges than adult horses (Silva and Furr, 2013), it was of interest to
determine whether inflammation in the older animal was associated with any particular
clinical biomarkers. For example bilirubin, a biomarker of liver function, has variable
associations with inflammation in other species, exhibiting anti-inflammatory properties
(Moreno-Otero et al., 1994) and even protecting against inflamm-aging in some studies
(Zelenka et al., 2016), while exhibiting pro-inflammatory effects in other studies (Qaisiya
et al., 2016).
Senior horses also frequently exhibit pituitary pars intermedia dysfunction (PPID),
commonly known as equine Cushing’s disease. This endocrinopathy is caused by
dopaminergic neurodegeneration of the hypothalamic neurons, causing hypertrophy,
hyperplasia, and often adenomas of the pituitary pars intermedia (Durham, 2016; Miller et
al., 2008b) and frequently results in hypertrichosis, polydipsia, polyuria, hyperhidrosis,
laminitis, muscle atrophy, and abnormal fat distribution (McFarlane, 2011).
Endocrinologically this frequently results in increased basal levels of circulating
adrenocorticotropin hormone (ACTH), while also resulting in a decreased ability of horses
to return to resting levels of ACTH after intravenous injection of thyrotropin releasing
hormone (TRH) (Beech et al., 2007). ACTH has been associated with increased gene
expression of pro-inflammatory IL-6 in septic foals (Gold et al., 2012); however, the
relationship of ACTH with inflammation is not well-characterized. PPID has been
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associated with total leukocyte-mediated cytokine dysregulation (McFarlane and
Holbrook, 2008). Therefore, it was of interest to examine whether various circulating
serum and PBMC-mediated markers of inflammation would be associated with PPID.
Further, the exact mechanisms that result in this hypothalamic dopaminergic
neurodegeneration found in many old horses remain unknown, and specific markers of
inflamm-aging being differentially associated with PPID may yield understanding of
underlying mechanisms involved in this pathology.
Thus, an exploratory study to examine the potential relationships between
inflammatory parameters and various vitamin, mineral, fatty acid, hematology,
biochemistry, body composition, and PPID parameters in senior horses was undertaken. It
was hypothesized that inflamm-aging would be inversely associated with markers of
muscle mass and with levels of known anti-inflammatory nutrients. It was also
hypothesized that specific markers of inflamm-aging would be differentially associated in
relation to PPID status and that inflamm-aging would not be associated with hematology
or blood biochemistry markers.
Methods and Materials
2.1. Animals and Study Design
Forty-two senior horses (mean age = 24.4 ± 3.0 yr [SD]; range = 18-29 yr) were
used in this study. Horses were of mixed-breeds and sex (33 mares, 11 geldings) with a
mean body condition score (BCS; according to the Henneke scale 1-9) (Henneke et al.,
1983) of 5.2 ± 0.8 and body weight (BW) of 531.2 ± 86.9 kg. All horses were free of
clinical signs of infectious disease and housed at the University of Kentucky, Department
of Veterinary Science Maine Chance Farm in Lexington, Kentucky on pasture during the
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winter season. Horses received a diet of 50% oats and 50% vitamin and mineral fortified
alfalfa pellets (5.5 kg per day, divided equally into meals fed at 0830 and 1400 h) with
mixed grass hay provided ad libitum (Table 3.1). All procedures were approved by the
University of Kentucky Institute of Animal Care and Use Committee.
Samples and measurements collected for all (n=42) horses included the following:
BW, BCS, muscle mass score, rump ultrasound, and blood samples. A subset of n=10 of
these horses also had deuterium oxide assessment of percent body fat and fat free mass
(FFM) performed. Horses were weighed (using a portable calibrated large-animal scale)
and assessed for BCS using the Henneke scale (1-9) (Henneke et al., 1983) by two
experienced assessors. Muscle mass was scored by two assessors using the previously
established 1-5 scale (Graham-Thiers and Kronfeld, 2005). Blood was collected within 2
hours after horses had eaten their morning meal. Percent body fat and fat free mass were
estimated using ultrasound (Kane, 1987; Lehnhard et al., 2004) and deuterium oxide
(Dugdale et al., 2011) methods within one week post blood collection. Furthermore,
thyrotropin releasing hormone (TRH) stimulation testing was performed on all horses
within 3 hours of their morning meal, with adrenocorticotropin hormone (ACTH) being
measured prior to and 10 minutes post intravenous TRH injection, to determine pituitary
function, as further described below. Twenty-eight of the 42 horses tested positive for
pituitary pars intermedia dysfunction (PPID) according to results from TRH stimulation.
2.2. Blood Sampling
All blood was collected from the jugular vein using an aseptic technique.
Heparinized blood was collected to isolate peripheral blood mononuclear cells (PBMCs),
which were processed fresh after collection. Serum was collected for analysis of vitamins,
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fatty acids, and inflammatory proteins (interleukin [IL]-6, tumor necrosis factor-alpha
[TNF-α], and C-reactive protein [CRP]), centrifuged (800g x 10 min x 22oC), and frozen
at -20oC until analysis. Serum was also collected to analyze trace mineral content (in royal
blue top, serum clot activator [silicone coated] tubes with hemogard closure to enable zinc
analysis [Fisher Scientific, Waltham, MA]), centrifuged (800g x 10 min x 22oC), and
frozen at -20oC until analysis. EDTA plasma was collected for ACTH analysis, centrifuged
(800g x 10 min x 22oC), and frozen at -20oC until analysis. Lithium heparinized whole
blood was collected and immediately analyzed for complete blood count with differential
and blood chemistry panel analysis.
2.3. PBMC Isolation, IFN-γ and TNF-α Intracellular Staining, and Flow Cytometry
Peripheral blood mononuclear cells were isolated from the collected heparinized
blood using a Ficoll-Paque Plus™ (Amersham Biosciences, Piscataway, NJ) density
gradient, as has been previously described (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006). PBMC were counted using a VICELL™ Counter-XR (Beckman
Coulter, Miami, FL) and plated at a concentration of 4x106 cells/mL in complete media
(RPMI 1640 [Gibco, Grand Island, NY] with 2.5% fetal equine serum [FES; BioWest,
Nuaillé, France], 55 μM 2-mercaptoethanol [Gibco], and 2 mM L-glutamine, 100 U/ml
penicillin, 0.1 mg/mL streptomycin [HyClone Pen/Strep/Glutamine solution; Thermo
Scientific]) (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). PBMC were
aliquoted in duplicate into 24-well plates, with brefeldin A (10 μg/mL; Sigma) added to all
wells, and phorbol 12-myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1
μM; Sigma) added to one well per sample. PBMC were incubated 4 hours at 37oC, 5%
CO2, then fixed with 2% paraformaldehyde overnight. To determine pro-inflammatory
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cytokine production, PBMC were stained intracellularly with IFN-γ FITC mouse antibovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg) and with TNF-α anti-equine
monoclonal antibody (HL801; kindly provided by Dr. Rob MacKay, University of Florida)
and secondary antibody FITC-conjugated goat F(ab’)2 anti-mouse IgG (H + L) (Invitrogen,
Carlsbad, CA; 2 mg/mL) (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006).
Flow cytometry was performed using a FACS Calibur flow cytometer (Becton Dickinson)
and Cell Quest® software (Becton Dickinson) (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006).
2.4. RNA Isolation and Reverse Transcription
Following the incubation in 24-well plates, aliquots (500 μL) of PBMC were
centrifuged in 1.5 mL microcentrifuge tubes, resuspended in 1 mL of Trizol® solution, and
stored at -80oC, following the manufacturer’s protocol. RNA was isolated by phenolchloroform extraction and stored at -80oC (Breathnach et al., 2006). Using an Epoch
microplate spectrophotometer (BioTek, Winooski, VT), RNA was quantified. Reverse
transcription was performed on 1 μg RNA in RNase-free water (41.5 μL total) using Master
Mix (16 μL avian myeloblastosis virus [AMV] buffer 5X, 16 μL MgCl2, 4 μL dNTP, 1 μL
RNasin, 1 μL oligo dT primer, and 0.5 μL AMV reverse transciptase per sample; Promega,
Madison, WI) and a thermocycler (Bio-Rad, Hercules, CA), with samples incubated at
42oC for 15 minutes and 95oC for 5 minutes (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006). Samples of cDNA were stored at -20oC until real time-polymerase
chain reaction (RT-PCR) analysis.
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2.5. Determination of Cytokine Gene Expression
cDNA samples were thawed at room temperature and loaded into the epMotion
5070 (Eppendorf) with 5 equine specific intron-spanning primers and probes including
IFN-γ, IL-1β, IL-6, IL-10, and TNF-α, (Applied Biosystems, Foster City, CA) in addition
to Beta-glucuronidase (β-GUS), the housekeeping gene (Adams et al., 2008; Adams et al.,
2009; Breathnach et al., 2006). RT-PCR was performed using the 7900HT Fast RT-PCR
System (Applied Biosystems), which incubated samples at 95oC for 10 minutes, followed
by 40 cycles of 95oC for 15s and 60oC for 60s (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006). The reaction volume for each sample was 10 µL of master mix,
with 5 µL Sensimix II Probe Kit (Bioline), 0.5 µL assay mix for the gene of interest
(primer/probe sets; Applied Biosystems), and 4.5 µL cDNA template (Adams et al., 2008;
Adams et al., 2009; Breathnach et al., 2006). Relative changes in cytokine gene expression
were quantified using the ΔΔCT method (Livak and Schmittgen, 2001). The average ΔCT
of all the wells treated with media alone served as the calibrator for each cytokine. Data
are reported as natural logs of relative quantity (RQ) values (RQ = 2

-ΔΔCT

) (Livak and

Schmittgen, 2001).
2.6. Inflammatory protein ELISAs
Using enzyme-linked immunosorbent assay (ELISA) methods previously
described in the horse, serum inflammatory protein concentrations of IL-6 (Burton et al.,
2009) and CRP (Lavoie-Lamoureux et al., 2012) were quantified in duplicate. Briefly, IL6 was measured by coating ELISA plates (Immunoplate Maxisorp, Nalge Nunc Int.,
Rochester, NY) with a polyclonal goat anti-horse IL-6 antibody (AF1886, R&D Systems,
Inc., Minneapolis, MN), blocking plates with phosphate buffered saline (PBS, pH 7.2)
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supplemented with 0.5% bovine serum albumin, washing with phosphate buffer (2.5 mmol
NaH2PO4, 7.5 mmol Na2HPO4, 145 mmol NaCl, 0.1% (v/v) Tween 20, pH 7.2), and
tagging with biotinylated goat anti-horse IL-6 (AF1886, R&D Systems, Inc., Minneapolis,
MN) and a streptavidin–horseradish peroxidase solution (Jackson ImmunoResearch Lab.,
West Grove, PA) (Burton et al., 2009). A recombinant equine IL-6 (1886-EL, R&D
Systems, Inc., Minneapolis, MN) in two-fold dilutions was used to create a standard curve,
ranging from 500-4 ng/mL (Burton et al., 2009). Reactions were pigmented and stopped
with TMB substrate solution (Thermo Scientific, Rockford, IL) & TMB stop solution
(KPL, Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD), respectively and
analyzed in duplicate colorimetrically at 450 nm of absorbance using an ELISA reader
(Bio-Rad Laboratories, Inc., Philadelphia, PA). The serum sample dilution was 1:50 or
1:100, with dilution factor taken into account when calculating protein concentrations. The
mean intra-assay coefficient of variation was 6.4%.
Serum CRP was quantified using a commercially available equine-specific CRP
ELISA kit (Kamiya Biomedical, Seattle, WA), according to manufacturer instructions
(Lavoie-Lamoureux et al., 2012), except all serum samples were diluted 1:300 instead of
1:100. The standard curve ranged from 200-6.25 ng/mL. ELISA reader (Bio-Rad) analysis
was performed at an absorbance of 450 nm. The mean intra-assay coefficient of variation
was 2.5%, while the mean inter-assay coefficient of variation was 0.8%.
2.7. Circulating vitamins and minerals
Serum vitamins and minerals were analyzed at Michigan State University
Diagnostic Center for Population and Animal Health (MSU DCPAH), except Vitamin B12
and folate, which were analyzed at Cornell University Animal Health Diagnostic Center
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(AHDC) Endocrinology Laboratory using American Association of Veterinary Laboratory
Diagnosticians (AAVLD) validated assays. Serum 25-hydroxyvitamin D was analyzed via
radioimmunoassay (RIA) using a commercially available 125 iodine-RIA kit (Dia Sorin,
Stillwater, MN). Vitamins A (retinol), E (α-tocopherol), and β-carotene were measured via
ultra high pressure liquid chromatography with a C18 column and photodiode array
detection (Waters, Milford, MA), following liquid-liquid extraction. Fatty acids, including
saturated and unsaturated, were measured via gas chromatography with a SP2556 column
and flame ionization detection (PerkinElmer Inc., Waltham, MA), following methyl
esterification preparation. Trace minerals including total zinc, selenium, cobalt, copper,
iron, manganese, and molybdenum were measured in serum via inductively coupled
plasma mass spectrometry (Agilent Technologies, Santa Clara, CA), following direct
dilution preparation. Serum vitamin B12 and folate were analyzed via chemiluminescence
immunoassay using an Immulite® 2000 (Siemens, Berlin, Germany).
2.8. Muscle measures
Estimated percent body fat, fat weight, and fat free mass (FFM) were determined
using ultrasound measurements of rump fat thickness at approximately 11 cm caudal from
the tail head and 10 cm off the midline. This measurement of rump fat was then used to
calculate the estimated percent body fat according to the equation: % body fat =
5.4*(ultrasound rump fat thickness in cm) + 2.47 (Kane, 1987; Lehnhard et al., 2004).
Estimated fat weight and FFM were calculated in turn using the equations: fat weight =
body weight*(% body fat); FFM = body weight – fat weight (Lehnhard et al., 2004).
Muscle mass scores were also determined by two assessors using the previously published
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scale of 1-5 (where 1=lowest; 5=highest), and scores were averaged prior to statistical
analysis (Graham-Thiers and Kronfeld, 2005).
Furthermore, percent body fat and fat free mass were determined in ten horses using
the deuterium oxide (D2O) dilution method previously validated in ponies (Dugdale et al.,
2011). (The horses assessed were n=5 with high inflammation and n=5 with low
inflammation, as determined by %IFN-γ.) Briefly, feed and water were removed from horse
pens, and a dose of 0.12 g/kg BW D2O (Cambridge Isotope Laboratories, Tewksbury, MA)
was administered through a temporary catheter in the left jugular vein. (All horses analyzed
had a BCS of 4-6, therefore, 0.12*BW could be used for all horses.) Blood samples were
collected by venipuncture of the right jugular vein immediately before and 4 hours after
D2O infusion. D2O was administered into the catheter (16Gx5 ½”; Hospira, Inc.; Lake
Forest, IL) with a 0.22 mm filter (Millex®GP Filter Unit, EMD Millipore, Darmstadt,
Germany) on the syringe tip to ensure sterility of the procedure, followed by immediate
administration of sterile saline (100 mL). Syringes were weighed to determine the exact
weight of D2O administered to each animal. Blood was immediately spun at 2000xg for 10
minutes at 4oC and placed on ice. Plasma was aliquoted with limited air exposure into airtight, o-ring screw cap vials (Fisher Scientific, Waltham, MA) and immediately placed in
freezer. Samples were stored at -80oC until analysis.
Metabolic Solutions (Nashua, NH) performed D2O content analysis in triplicate
using cavity ring-down spectroscopy (CRDS) with a liquid water isotope analyzer
automated injection system, version 2 upgrade (Los Gatos Research, Mountain View, CA)
as has previously been published (Thorsen et al., 2011). To remove plasma proteins: zinc
sulfate monohydrate (5 mg) was added to plasma (25-50 µL), samples were vortexed, and
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samples were spun at 6000g for 10 minutes at room temperature (22oC) to precipitate
proteins. The supernatant was injected six times, with the last three being averaged to
determine values. A standard curve was generated using known values of D2O. Values
were determined as deltas relative to the V-SMOW (Vienna Standard Mean Ocean Water)
standard in parts per thousand (ppt). Intra-run variation was <2 delta ppt/mL and inter-run
variation is <3.5 delta ppt/mL. D2O analysis was performed on samples pre and post D2O
administration as well as on D2O infusate. The calculation of total body water (TBW)
adapted from Dugdale et al. (2011) was conducted as follows (Dugdale et al., 2011):
TBW (kg) = W*A/a*[(delta of dose – delta of dilution tap water)/(delta of post – delta of
pre)]/1000/1.04
Here, W= water needed to dilute the D2O infusate dose to enable CRDS measurement
(58.9225 mg), A= amount of D2O (g) administered to the horse, a= amount of D2O infusate
dose diluted and measured via CRDS (0.0276 mg), delta of D2O infusate dose relative to
VSMOW (2595.79 ppt/mL), delta of dilution tap water relative to VSMOW (-81.38
ppt/mL), 1000= necessary to convert g to kg, and 1.04= factor of overestimation of D2O
method due to deuterium binding to protein and non-exchangeable areas.

Using the adjustment factor of 0.723 adapted by Pace and Rathbun (Pace and Rathbun,
1945), equations were also used to determine percent body fat and fat free mass:
% Body fat = 100 – (TBW / BW / 0.732)
Fat Free Mass (FFM) = TBW / 0.732
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2.9. Pituitary Function
ACTH levels were determined by Cornell AHDC Endocrinology Laboratory via
chemiluminescence immunoassay using an Immulite® 1000 (Siemens, Berlin, Germany),
as previously published in the horse (Place et al., 2010).
As a dynamic measure of pituitary function, TRH stimulation was also performed.
TRH (Sigma-Aldrich, St. Louis, MO) was stored at -20oC until dissolved in saline. Using
sterile techniques in a biochemical hood, TRH was dissolved in 0.9% saline (1 mg/mL),
aliquoted into sterile microcentrifuge tubes, and immediately frozen at -80oC (Beech et al.,
2007; McFarlane et al., 2006). The morning of TRH testing, the aliquots were thawed at
room temperature, and using sterile techniques in a chemical hood 1 mL of TRH solution
was drawn into each of the syringes, which were immediately placed on ice. Blood was
collected aseptically from the jugular vein in EDTA-containing tubes prior to and 10
minutes post intravenous TRH administration and placed on ice (Diez de Castro et al.,
2014). The blood was then centrifuged at 800g for 10 minutes at room temperature and
placed back on ice. Plasma was aliquoted and stored at -20oC until shipment on dry ice to
Cornell AHDC for ACTH analysis. Horses with ACTH values 10 minutes post TRH
injection of >110 pg/mL were considered PPID, as recommended by the Equine
Endocrinology Group (Restifo et al., 2016).
2.10. Hematological and Biochemical Analyses
Blood was analyzed by Rood and Riddle Equine Hospital Laboratory, Lexington,
Kentucky to determine complete blood count (CBC) with differential and blood chemistry
panel. A Beckman Coulter ACT/DIFF hematology machine and Beckman Coulter AU480
serum chemistry analyzer were used to determine CBC and blood chemistry, respectively.
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Specifically measured were: hemoglobin (Hgb), packed cell volume (PCV), red blood cells
(RBC), white blood cells (WBC), total protein, mature neutrophils (segs), immature
neutrophils (bands), lymphocytes (lymph), monocytes (mono), eosinophils (eos), sodium,
potassium,

chloride,

albumin,

transaminase/aspartate aminotransferase

serum
(SGOT/AST),

glutamic
alkaline

oxaloacetic

phosphatase,

total

bilirubin, direct bilirubin, creatine kinase (CK), creatinine, glucose, gamma-glutamyl
transferase (GGT), blood urea nitrogen (BUN), phosphorus, calcium, sorbitol
dehydrogenase (SDH), and lactate dehydrogenase (LDH).
2.11. Statistical Analysis
Prior to data analysis, WINPEPI DESCRIBE (version 3.07) computer program for
epidemiologists (Abramson, 2011) was used to determine outliers. Non-normally
distributed data were natural log-transformed to achieve a normal distribution. Outliers at
each end of the distribution, defined as values further than five times the median absolute
deviation (MAD) from the median were then excluded prior to analysis to achieve normal
distribution.
Data

were

analyzed

with

SPSS

version 24 (IBM

Corp,

Armonk,

NY). Bivariate Pearson correlations were performed among the various parameter
values. Partial correlations among the various parameters were also analyzed with age as a
covariate. (Breed and sex were not included as covariates, given the population of horses
examined were predominantly female [79%] and over half of the horses were
Thoroughbreds, with quite a variety of other breeds composing the rest of the population.)
The few variables that were not normally distributed following log-transformation (IL-6
ELISA,

C22:2n6c,

and

C22:6n3c)

were
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analyzed

using

non-parametric

tests: bivariate Spearman correlations and partial Spearman correlations with age as a
covariate. For comparisons of deuterium oxide method with ultrasound and muscle scoring
to determine body composition, data were analyzed via partial Pearson correlations and
with both age and body weight as covariates for n=10 horses that underwent D2O analysis.
For all analyses, data with P≤0.05 was considered significant. Results tables depict
significant relationships between variables.
Results
3.1. Relationships of Inflammation to Serum Levels of Vitamins, Minerals, and Fatty Acids
Lymphocyte production of IFN-γ and TNF-α were correlated with various serum
vitamins, minerals, and fatty acids. Specifically, the percent of lymphocytes producing
IFN-γ (% IFN-γ) exhibited a positive correlation with serum folate and selenium and with
fatty acids C20:2n6c, C20:4n6c, C22:2n6c, C22:5n3c, and C24:1n9c (P≤0.05), while %
IFN-γ exhibited a negative correlation with serum C16, C18:1n9c, and iron (P≤0.05);
however, when the model was adjusted for age, only relationships with C22:2n6c and
C22:5n3c remained significant (P≤0.05) (Table 3.2). The IFN-γ MFI was positively
correlated with folate, selenium, and fatty acids C20:2n6c, C20:4n6c, C22:5n3c, and
C24:1n9c (P≤0.05) and was negatively correlated with fatty acid C16 (P≤0.05) (Table 3.2).
After adjusting for age, only zinc, C22:2n6c, and C22:5n3c were significant (P≤0.05)
(Table 3.2). The percent of lymphocytes producing TNF-α (% TNF-α) exhibited a positive
correlation with serum folate, selenium, C20:2n6c, C22:2n6c, C22:5n3c, and C24:1n9c
(P≤0.05), and % TNF-α exhibited a negative correlation with C16 and C18:1n9c (P≤0.05).
After adjusting for age, only folate, C20:2n6c, C22:2n6c, and C22:5n3c exhibited a
significant relationship with % TNF-α (P≤0.05) (Table 3.2). Tumor necrosis factor-α MFI
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was positively correlated with serum folate and fatty acid C22:2n6c and negatively
correlated with C16 (P≤0.05); after adjusting for age, the relationship of TNF-α MFI with
folate and C22:2n6c remained significant (P≤0.05) (Table 3.2).
Peripheral blood mononuclear cell gene expression of various inflammatory
cytokines was also correlated with various serum vitamins, minerals, and fatty acids. Gene
expression of IFN-γ was positively correlated with serum folate, C20:4n6c, and C22:5n3c
(P≤0.05) and was negatively correlated with C16 and C18:1n9c (P≤0.05); after the model
was adjusted for age folate, C22:2n6c, and C22:5n3c were significantly associated with
IFN-γ RQ (P≤0.05) (Table 3.2). Gene expression of IL-10 (IL-10 RQ) was positively
correlated (P≤0.05) with serum folate, selenium, C20:2n6c, C20:4n6c, C22:5n3c, and
C24:1n9c and negatively correlated (P≤0.05) with iron, C16, and C18:1n9c (Table 3.2).
Folate and C22:5n3c were still positively associated (P≤0.05) with IL-10 RQ after
adjusting for age (Table 3.2). Interleukin-1β RQ was negatively correlated (P≤0.05) with
zinc (Table 3.2). After adjusting the model for age, zinc remained negatively associated
with IL-1β RQ, and fatty acid C16 became positively associated with IL-1β RQ (P≤0.05)
(Table 3.2). Interleukin-6 RQ exhibited a positive correlation with fatty acids C18,
C18:3n3c, and C22:5n3c and showed a negative correlation with C16. Upon including age
in the model, C16:1n7c, C18, C18:3n3c, and C22:5n3c were positively correlated with IL6, while C18:1n9c exhibited a negative correlation with IL-6 (P≤0.05) (Table 3.2). Tumor
necrosis factor-α RQ was positively correlated (P≤0.05) with folate, selenium, C20:2n6c,
C22:2n6c, C22:4n6c, and C22:5n3c; upon including age in the model, all of these
correlations remained significant except with selenium and C22:4n6c (P>0.05).
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Serum inflammatory proteins also correlated with some vitamins, minerals, and
fatty acids. Specifically, Serum CRP exhibited a directly proportional relationship (P≤0.05)
with copper and an inverse relationship (P≤0.05) with vitamin B12 and selenium; after
adjusting for age, copper and vitamin B12 retained significant relationships with CRP
(P≤0.05). IL-6 exhibited a directly proportional relationship (P≤0.05) with folate,
C16:1n7c, C18:3n6c, C20:1n9c, and C22:3n3c, with all relationships remaining significant
(P≤0.05) after adjusting for age, as well as C22:2n6c and C20:3n3c become positively and
negatively correlated (P≤0.05) with serum IL-6, respectively.
In summary, C22:2n6c, C22:5n3c, and folate particularly stood out as being
positively associated with markers of inflammation after taking age into account as a
covariate. Docosadienoic acid (C22:2n6c) exhibited a positive correlation with % IFN-γ,
IFN-γ MFI, % TNF-α, TNF-α MFI, IFN-γ RQ, TNF-α RQ, and serum IL-6.
Docosapentaenoic acid (DPA; C22:5n3c) was positively correlated with % IFN-γ, IFNγ MFI, % TNF-α, IFN-γ RQ, IL-10 RQ, IL-6 RQ, and TNF-α RQ. Folate was also
positively correlated with % TNF-α, TNF-α MFI, IFN-γ RQ, IL-10 RQ, TNF-α RQ, and
serum IL-6. Some other fatty acids were correlated (P≤0.05) with two inflammatory
parameters, including: C20:2n6c with % TNF-α and TNF-α RQ (positive correlation) and
C16:1n7c with IL-6 RQ and serum IL-6 (positive).
3.2. Relationships of Inflammation to Hematological (Complete Blood Count [CBC]) and
Biochemical Parameters
Lymphocyte production of IFN-γ and TNF-α were correlated with various
measures of overall health, as determined by CBC and blood chemistry panel measures.
Specifically, % IFN-γ was positively correlated (P≤0.05) with direct bilirubin, hemoglobin,
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total bilirubin, and WBC counts (Table 3.3). Upon adjusting the model for age, all
parameters remained positively associated with % IFN-γ (P≤0.05) (Table 3.3). Interferonγ MFI exhibited a negative correlation (P≤0.05) with eosinophils; this relationship was
retained when adjusted for age, and mature neutrophils also became negatively correlated
(P≤0.05) with IFN-γ MFI upon age-adjustment (Table 3.3). Interferon-γ MFI exhibited a
positive correlation (P≤0.05) with calcium, lymphocytes, direct bilirubin, and total
bilirubin, which was also retained when adjusted for age for all parameters except calcium
(Table 3.3). Percent TNF-α was positively correlated with direct bilirubin, total bilirubin,
and WBC, while % TNF-α was negatively correlated with eosinophils (P≤0.05) (Table
3.3). After adjusting the model for age, the relationships of % TNF-α with WBC and total
bilirubin as well as between % TNF-α and eosinophils remained significant (P≤0.05)
(Table 3.3). Tumor necrosis factor-α MFI was negatively correlated (P≤0.05) with sodium,
SDH, and SGOT/AST and was positively correlated (P≤0.05) with direct and total
bilirubin. Only the relationships of TNF- α MFI with SGOT/AST and total bilirubin
remained after adjusting for age (P≤0.05) (Table 3.3).
Peripheral blood mononuclear cell gene expression of inflammatory cytokines was
also correlated with various measures examined by CBC and chemistry panel. Interferonγ RQ was positively correlated (P≤0.05) with WBC, direct bilirubin, and total bilirubin,
and was negatively correlated with eosinophils. All relationships except total bilirubin were
retained following age adjustment, and the positive correlation between IFN-γ RQ and
lymphocytes became significant (P≤0.05) (Table 3.3). Interleukin-10 RQ was positively
associated (P≤0.05) with WBC, direct bilirubin, and total bilirubin and was negatively
associated with SDH. Following age adjustment, the relationship of IL-10 RQ with
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eosinophils became significant in addition to the relationship between IL-10 and WBC
remaining significant (P≤0.05). Interleukin-1β RQ was positively associated with mature
neutrophils and negatively associated with CK, hemoglobin, and lymphocytes (P≤0.05);
following age adjustment, all relationships remained significant, as well as the negative
correlation between IL-1β RQ and creatinine becoming significant (P≤0.05). Interleukin-6
RQ was positively correlated (P≤0.05) with WBC and lymphocytes and negatively
correlated (P≤0.05) with neutrophils and SDH, with all relationships except WBC (P≤0.05)
being retained following age adjustment. Tumor necrosis factor-α RQ was positively
associated with direct bilirubin and negatively correlated with LDH, SDH, and SGOT/AST
(P≤0.05); only the relationship with SGOT/AST remained significant following ageadjustment (P≤0.05).
Additionally, serum inflammatory proteins exhibited relationships with various
aspects of immune health examined via CBC and chemistry panel. Serum CRP was
positively correlated with SDH and negatively correlated with BUN and creatinine. After
model adjustment for age, relationships with BUN and creatinine remained significant,
with the negative correlation between CRP and SGOT/AST also becoming significant
(P≤0.05) (Table 3.3). Serum IL-6 was negatively correlated (P≤0.05) with alkaline
phosphatase, CK, LDH, and SGOT/AST, and was positively correlated with phosphorus,
neutrophils, and total protein (P≤0.05). All relationships were retained (P≤0.05) following
model adjustment for age, as well as the negative correlation between serum IL-6 and RBC
becoming significant (P≤0.05) (Table 3.3).
In summary, various CBC and chemistry measures were significantly correlated
with inflammation following age-adjustment. Specifically, inflammation was positively
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correlated with total bilirubin (% IFN-γ, IFN-γ MFI, % TNF-α, TNF-α MFI), WBC (%
IFN-γ, % TNF-α, IFN-γ RQ, IL-10), and direct bilirubin (% IFN-γ, IFN-γ MFI, IFN-γ RQ)
(P≤0.05). Inflammation was negatively correlated with eosinophils (IFN-γ MFI, % TNFα, IFN-γ RQ, IL-10), SGOT/AST (TNF-α MFI, CRP, TNF-α RQ, serum IL-6), and CK
(IL-1β & serum IL-6) (P≤0.05). Lymphocytes, neutrophils, and hemoglobin all exhibited
both negative and positive relationships with inflammatory markers, specifically:
lymphocytes (IFN-γ MFI, IFN-γ RQ, IL-6 RQ – positive correlation; IL-1β – negative
correlation), neutrophils (IL-1β RQ, serum IL-6 – positive; IFN-γ MFI, IL-6 RQ –
negative), and hemoglobin (% IFN-γ -positive; IL-1β RQ-negative).
3.3. Relationships of Inflammation to Body Composition Measures
Relationships between inflammation and body composition were also determined.
Serum IL-6 exhibited a directly proportional relationship with body weight both prior to
(R=0.321; p=0.038) and following age-adjustment (R=0.551; P≤0.001). Serum IL-6 also
appeared to be positively correlated with fat free mass as estimated by ultrasound prior to
(R=0.322; p=0.037) and following age-adjustment of the model (R=0.534; P≤0.001);
however, upon taking body weight into the model as a covariate in addition to age, the
association between IL-6 and FFM disappeared (R=0.011; p=0.947). No other measures of
body composition (including average muscle score, BCS, body weight, % body fat via
ultrasound, FFM via ultrasound, and for the subset of n=10 horses % body fat via D2O and
FFM via D2O) exhibited relationships (P>0.05) with the inflammatory measures examined.
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3.4. Relationships of PPID to Inflammation, Vitamins, Minerals, Fatty Acids,
Hematological, Biochemical, and Body Composition Measures
The presence or absence of the endocrinopathy PPID was associated with various
vitamin, mineral, fatty acid, CBC, chemistry panel, and body composition parameters
examined. Pituitary pars intermedia dysfunction status was positively associated (P≤0.05)
with basal ACTH and folate and was negatively associated with vitamin B12 (Table 3.4).
Adjusting the model for age yielded directly proportional relationships (P≤0.05) between
PPID status and basal ACTH, serum CRP, and eosinophils (Table 3.4). After adjusting for
age, PPID status was also negatively correlated (P≤0.05) with RBC, creatinine, vitamin
B12, and fatty acid C20:4n6c (Table 3.4).
Basal ACTH, a known indicator of pituitary function, also exhibited some
relationships with the various parameters examined. Basal ACTH was negatively
correlated (P≤0.05) with vitamin B12. When age adjustment was taken into account, basal
ACTH exhibited a significant positive correlation with fatty acid C16, while exhibiting a
significant negative correlation with direct bilirubin (P≤0.05) (Table 3.4).
3.5. Relationships of Age to Inflammation, Vitamins, Minerals, Fatty Acids, Complete
Blood Count, Chemistry Panel, Body Composition, and PPID Measures
Even within this population of senior horses, age was associated with various
vitamin, mineral, fatty acid, hematological, biochemical, body composition, and PPID
parameters. Among the inflammatory parameters, age was positively correlated with the
percent of lymphocytes producing IFN-γ and TNF-α, as well as with gene expression of
IFN-γ, IL-10, and TNF-α (P≤0.05) (Table 3.5). Vitamin E, selenium, and fatty acids
C18:2n6c, C20:4n6c, and C24:1n9c also exhibited positive correlations with age, while
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fatty acids C16, C16:1n7c, C18:1n7c, C18:1n9c, and C20:1n9c exhibited negative
correlations with age (P≤0.05) (Table 3.5). Among CBC and chemistry panel parameters,
only SDH was inversely proportional to age (P≤0.05) (Table 3.5). Various measures of
body composition exhibited negative correlations with age including BCS, body weight,
FFM as estimated by ultrasound, and muscle score (P≤0.05) (Table 3.5). And within this
group of old horses, both PPID status and basal ACTH were directly proportional to age
(P≤0.05) (Table 3.5).
3.6. Comparison of D2O Methods with Ultrasound and Muscle Scoring in Determining
Body Composition
When examining D2O methods vs. ultrasound for the subset of 10 horses with age
and body weight as covariates, results generally showed poor correlation (P>0.05) (Table
3.6). However, FFM measurements via D2O and muscle score were strongly correlated
(R=0.895; p=0.001) (Table 3.6).
Discussion
The occurrence of inflamm-aging in senior horses has been well-established
(Adams et al., 2008; Adams et al., 2009). However, what remains to be determined are the
implications of inflamm-aging on the overall health of the horse and how markers of
inflamm-aging may be related to other parameters associated with nutritional status, health,
and wellbeing. It was expected that inflamm-aging would be inversely associated with
muscle measures and known anti-inflammatory nutrients, while specific markers of
inflammation would be differentially associated with PPID status due to cytokine
dysregulation. Thus, an old horse population was examined to determine whether various
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vitamin, mineral, fatty acid, hematological, biochemical, body composition, and PPID
parameters showed any significant associations with certain inflammatory measures.
In this study docosadienoic acid (C22:2n6c), docosapentaenoic acid (DPA;
C22:5n3c), and folate were all positively associated with numerous inflammatory
parameters. Docosadienoic acid has exhibited antioxidant activity in previous in vitro
research, exhibiting some of the highest cyclooxygenase enzyme inhibition among the
numerous fatty acids examined (Henry et al., 2002). The results showing that C22:2n6c
then is positively associated with inflammation is somewhat surprising, given that
oxidative stress and inflammation frequently occur together; however, little research on
C22:2n6c has been conducted thus far. Docosapentaenoic acid was also positively
associated with various inflammatory markers despite being an omega-3 fatty acid, which
are generally considered to be anti-inflammatory. In a study examining metabolic
syndrome in obese adolescents, changes in DPA specifically were positively associated
with changes in anti-inflammatory adiponectin and were negatively associated with proinflammatory leptin and leptin/adiponectin ratio, indicating that DPA tends to be associated
with an anti-inflammatory status (Masquio et al., 2016). A recent human study of ulcerative
colitis (a type of inflammatory bowel disease), showed an interesting caveat in that serum
DPA concentrations were higher in patients with pro-inflammatory ulcerative colitis
compared to healthy controls, although the opposite relationship was found at the tissue
level (Wiese et al., 2016). Similarly to these studies involving other inflammatory
conditions, inflamm-aging appears to be associated with altered fatty acid metabolism.
Additionally, in this study, markers of inflammation were positively associated with folate
concentrations, although some previous studies have suggested folate to have anti-
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inflammatory properties (Chen et al., 2016; Cianciulli et al., 2016), whereas other studies
have found no association (Cao et al., 2016). One possible explanation for these perhaps
unexpected associations between markers of inflammation and (anti-inflammatory) folate
and fatty acid concentrations is that these anti-inflammatory compounds have been released
from tissues into the bloodstream in an effort to moderate the elevated systemic
inflammation inherent with inflamm-aging, i.e. a compensatory effect.
Some hematological and biochemical parameters were also associated with
markers of inflammation in this study. Specifically direct bilirubin, total bilirubin, and
WBC were positively associated with various inflammatory parameters, while
SGOT/AST, eosinophils, and CK were negatively associated with inflammatory
parameters. The positive correlations between bilirubin and inflammation are somewhat
expected, as some studies have shown bilirubin to be associated with neuro-inflammation
(Liu et al., 2016a; Qaisiya et al., 2016). However in a rodent model examining inflammaging specifically, mild hyperbilirubinemia was suggested to be protective against
inflamm-aging (Zelenka et al., 2016), and another study found a negative association
between serum bilirubin and the number of pro-inflammatory CD8+ T cells (Moreno-Otero
et al., 1994). SGOT/AST has also previously been associated with inflammation (Tiwari
et al., 2016), with experimentally-induced reductions in inflammation likewise being
associated with decreases in SGOT/AST (Seif El-Din et al., 2016), which is in contrast to
the negative correlation between SGOT/AST and inflammation found in this study. The
relationship of inflammation to liver disease as a whole is complex in that increasing age
and inflamm-aging in humans have been associated with an increased prevalence of liver
disease; however, in the very elderly (>70 years), the incidence of liver disease is very low
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(Sheedfar et al., 2013). The complexity of the relationship between liver disease and
inflammation may to some degree explain these seemingly contradictory results for
bilirubin and SGOT/AST in relation to inflammation. Furthermore, SGOT/AST is not a
specific biomarker for liver damage, as it can also reflect muscle (and other soft tissue)
damage, which may further explain the inconclusiveness of these results. Creatine kinase
(CK), a common biomarker of muscle damage, exhibited an inverse relationship with
inflammation as well. This was somewhat surprising, considering myositis and myopathies
are generally associated with inflammation. However, studies have also shown decreased
levels of CK in association with several inflammatory rheumatic diseases as well as with
inflammatory bowel disease tissue (Kitzenberg et al., 2016; Lee et al., 2000; Sanmarti et
al., 1996), supporting the results of the current study. Furthermore, CK and SGOT/AST
values were greater than the reference range for over half of the horses sampled, suggesting
that old horses may exhibit elevated levels of the muscle damage biomarkers, potentially
due to sarcopenia. White blood cell counts being positively correlated with inflammation
is well-documented. Eosinophils (percentage of WBC count) being negatively correlated
with inflammation is not surprising given that elevated levels of eosinophils, which are
associated with parasitic infections, elicit a TH-2 immune response that could be decreasing
the inflammatory response associated with aging. However, the horses had been dewormed
within a month prior to the study.
Body composition parameters showed few correlations with the systemic
inflammatory markers examined. This was somewhat unexpected, given the association of
both inflamm-aging and sarcopenia with aging. And no relationships between
inflammation and muscle measurements remained after adjusting for age, and in the case
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of FFM estimated by ultrasound, adjusting for body weight as well. This indicates that
some other aspect of the aging process may be contributing to sarcopenia aside from
systemic inflamm-aging; however, if investigated in a population of both old and young
horses, a relationship between inflamm-aging and sarcopenia may become apparent.
Muscle composition as determined by D2O analysis (for n=10 horses) did not
exhibit strong correlations when compared to ultrasound methods after modeling with body
weight and age as covariates. This may give further reasons for the general lack of
relationships between inflammation and body composition parameters discussed
previously for the n=42 horses. However, the strong positive correlation between D2O
analysis and muscle scoring even after taking body weight and age into account suggests
muscle scoring as a valuable method of muscle assessment.
PPID measures, including basal ACTH and PPID status as defined by TRH testing,
were also associated with some of the various parameters analyzed in this study. Notably,
vitamin B12 exhibited a negative correlation with PPID status regardless of including age
as a covariate and also exhibited a negative correlation with basal ACTH. Vitamin B12 is
key to proper functioning of the brain and nervous system, with case studies showing
improvements in nervous system function after treatment with B12 for those deficient in
this vitamin (Kumar, 2004; Shyambabu et al., 2008). A recent human study has shown
vitamin B12 to be negatively associated with inflammation (Al-Daghri et al., 2016),
similarly to the current study in which vitamin B12 was negatively correlated with CRP.
Studies have also found that B12 deficiencies may be associated with Parkinson’s disease
(Orozco-Barrios et al., 2009) and with increased risk for white matter hyperintensities (de
van der Schueren et al., 2016), a predictor of Alzheimer’s disease (Provenzano et al., 2013).
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Human patients with active Cushing’s disease have exhibited decreased levels of vitamin
B12, while recovered patients did not, suggesting a role of vitamin B12 in disease state
(Faggiano et al., 2005). In the present study, vitamin B12 levels for all horses were within
the normal range except for two horses that exceeded normal range; thus the horses did not
appear to be deficient in this nutrient. However, the results of the present study showing a
negative relationship of PPID (or equine Cushing’s disease) with vitamin B12 support
those previously published in the human with Cushing’s disease (Faggiano et al., 2005).
Eosinophils were also positively correlated with PPID status, which is not surprising due
to the fact that PPID horses exhibit higher levels of IL-8 (McFarlane and Holbrook, 2008),
a chemoattractant of eosinophils (Erger and Casale, 1995). Furthermore, PPID horses tend
to have higher fecal egg counts than do similarly aged healthy horses, which may also
account for the higher percentage of eosinophils in PPID horses (McFarlane et al., 2010).
Age itself was examined in relation to the various parameters to determine where
it might have the strongest associations. The modeling for other parameters incorporated
age as a covariate due to: 1) the number of relationships it appeared to impact and 2) the
fact that inflammation was the primary focus of this study within a group of senior horses,
and it was not desired to have the potentially confounding variable of age as a component
of inflamm-aging. It is known that the body undergoes various changes when entering
senior years, which may have effects on numerous variables. However, to better understand
the process of aging in the senior horse, relationships between age and the various
parameters were determined. When examining the various inflammatory measures, many
parameters were positively correlated with age as expected, based on previous studies
regarding inflamm-aging in the horse and other species (Adams et al., 2008; Franceschi et
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al., 2007). Numerous fatty acids being negatively correlated with age was also
unsurprising, as these results are similar to those found in humans (Ferrucci et al., 2006).
The positive correlation between age and both vitamin E and selenium may suggest either
a protective effect in which horses with higher levels of vitamin E and selenium tend to
live longer, or an inability of senescent cells to uptake these nutrients, thereby leaving them
sequestered in circulation. A recent mouse model publication found that selenium
deficiency was associated with longevity, despite having decreased healthspan (delayed
wound healing as well as earlier onset of age-associated decreased glucose tolerance,
decreased insulin sensitivity, and osteoporosis, etc.) (Wu et al., 2016). This demonstrates
that the relationship between age and selenium may be rather complex. Numerous body
composition parameters including muscle measures were negatively correlated with age as
expected, since horses experience sarcopenia. PPID measures (including basal ACTH and
PPID status, as defined by TRH testing) were also associated with increased age, which is
expected, as PPID is generally an endocrinopathy of the senior horse (McFarlane, 2011),
and presumably would become more common with increasing age.
This exploratory study demonstrates the various complex relationships between
inflammatory parameters and various vitamin, mineral, fatty acid, hematological,
biochemical, body composition, and PPID parameters in senior horses. Further study of
the various relationships determined, particularly the relationship of inflammatory markers
with fatty acids and folate as well as the relationship of PPID status with vitamin B12 and
eosinophils, will aid understanding of the process of aging in the horse, with the goal of
promoting longevity and healthspan.
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Table 3.1. Nutrient composition (DM basis) of feed and hay1
Component
DM, %
DE, Mcal/kg
CP, %
ADF, %
NDF, %
Ca, %
P, %
Mg, %
K, %
Na, %
Fe, ppm
Zn, ppm
Cu, ppm
Mn, ppm
1

Oats
92
3.34
12.6
11.1
24.7
0.13
0.4
0.14
0.53
0.028
91
35
9
49

Alfalfa
Pellets
90.8
3.01
13.6
21.6
37.3
0.82
0.59
0.33
1.13
0.206
313
128
56
128

Grass
Hay
92.6
1.94
14.7
43.8
66.1
0.54
0.42
0.29
1.46
0.078
265
36
11
115

Analyzed by Equi-Analytical Laboratories (Ithaca, NY).
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Table 3.2. Comparisons of various inflammatory measures to serum levels of vitamins,
minerals, and fatty acids1,2

Ln(IFN-γ RQ)

TNF-α
MFI

% TNF-α

IFN-γ MFI

% IFN-γ

Inflammatory
Parameter

Comparison
Parameter
C16:0
C18:1n9c
C20:2n6c
C20:4n6c
C22:2n6c
C22:5n3c
C24:1n9c
Folate
Iron
Selenium
C16:0
C20:2n6c
C20:4n6c
C22:2n6c
C22:5n3c
C24:1n9c
Folate
Selenium
Zinc
C16:0
C18:1n9c
C20:2n6c
C22:2n6c
C22:5n3c
C24:1n9c
Folate
Selenium
C16:0
C22:2n6c
Folate
C16:0
C18:1n9c
C20:4n6c
C22:2n6c
C22:5n3c
Folate

Pearson correlations
Correlation
p-value
Coefficient
-0.343
0.028†
-0.327
0.048†
0.333
0.031†
0.380
0.013†
0.335
0.030†
0.405
0.009†
0.364
0.019†
0.309
0.047†
-0.351
0.023†
0.386
0.013†
-0.361
0.020†
0.320
0.039†
0.345
0.025†
0.286
0.066
0.405
0.009†
0.338
0.031†
0.347
0.024†
0.362
0.020†
0.244
0.135
-0.432
0.005†
-0.390
0.017†
0.368
0.016†
0.362
0.018†
0.458
0.003†
0.342
0.028†
0.398
0.009†
0.339
0.030†
-0.330
0.038†
0.366
0.019†
0.410
0.008†
-0.377
0.015†
-0.381
0.020†
0.313
0.044†
0.257
0.101
0.455
0.003†
0.404
0.008†
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Age-adjusted
Correlation
p-value
Coefficient
-0.177
0.275
-0.225
0.186
0.276
0.081
0.276
0.081
0.407
0.008*
0.357
0.024*
0.216
0.181
0.222
0.164
-0.281
0.075
0.263
0.101
-0.256
0.111
0.277
0.080
0.272
0.085
0.349
0.025*
0.369
0.019*
0.226
0.160
0.290
0.066
0.277
0.083
0.316
0.050*
-0.269
0.093
-0.252
0.138
0.310
0.048*
0.445
0.004*
0.412
0.008*
0.151
0.354
0.313
0.046*
0.182
0.262
-0.214
0.191
0.459
0.003*
0.357
0.024*
-0.210
0.194
-0.255
0.133
0.182
0.254
0.331
0.035*
0.409
0.009*
0.322
0.040*

Table 3.2. (cont.) Comparisons of various inflammatory measures to serum levels of
vitamins, minerals, and fatty acids1,2
Pearson correlations
Age-adjusted
Correlation
Correlation
p-value
p-value
Coefficient
Coefficient
-0.312
-0.120
0.461
C16:0
0.047†
†
-0.386
-0.250
0.142
C18:1n9c
0.018
0.339
0.277
0.080
C20:2n6c
0.028†
†
0.322
0.189
0.236
C20:4n6c
0.038
†
0.417
0.366
0.020*
C22:5n3c
0.007
0.320
0.136
0.404
C24:1n9c
0.041†
†
0.460
0.384
0.013*
Folate
0.002
-0.305
-0.219
0.168
Iron
0.050†
†
0.365
0.215
0.183
Selenium
0.019
0.258
0.118
0.327
0.048*
C16:0
-0.354
-0.352
0.035*
Zinc
0.031†
-0.311
-0.212
0.189
C16:0
0.048†
0.241
0.150
0.354
0.034*
C16:1n7c
0.364
0.333
0.033*
C18:0
0.018†
†
-0.484
-0.421
0.011*
C18:1n9c
0.002
0.300
0.060
0.356
0.026*
C18:3n3c
†
0.455
0.421
0.007*
C22:5n3c
0.003
0.407
0.363
0.020*
C20:2n6c
0.008†
†
0.468
0.537
<0.001*
C22:2n6c
0.002
0.335
0.305
0.056
C22:4n6c
0.032†
†
0.370
0.324
0.042*
C22:5n3c
0.017
†
0.401
0.336
0.032*
Folate
0.008
†
0.356
0.245
0.128
Selenium
0.023
†
0.417
0.368
0.018*
Copper
0.006
-0.338
-0.249
0.121
Selenium
0.031†
†
-0.321
-0.374
0.016*
Vitamin B12
0.038
0.342
0.465
0.004*
C16:1n7c
0.038†
†
0.339
0.354
0.023*
C18:3n6c
0.028
†
0.361
0.479
0.002*
C20:1n9c
0.020
-0.222
0.164
-0.315
0.048*
C20:3n3c
0.289
0.063
0.318
0.043*
C22:2n6c
†
0.329
0.334
0.035*
C22:3n3c
0.036
0.351
0.316
0.044*
Folate
0.023†
1
†
A cross ( ) is used to denoted P≤0.05 for Pearson correlations. An asterisk (*) is used to denote
P≤0.05 for age-adjusted models.
2
Spearman correlations and age-adjusted non-parametric analysis were performed for C22:2n6c
and IL-6 ELISA due to non-normal distribution.
3
IFN-γ = interferon-γ; % gated = percent of lymphocytes producing the cytokine; MFI = mean
fluorescence intensity; TNF-α = tumor necrosis factor-α; IL = interleukin; CRP = C-reactive
protein; ELISA = enzyme-linked immunosorbent assay
Comparison
Parameter

Ln(IL-6 ELISA)

Ln(CRP
Ln(TNF-α RQ)
ELISA)

Ln(IL-6 RQ)

Ln(I
L-1β
RQ)

Ln(IL-10 RQ)

Inflammatory
Parameter
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Comparison
Parameter
D. Bili
Hgb
T. Bili
WBC
Calcium
D. Bili
Eosinophils
Lymphocytes
Seg
T. Bili
D. Bili
Eosinophils
T. Bili
WBC
D. Bili
Sodium
SDH
SGOT/AST
T. Bili
D. Bili
Eosinophils
Lymphocytes
T. Bili
WBC
D. Bili
Eosinophils
SDH
T. Bili
WBC
CK
Creatinine
Hgb
Lymphocytes
Seg
Lymphocytes
SDH
Seg
WBC

Ln(IL-6
RQ)

Ln(IL-1β RQ) Ln(IL-10 RQ) Ln(IFN-γ RQ) TNF-α MFI

% TNF-α

IFN-γ MFI

Inflammatory
Parameter
% IFN-γ

Table 3.3. Comparisons of various inflammatory measures to complete blood count and
chemistry panel measures1-3
Pearson correlations
Correlation
p-value
Coefficient
0.413
0.006†
0.350
0.025†
0.416
0.007†
0.470
0.002†
0.312
0.050†
0.378
0.014†
-0.419
0.006†
0.377
0.015†
-0.293
0.063
0.408
0.008†
0.372
0.015†
-0.329
0.033†
0.424
0.006†
0.404
0.008†
0.358
0.022†
-0.319
0.042†
-0.374
0.025†
-0.345
0.027†
0.423
0.007†
0.404
0.008†
-0.322
0.038†
0.288
0.068
0.365
0.019†
0.452
0.003†
0.368
0.017†
-0.299
0.054
-0.325
0.050†
0.330
0.035†
0.389
0.011†
-0.362
0.028†
-0.289
0.074
-0.397
0.014†
-0.448
0.004†
0.431
0.006†
0.384
0.013†
-0.401
0.014†
-0.350
0.025†
0.321
0.038†
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Age-adjusted
Correlation
p-value
Coefficient
0.352
0.024*
0.319
0.045*
0.352
0.026*
0.416
0.007*
0.280
0.084
0.330
0.035*
-0.432
0.005*
0.418
0.007*
-0.336
0.034*
0.359
0.023*
0.297
0.059
-0.359
0.021*
0.356
0.024*
0.336
0.032*
0.310
0.052
-0.263
0.101
-0.311
0.069
-0.321
0.043*
0.378
0.018*
0.336
0.032*
-0.348
0.026*
0.365
0.021*
0.292
0.068
0.392
0.011*
0.293
0.063
-0.326
0.038*
-0.181
0.290
0.251
0.119
0.318
0.043*
-0.356
0.033*
-0.337
0.038*
-0.429
0.008*
-0.443
0.005*
0.425
0.008*
0.422
0.007*
-0.344
0.040*
-0.391
0.013*
0.268
0.090

Table 3.3. (cont.) Comparisons of various inflammatory measures to serum levels of
vitamins, minerals, and fatty acids1,2
Inflammatory
Parameter

Comparison
Parameter

Pearson correlations
Correlation
p-value
Coefficient
0.317
0.041†
-0.363
0.018†
-0.387
0.018†
-0.468
0.002†
-0.447
0.003†
-0.505
0.001†
0.331
0.045†
-0.285
0.067
-0.433
0.005†

Age-adjusted
Correlation
p-value
Coefficient
0.254
0.109
-0.307
0.051
-0.291
0.086
-0.446
0.004*
-0.405
0.010*
-0.473
0.002*
0.205
0.230
-0.348
0.026*
-0.449
0.004*

Ln(IL-6 ELISA)

Ln(CRP
ELISA)

Ln(TNF-α
RQ)

D. Bili
LDH
SDH
SGOT/AST
BUN
Creatinine
SDH
SGOT/AST
Alk.
Phosphatase
-0.417
-0.411
0.009*
CK
0.008†
†
-0.426
-0.407
0.008*
LDH
0.005
†
0.311
0.410
0.008*
Phosphorus
0.045
-0.296
0.057
-0.337
0.031*
RBC
†
0.378
0.363
0.021*
Seg
0.015
-0.514
-0.511
0.001*
SGOT/AST
0.001†
†
0.401
0.406
0.008*
Total Protein
0.008
1
Complete blood count analysis by Rood and Riddle Equine Hospital (Lexington, KY).
2
A cross (†) is used to denoted P≤0.05 for Pearson correlations. An asterisk (*) is used to denote
P≤0.05 for age-adjusted models.
3
Spearman correlations and age-adjusted non-parametric analysis were performed for IL-6 ELISA
due to non-normal distribution.
4
IFN-γ = interferon-γ; % = percent of lymphocytes producing the cytokine; MFI = mean
fluorescence intensity; TNF-α = tumor necrosis factor-α; IL = interleukin; CRP = C-reactive
protein; ELISA = enzyme-linked immunosorbent assay; D. Bili = direct bilirubin; Hgb =
hemoglobin; T. Bili = total bilirubin; WBC = white blood cells; Seg = mature neutrophils; SDH =
sorbitol dehydrogenase; CK = creatine kinase; LDH = lactate dehydrogenase; SGOT/AST =
serum glutamic oxaloacetic transaminase/aspartate aminotransferase; BUN = blood urea nitrogen;
Alk. Phosphatase = alkaline phosphatase; RBC = red blood cells.
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Table 3.4. Comparisons of measures of PPID to various inflammatory, vitamin, mineral,
fatty acid, complete blood count, chemistry panel, and body composition measures1-3

Ln(Basal
ACTH)

PPID Status

PPID
Parameter

Comparison
Parameter
RBC
Eosinophils
Creatinine
Ln(CRP ELISA)
Vitamin B12
Folate
C20:4n6c
Ln(Basal
ACTH)

Pearson correlations
Correlation
p-value
Coefficient
-0.205
0.193
0.269
0.084
-0.228
0.146
0.185
0.240
-0.547
<0.001†
0.307
0.048†
-0.078
0.621

Age-adjusted
Correlation
Coefficient
-0.311
0.311
-0.383
0.368
-0.556
0.201
-0.308

p-value
0.048*
0.048*
0.013*
0.018*
<0.001*
0.208
0.050*

0.595

<0.001†

0.482

0.002*

C16:0

0.113

0.486

0.527

0.001*

D. Bili

-0.165

0.304

-0.331

0.037*

-0.300

0.060

Vitamin B12

†

-0.333

0.033

1

Complete blood count analysis by Rood and Riddle Equine Hospital (Lexington, KY).
Pituitary pars intermedia dysfunction (PPID) status is determined by thyrotropin releasing
hormone stimulation, with adrenocorticotropin hormone (ACTH) ≥110 pg/mL being considered
PPID and ACTH<110 pg/mL considered non-PPID.
3
A cross (†) is used to denoted P≤0.05 for Pearson correlations. An asterisk (*) is used to denote
P≤0.05 for age-adjusted models.
4
PPID = Pituitary par intermedia dysfunction; ACTH = adrenocorticotropin hormone; RBC = red
blood cells; CRP = C-reactive protein; ELISA = enzyme-linked immunosorbent assay; D. Bili =
direct bilirubin
2
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Table 3.5. Comparisons of various inflammatory, vitamin, mineral, fatty acid, complete
blood count, chemistry panel, body composition, and PPID measures to age1-3
Pearson correlations with Age
Correlation
p-value
Coefficient
0.382
0.013*
% IFN-γ
0.436
0.004*
% TNF-α
0.423
0.005*
Ln(IFN-γ RQ)
0.434
0.004*
Ln(IL-10 RQ)
0.330
0.033*
Ln(TNF-α RQ)
-0.529
<0.001*
C16:0
-0.332
0.044*
C16:1n7c
-0.410
0.008*
C18:1n7c
-0.501
0.002*
C18:1n9c
0.551
<0.001*
C18:2n6c
-0.372
0.017*
C20:1n9c
0.377
0.014*
C20:4n6c
0.454
0.003*
C24:1n9c
0.438
0.004*
Selenium
0.491
0.001*
Vitamin E
-0.410
0.012*
SDH
-0.454
0.003*
BCS
-0.607
<0.001*
Body weight
-0.602
<0.001*
FFM (ultrasound)
-0.309
0.047*
Muscle Score
0.462
0.002*
PPID Status
0.454
0.003*
Ln(Basal ACTH)
1
Complete blood count analysis by Rood and Riddle Equine Hospital (Lexington, KY).
2
All parameters with P≤0.05 are shown in this table.
3
IFN-γ = interferon-gamma; % = percent of lymphocytes producing the cytokine; TNF-α = tumor
necrosis factor-α; IL = interleukin; SDH = sorbitol dehydrogenase; BCS = body condition
score; FFM = fat free mass; PPID = pituitary pars intermedia dysfunction; ACTH =
adrenocorticotropin hormone
Comparison
Parameter
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Table 3.6. Comparison of deuterium oxide methods of body composition determination
with body composition determinations via ultrasound and muscle scoring1,2

FFM (D2O)

% Body Fat
(ultrasound)

Muscle Score

Body
Composition
Parameter

Pearson correlations adjusted for Age
& Body weight
Comparison Parameter
Correlation
Coefficient

p-value

% Body Fat (ultrasound)

0.035

0.929

% Body Fat (D2O)

-0.529

0.143

FFM (ultrasound)

-0.031

0.937

FFM (D2O)

0.895

0.001*

% Body Fat (D2O)

-0.618

0.076§

FFM (ultrasound)

-0.651

0.057§

FFM (D2O)

0.375

0.321

% Body Fat (ultrasound)

0.375

0.321

% Body Fat (D2O)

-0.683

0.043*

FFM (ultrasound)

-0.124

0.751

1

Correlations with age and body weight as covariates are displayed; correlation p-values
denoted with (*) indicate P≤0.05, while (§) indicate P≤0.10.
2
BCS= body condition score; D2O = deuterium oxide; FFM = fat free mass
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CHAPTER 4
PERIPHERAL BLOOD MONONUCLEAR CELL-MEDIATED INFLAMMAGING AND IMMUNOSENESCENCE OF AGED HORSES WITH VS.
WITHOUT PITUITARY PARS INTERMEDIA DYSFUNCTION (PPID).
Abstract
Pituitary pars intermedia dysfunction (PPID) is an endocrine disorder commonly
affecting senior equids (≥20 years). This endocrine disease results in various clinical signs,
including hypertrichosis and immunosuppression. The senior horse population is also
affected by immune changes associated with advanced age, including immunosenescence
(decreased immune response) and inflamm-aging (low-grade, systemic inflammation).
These age-associated changes occur both systemically and specifically mediated by
peripheral blood mononuclear cells (PBMC). To determine whether the presence of PPID
affects these already immune-compromised senior horses, PBMC-mediated cytokine
expression and production as well as lymphocyte proliferation were compared in agematched PPID and non-PPID horses. It was hypothesized that PPID affects cell-mediated
immunity differentially from the process of aging alone.
Heparanized blood was collected from n=6 PPID (mean age ± SEM = 24.7±0.9
years) and n=6 non-PPID horses (23.3±1.0 years) of mixed breeds and sex. PPID Status
was determined using thyrotropin releasing hormone (TRH) stimulation testing, with
adrenocorticotropin hormone (ACTH) levels <110 pg/mL at 10 minutes post TRH
injection (i.v.) being considered non-PPID horses. Ficoll gradient centrifugation was used
to isolate PBMC from heparinized blood. Intracellular staining for pro-inflammatory
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cytokines and flow cytometry were then performed on cells stimulated with Phorbol 12myristate 13-acetate (PMA; 4 hr, 5% CO2, 37oC) and phytohemagglutinin (PHA; 72 hr,
5% CO2, 37oC). Reverse transcription and real time-polymerase chain reaction (RT-PCR)
were also performed on PMA-stimulated PBMC to determine gene expression of
interleukin(IL)-2, IL-4, IL-6, interferon(IFN)-γ, and tumor necrosis factor(TNF)-α.
Lymphocyte proliferation was also analyzed using flow cytometry for PBMC stained with
carboxyfluorescein succinimidyl ester (CFSE) and stimulated with concanavalin A (96 hr,
5% CO2, 37oC). SigmaPlot version 12.3 was used to perform t-tests between PPID and
non-PPID horses for the various immune measures, with a two-way ANOVA with repeated
measures used to perform lymphocyte proliferation analysis. Data with p<0.05 were
considered significant.
No significant differences between PPID and non-PPID horses were found for any
of the various immune measures including intracellular staining, gene expression, and
lymphocyte proliferation (p>0.05). Therefore, the immunosuppression and increased
susceptibility to infections associated with PPID do not appear to affect lymphocytemediated inflamm-aging or immunosenescence in the senior horse. Further research is
warranted to elucidate the mechanisms underlying PPID in order to better manage and even
prevent PPID in the horse.
Introduction
Pituitary pars intermedia dysfunction (PPID) is an endocrine disease prevalent among
equids, in which 15-30% of the senior horse population is affected (≥20 years) (McFarlane,
2011). This endocrine disease is caused by dopaminergic neurodegeneration of the
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pituitary pars intermedia, leading to elevated levels of circulating adrenocorticotropin
hormone (ACTH), α-melanocyte stimulating hormone (α-MSH), and other peptides
cleaved from the prohormone pro-opiomelanocortin (POMC) (McFarlane, 2011). The
elevated levels of these hormones and peptides are then thought to contribute to the clinical
signs of PPID, although the exact mechanisms remain largely unclear (Hart et al., 2016).
These clinical signs of PPID include: hypertrichosis, polydipsia, polyuria, hyperhidrosis,
muscle atrophy, laminitis, abnormal fat distribution, immunosuppression and opportunistic
infections, behavioral abnormalities, reproductive infertility, and neurologic impairment
(McFarlane, 2011).
Senior horses are also known to exhibit age-related immune changes including:
inflamm-aging (increased low-grade inflammation systemically) and immunosenescence
(decreased immune response) (Adams et al., 2008). Many of these age-related immune
changes occur not only in circulation but also are specifically mediated by peripheral blood
mononuclear cells (PBMC) (Adams et al., 2015; Adams et al., 2008). Given that senior
horses are already immune-compromised, the concurrent presentation of the PPID in these
senior horses may further decrease their ability to respond effectively to pathogens, leading
to the immunosuppression and susceptibility to opportunistic infections characteristic of
the PPID horse.
Furthermore, given the high prevalence of this endocrine disease within the senior
horse population, understanding how the disease affects immunity of the aged horse
already experiencing inflamm-aging and immunosenescence, may improve management
of these immune-compromised horses. According to McFarlane et al. (2015), PPID horses
have exhibited decreased neutrophil function (McFarlane et al., 2015). However, effects of
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PPID on PBMC function have not yet been determined. Thus, whether cell-mediated
immunity differs between age-matched PPID and non-PPID horses was examined,
particularly in relation to PBMC cytokine gene expression, lymphocyte inflammatory
cytokine production, and lymphocyte proliferation. It was hypothesized that PPID affects
cell-mediated immunity differentially from the process of aging alone.
Methods and Materials
2.1. Animals
Six aged, PPID horses (mean age ± SEM = 24.7±0.9 years) and six aged, non-PPID
horses (23.3±1.0 years) of mixed breeds and sex were used in this study. PPID status was
determined by thyrotropin releasing hormone (TRH) stimulation testing, examining ACTH
concentration in EDTA plasma 10 minutes post intravenous injection, with horses with
ACTH levels above 110 pg/mL being considered PPID, as recommended by the Equine
Endocrinology Group (Restifo et al., 2016). The ACTH analysis was performed by Cornell
Animal Health Diagnostic Center, Endocrinology Laboratory using chemiluminescence
immunoassay (Immulite® 1000; Siemens, Berlin, Germany)(Place et al., 2010). All PPID
horses had ACTH responses to TRH stimulation of at least 500 pg/mL during non-fall
testing as well as clinical signs of PPID, an indication these horses had more advanced
stages of PPID. Mean ACTH levels ± SEM were 875.3±127.2 and 61.3±6.9 pg/mL for
PPID and non-PPID horses, respectively. None of the horses in this study had received
treatment for PPID during or within a year prior to sampling. Horses were maintained on
pasture and mixed grass hay at the University of Kentucky, Department of Veterinary
Science Maine Chance Farm. To maintain body weight, all non-PPID and three PPID
horses regularly received a mixture of 50% oats, 50% alfalfa pellets, while the other three
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PPID horses received only hay. Differences in diet were taken into consideration with
statistical analysis below. All procedures were approved by the University of Kentucky
Institute of Animal Care and Usage Committee.
2.2. Sample Collection & Culture Preparation.
All horses were screened using TRH testing in May in order to determine PPID
status using the established ACTH reference range for non-fall months (Restifo et al.,
2016). Four months following endocrine testing, peripheral blood samples were collected
from all horses to evaluate immune measures. Heparinized blood was collected aseptically
by jugular venipuncture to isolate peripheral blood mononuclear cells using a Ficoll-Paque
Plus™ (Amersham Biosciences, Piscataway, NJ) density gradient. A VICELLTM CounterXR (Beckman Coulter, Miami, FL) was used to enable plating of cells at a concentration
of 4x106 and stimulating with phorbol 12-myristate 13-acetate (PMA; 25 ng/mL; Sigma)
and ionomycin (1 μM; Sigma) for 4 hours, 37oC, 5% CO2, prior to intracellular staining
and RNA isolation (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard
et al., 2016).
Cells

used

for

proliferation

analysis

were

fluorescently tagged

with

carboxyfluorescein succinimidyl ester (CFSE), plated at a concentration of 2x106/mL
media, and stimulated with concanavalin A (2.5, 5, and 10 µL) for 96 hours, 37oC, 5%CO2,
as previously described (Adams et al., 2008). The only exception was the use of fetal equine
serum (Biowest, Nuaillé, France) instead of fetal bovine serum (FBS) to quench the CFSE
reaction and for subsequent washes.
PBMC were also frozen in liquid nitrogen in media containing FBS and dimethyl
sulfoxide (DMSO) for later analysis, at which point they were thawed, washed, stimulated
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with phytohemagglutinin (PHA; 50 µg/mL), and incubated for 72 hours, 37oC, 5%CO2 (the
last 4 hr of which, Brefeldin A was added) prior to intracellular staining. The concentration
of PHA used for stimulation was based on titrations performed prior to sample analysis.
2.3. IFN-γ and TNF-α Intracellular Staining
PMA-stimulated PBMC were fixed with 2% paraformaldehyde (Sigma), and
incubated at 4oC overnight prior to intracellular staining. Cells were then treated with
saponin buffer [PBS supplemented with 1% fetal bovine serum, 0.1% saponin (Sigma),
and 0.1% sodium azide (Sigma)] and stained for IFN-γ and TNF-α using IFN-γ FITC
mouse anti-bovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg; 1:100 dilution) or TNFα anti-equine monoclonal antibody (HL801; kindly provided by Dr. Rob MacKay,
University of Florida; 1:10 dilution) and secondary antibody FITC-conjugated goat F(ab’)2
anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL; 1:1000 dilution) respectively, as previously
described (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al.,
2016). PHA-stimulated PBMC were likewise intracellularly stained according to the same
protocol for IFN-γ.
2.4. Flow Cytometry
For PMA-stimulated, intracellularly-stained PBMC, a Becton Dickenson
FASCalibur Flow cytometer and Cell Quest® software were used to determine percent of
lymphocytes producing each cytokine and to determine mean fluorescence intensity
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006; Siard et al., 2016).
For PHA-stimulated, intracellularly-stained PBMC, a flow cytometer (Becton
Dickenson) was also used to determine percent of lymphocytes producing IFN-γ and to
determine IFN-γ MFI.
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For lymphocyte proliferation, a flow cytometer (Becton Dickenson) and ModFit
LT™ 3.0 were used to determine lymphocyte proliferation index, based on generational
divisions (Adams et al., 2008).
2.5. RNA Isolation, Reverse Transcription, and Real-Time Polymerase Chain Reaction
Following the 4 hour stimulation with PMA/ionomycin, PBMC were resuspended
in Trizol® solution and stored at -80oC until RNA isolation. RNA isolation was performed
using a phenol-chloroform extraction (Breathnach et al., 2006). An Epoch microplate
spectrophotometer (BioTek, Winooski, VT) was used to determine amounts of RNA in
each sample, prior to RNA reverse transcription. To perform reverse transcription, a
thermocycler (Applied Biosystems, Foster City, CA) and master mix reagents (16 μL avian
myeloblastosis virus [AMV] buffer 5X, 16 μL MgCl2, 4 μL dNTP, 1 μL RNasin, 1 μL
oligo dT primer, and 0.5 μL AMV reverse transciptase per sample; Promega, Madison,
WI) were used, incubating samples at 42oC for 15 minutes and 95oC for 5 minutes (Adams
et al., 2008; Adams et al., 2009; Breathnach et al., 2006). Following reverse transcription,
samples were stored at -20oC. Real-time polymerase chain reaction was then performed,
implementing use of an epMotion 5070 (Eppendorf) to automatically aliquot cDNA
samples and 5 equine specific intron-spanning primers and probes, in addition to using the
7900HT Fast RT-PCR System (Applied Biosystems), which incubated samples for 10 min
at 95oC, followed by 40 cycles of 95oC for 15s and 60oC for 1 min (Adams et al., 2008;
Adams et al., 2009; Breathnach et al., 2006). The primers and probes analyzed included:
IFN-γ, IL-2, IL-4, IL-6, and TNF-α, in addition to Beta-glucuronidase (β-GUS), the
housekeeping gene (Applied Biosystems) (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006). Following linear regression, the ΔΔCT method was used to
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determine relative quantities for each cytokine (RQ = 2

–ΔΔCT

)(Livak and Schmittgen,

2001). The calibrator for each cytokine was the average ΔCT of all the unstimulated
samples (one per horse).
2.5. Statistical Analysis.
Statistical analysis was performed using SigmaPlot version 12.3 (Systat Inc.,
Richmond, CA). T-tests comparing PPID and non-PPID horses were performed to
determine any differences in inflammation due to PPID status. (PHA-stimulated
inflammatory data only included n=5 PPID horses due to one horse having insufficient
cells to stimulate with PHA as well as perform the other assays.) Proliferation data was
analyzed using a two-way ANOVA with repeated measures to determine any differences
between PPID and non-PPID horses at the three different concentrations of concanavalin
A mitogen used to stimulate the PBMC. Bar graphs (mean +/- standard deviation) were
used when comparing PPID and Non-PPID horses for the various parameters. T-tests were
also used to evaluate differences between the n=3 PPID horses receiving feed and n=3
PPID horses not receiving feed. (As there were no differences between fed and non-fed
horses in various parameters, all data for PPID horses were grouped together for analysis
when making comparisons with Non-PPID horses.) All data was normally distributed
according to the Shapiro-Wilk normality test, with some data requiring log-transformation
to achieve normality. Data with p<0.05 were considered statistically significant, while
p<0.10 were considered trends.
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Results
3.1. Inflammatory Cytokine Intracellular Staining
Various comparisons of immune measures mediated by PBMC were compared in
PPID and age-matched non-PPID horses. After examining flow cytometry data for PPID
and non-PPID horses, no significant differences were seen for either PMA or PHAstimulated lymphocytes in regard to the percent of lymphocytes producing inflammatory
IFN-γ (Fig. 4.1A&C) and mean fluorescence intensity (Fig. 4.1B&D) (p>0.05). Likewise,
flow cytometry data for PPID and non-PPID horses did not significantly differ for
percentage of lymphocytes producing pro-inflammatory TNF-α or for TNF-α MFI (Fig.
4.2A&B) (p>0.05).
3.2. Lymphocyte Proliferation
Lymphocyte proliferation also did not show significant differences between PPID
and non-PPID horses (p=0.282); however, a difference in proliferation in relation to
mitogen concentration was present (p<0.001), as expected, with the 2.5 µL concentration
of Con A yielding significantly lower lymphocyte proliferation than the other two
concentrations (Fig. 4.3).
3.3. Real-Time Polymerase Chain Reaction Gene Expression
PCR results also did not display differences between PPID and non-PPID horses
(p>0.05); however, due to the variation associated with PCR data, it is possible that in a
larger data set differences may occur (Fig. 4.4A-E).
3.4. Feeding Status Analysis of PPID Horses
Within the PPID horse group, n=3 horses received feed (50% alfalfa pellets, 50%
oats) regularly while n=3 horses were fed hay alone, in order to maintain body weight. T-
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tests were run between fed horses and those that did not receive feed, and again, no
significant differences were found. This may be in part due to the sample size; however, in
order to sample a group of healthy horses with naturally occurring signs of PPID and TRH
stimulation testing results to support advanced PPID status, sample size was limited. And,
in order not to change their diets for the purposes of this study, which may elicit changes
in immune parameters, horses were sampled while continuing maintenance diets.
Discussion
The PPID horse is known to experience immunosuppression and increased
susceptibility to opportunistic infections as one of the clinical manifestations of this
endocrinopathy. Despite the reported increases in bacterial infections, such as
dermatophilosis, pneumonia, and abscesses found in PPID horses (McFarlane, 2011), few
studies have been performed to determine the specific mediators for these deficiencies in
immunity. Furthermore, senior horses (the demographic in which PPID primarily occurs)
exhibit inflamm-aging and immunosenescence, which are specifically mediated by PBMC
as well as occurring systemically (Adams et al., 2008). Thus, PBMC were examined as a
potential source of immunosuppression in the PPID, aged horse.
In this study, no differences were observed in any of the immune parameters
analyzed in which PBMC were specifically examined regarding: intracellular staining,
cytokine gene expression, and proliferation. Thus, the cell-mediated responses of adaptive
immunity do not seem to be affected by PPID status of the horse. Although PPID has been
associated with immunosuppression, it appears this compromise of immunity is not
mediated by PBMC. Some work has shown total leukocyte cytokine dysregulation in PPID
horses (McFarlane and Holbrook, 2008) as well as evidence that neutrophils contribute to
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the effects of PPID on immune function of the aged horse (McFarlane et al., 2015).
Specifically, neutrophils from aged, PPID horses have exhibited decreased oxidative burst
activity and decreased adhesion, which may contribute to immunosuppression (McFarlane
et al., 2015).
Of note, PMA-stimulated neutrophils from PPID and control horses did not
significantly differ in the McFarlane et al, 2015 study, although neutrophils that were
unstimulated or stimulated submaximally exhibited significantly decreased adhesion in
PPID horses compared to non-PPID horses (McFarlane et al., 2015). In the current study,
using an optimal dose of PHA to stimulate PBMC also does not identify significant
differences between PPID and non-PPID horses in flow cytometry measures of either
percentage of lymphocytes producing IFN-γ or IFN-γ MFI. Additionally, the proliferation
assay was performed using concanavalin A at various concentrations, and likewise no
significant differences were found between PPID and non-PPID horses regarding
lymphocyte proliferation. Therefore, the lack of significant differences between PPID and
non-PPID horses in relation to lymphocyte function is likely not a matter of the type of
mitogen.
Some of the peptides produced by cleavage of POMC have established
immunomodulatory effects, which may help compose a neuro-endocrine-immune axis
(Bohm and Luger, 2004; Brazzini et al., 2003). Alpha-MSH particularly has long been
established as a potent anti-inflammatory, anti-oxidant agent (Bhardwaj et al., 1996;
Catania et al., 1999; Luger and Brzoska, 2007; Oktar et al., 2004). Mechanistically, α-MSH
downregulates nuclear factor (NF)-κβ activity stimulated by lipopolysaccharide (LPS)
(Luger et al., 2000). Furthermore, this hormone has specifically exhibited anti-
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inflammatory effects on PBMC in humans through increasing IL-10 gene expression and
protein production; however monocytes, not T lymphocytes, were responsible for the antiinflammatory response elicited by the addition of α-MSH (Bhardwaj et al., 1996). Since
only the PCR data in the current study included monocytes as well as lymphocytes, this
may in part explain the lack of differences between PPID and non-PPID horses. In regards
to PCR data, as mentioned previously, no significant differences were found for PPID vs.
non-PPID; however, due to the variability of PCR data, some differences may become
significant if the sample size were increased. Studies examining monocytes in the PPID
horse specifically have not yet been performed to determine whether the increased levels
of α-MSH in the PPID horse may yield monocyte-mediated anti-inflammatory effects
similar to studies examining human monocytes (Bhardwaj et al., 1996; Catania et al., 1999;
Yang et al., 2015). In addition to direct anti-inflammatory effects of α-MSH alone,
McFarlane et al. (2015) found that in horses the ratio of insulin to α-MSH was positively
correlated with oxidative burst activity (McFarlane et al., 2015), indicating that a
relationship of relative hormone amounts may influence immunity of the PPID horse.
ACTH, the other key hormone cleaved from POMC, has been positively associated with
IL-6 expression in septic foals (Gold et al., 2012); however the relationship between ACTH
and inflammation has not been clearly established. Additionally, much of the circulating
ACTH is thought to be biologically inactive due to the fact that PPID horses do not appear
to exhibit elevated cortisol levels despite their increased levels of ACTH (McFarlane et al.,
2015).
Still, more research is needed regarding the pathogenesis of PPID and its effects on
the immune system, particularly how this endocrinopathy is associated with
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immunosuppression and susceptibility to opportunistic infections in the aged horse.
Furthermore, it is not yet understood what causes the dopaminergic neurodegeneration of
the pituitary pars intermedia. A variety of factors including oxidative stress, infectious
disease, nutritional deficiencies, or even inflammation may play a role in the development
of this endocrine dysfunction, but clearly more research is warranted.
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Figure 4.1. Lymphocyte production of IFN-γ in vitro for PPID vs. Non-PPID horses.
Percentage of PMA-stimulated lymphocytes (A) producing IFN-γ and (B) mean
fluorescence intensity of IFN-γ for n=6 PPID and n=6 age-matched non-PPID horses.
Percentage of PHA-stimulated lymphocytes (C) producing IFN-γ and (D) mean
fluorescence intensity of IFN-γ for n=5 PPID and n=6 age-matched non-PPID horse.
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Figure 4.2. Lymphocyte production of TNF-α in vitro for PPID vs. Non-PPID horses.
Percentage of lymphocytes (A) producing TNF-α and (B) mean fluorescence intensity of
TNF-α for n=6 PPID and n=6 age-matched non-PPID horses.
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blood mononuclear cells (PBMC) from n=6 PPID and n=6 age-matched Non-PPID horses
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CHAPTER 5
EFFECTS OF POLYPHENOLS INCLUDING CURCUMINOIDS,
RESVERATROL, QUERCETIN, PTEROSTILBENE, AND
HYDROXYPTEROSTILBENE ON LYMPHOCYTE PRO-INFLAMMATORY
CYTOKINE PRODUCTION OF SENIOR HORSES IN VITRO
Veterinary Immunology and Immunopathology, 2016: 173, 50-59

Abstract
Senior horses (aged ≥20 years) exhibit increased chronic, low-grade inflammation
systemically, termed inflamm-aging. Inflammation is associated with many afflictions
common to the horse, including laminitis and osteoarthritis, which are commonly treated
with the non-steroidal anti-inflammatory drugs (NSAIDs) flunixin meglumine and
phenylbutazone. Although these NSAIDs are effective in treating acute inflammatory
problems, long-term treatment with NSAIDs can result in negative side effects. Thus,
bioactive polyphenols including curcuminoids, resveratrol, quercetin, pterostilbene, and
hydroxypterostilbene were investigated to determine their effectiveness as antiinflammatory agents in vitro. Heparinized blood was collected via jugular venipuncture
from senior horses (n=6; mean age=26 ± 2 years), and peripheral blood mononuclear cells
(PBMC) were isolated using a Ficoll density gradient. PBMC were then incubated 22 hours
at 37oC, 5% CO2 with multiple concentrations (320, 160, 80, 40, 20, 10 µM) of all five
polyphenols

(curcuminoids,

resveratrol,

quercetin,

pterostilbene,

and

hydroxypterostilbene), dissolved in DMSO to achieve the aforementioned concentrations.
PBMC were stimulated the last 4 hours of the incubation period with phorbol 12-myristate
13-acetate (PMA)/ionomycin and Brefeldin A (BFA). A Vicell-XR counter evaluated cell
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viability following incubation. PBMC were stained intracellularly for interferon gamma
(IFN-γ) and tumor necrosis factor alpha (TNF-α) and analyzed via flow cytometry. Data
was analyzed by one-way analysis of variance (ANOVA). Viability of PBMC incubated
with various compound concentrations were compared with PBMC incubated with DMSO
alone (positive control) to determine at what concentration each compound caused
cytotoxicity. The highest concentration at which cell viability did not significantly differ
from the positive control was: 20 µM for curcuminoids, 40 µM for hydroxypterostilbene,
80 µM for pterostilbene, and 160 µM for quercetin and resveratrol. Flunixin meglumine
and phenylbutazone were then evaluated within this range of optimal concentrations for
the polyphenol compounds (160, 80, 40, 20 µM) to compare the polyphenols to NSAIDs
at equivalent concentrations. The highest concentration at which viability did not
significantly differ from the positive control was: 40 µM for flunixin meglumine and 160
µM for phenylbutazone. All five polyphenols and flunixin meglumine significantly
decreased lymphocyte production of IFN-γ, while only hydroxypterostilbene,
pterostilbene, quercetin, and resveratrol significantly reduced lymphocyte production of
TNF-α compared to the positive control (p<0.05). Polyphenols performed similarly to or
more effectively than common NSAIDs in reducing lymphocyte production of
inflammatory cytokines of the senior horse in vitro. This study therefore supports the
further investigation of polyphenols to determine whether they may be effective antiinflammatory treatments for chronic inflammation in the horse.
Introduction
The senior horse population is growing globally, with horses 20 years or older
comprising an estimated 7.6% of the population in the United States (USDA., 2006) and
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horses ≥15 years old comprising 29% of the population in the United Kingdom (Ireland et
al., 2011a). In addition to increasing lifespan, healthspan must be taken into account. With
increased age, an increase in inflammation at both the gene expression [interleukin (IL)1β, IL-15, IL-18 and TNF-α] and protein levels [tumor necrosis factor-alpha (TNF-α)] has
been characterized in the horse (Adams et al., 2008; Katepalli et al., 2008). This increased
inflammation with aging indicates that horses, like many other species, exhibit inflammaging or low-grade, chronic inflammation that occurs systemically with aging (Franceschi
et al., 2007). Although clearly established clinical conditions of the horse associated with
inflamm-aging have not yet been discovered, human studies have shown that inflammation
is characterized as a risk factor for developing various diseases and is associated with
increased morbidity and mortality (Freund et al., 2010). Inflamm-aging in the horse
therefore likely has detrimental effects.
In addition to systemic inflamm-aging, many horses develop various chronic
inflammatory conditions over the course of their lives, ranging from laminitis to
osteoarthritis. These conditions are frequently treated with common non-steroidal antiinflammatory drugs (NSAIDs), such as flunixin meglumine and phenylbutazone. NSAIDs
are quite useful for treating acute inflammatory conditions; however, long-term use can
result in various harmful side effects, such as stomach ulcers, gastric oxidative stress,
hypoalbuminemia, neutropenia, liver damage, and kidney damage (Bessone, 2010;
Ingrasciotta et al., 2015; Martinez Aranzales et al., 2015; McConnico et al., 2008; Monreal
et al., 2004; Reed et al., 2006). Thus, various anti-inflammatory polyphenols including
curcuminoids, resveratrol, quercetin, pterostilbene, and hydroxypterostilbene were
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investigated to determine their effects on inflammation of the senior horse in vitro as an
alternative to the use of NSAIDs in treating chronic inflammation.
Polyphenol compounds have been shown to exhibit anti-inflammatory properties
in various capacities both in vitro and in vivo, including decreasing peripheral blood
mononuclear cell (PBMC) inflammatory gene expression, as reviewed by Afman et al.
(Afman et al., 2014). Furthermore, the polyphenolic compound curcumin has decreased
PBMC production of pro-inflammatory IL-8 (Literat et al., 2001). Curcumin has
traditionally been used in Asia since ancient times to treat various maladies including many
inflammatory conditions (Jeenger et al., 2015); moreover, this polyphenol has recently
gained popularity in research and the health market, for its various anti-inflammatory,
antioxidant, anti-tumorigenic properties (Franck et al., 2008; Schaaf et al., 2009;
Venkatesan and Chandrakasan, 1995). Curcumin is derived from the root of Curcuma
longa, and comprises 77% of the curcuminoids found in turmeric, making curcumin the
primary curcuminoid (Kumar et al., 2010). Resveratrol is a phytoalexin found most notably
in red wine, which has shown anti-inflammatory activities both dependent and
independently of NF-κB activation (a key transcription factor in pro-inflammatory
cytokine expression) (Birrell et al., 2005; Kumar and Sharma, 2010; Samsami-Kor et al.,
2015). Moreover, resveratrol supplementation has decreased NF-kB activity in PBMC as
well as decreasing pro-inflammatory high sensitivity C-reactive protein (hs-CRP) and
TNF-α in plasma (Samsami-Kor et al., 2015). Resveratrol has been found specifically to
act as an antioxidant in equine neutrophils in vitro, as well (Kohnen et al., 2007). Quercetin
is an antioxidant flavonoid found in various plants including teas and onions and has been
shown to decrease inflammation in high-fat diet mice (Das et al., 2013) and high-fructose
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diet rats (Vazquez Prieto et al., 2015). Pterostilbene, an analog of resveratrol and the
primary antioxidant component of blueberries, has demonstrated anti-inflammatory
properties, decreasing inflammation produced by adipocytes as well as decreasing
inflammation produced as a result of myocardial ischemia and reperfusion (Hsu et al.,
2013; Lv et al., 2015; Wang et al., 2015). Hydroxypterostilbene, an analog of pterostilbene
found in the plant Sphaerophysa salsula, has recently been shown to decrease the proinflammatory enzyme COX-2 and to downregulate multiple pro-inflammatory pathways
including PI3K/Akt and MAPK signaling (Cheng et al., 2014). These various polyphenol
compounds possessing anti-inflammatory properties are of interest as alternative antiinflammatory therapies to the traditional long-term use of NSAIDs in treating chronic
inflammatory conditions.
Thus, we hypothesize that polyphenols including curcuminoids, resveratrol,
quercetin, pterostilbene, and hydroxypterostilbene will significantly reduce inflammation
of the senior horse in vitro, similarly to common NSAIDs phenylbutazone and flunixin
meglumine. PBMC will particularly be examined for the following reasons: PBMC have
been shown to contribute to chronic, low-grade inflammation (Adams et al., 2008); are
easily accessible (Literat et al., 2001); and previous research has demonstrated the effects
of polyphenols on PBMC (Afman et al., 2014; Literat et al., 2001; Samsami-Kor et al.,
2015). This study is the first step in determining the ability of polyphenols to decrease
inflammation in the horse in vivo.
Thus far, clearly established clinical conditions of the horse associated with
inflamm-aging have not been discovered. Based on human studies, however, it is
anticipated that decreasing inflamm-aging may be beneficial to healthspan and lifespan.
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Furthermore, the horse exhibiting inflamm-aging was used as a model to determine
whether polyphenols could decrease chronic inflammation of the horse. NSAIDs were used
as a comparison to polyphenols in determining how various anti-inflammatory treatments
(including both nutraceuticals and pharmaceuticals) affected circulating inflammatory
cytokine production by PBMCs in the horse. The use of polyphenols could then potentially
have further implications for the management of chronic inflammatory conditions, such as
osteoarthritis and recurrent laminitis in the horse.
Methods and Materials
2.1. Animals
Six senior horses (mean age = 26 ± 2 years) were used in this study, exhibiting no
clinical abnormalities (eg nasal discharge, cough) upon physical assessment. When
examining basal adrenocorticotropin hormone (ACTH), three of the horses were pituitary
pars intermedia dysfunction (PPID) negative [with plasma levels within normal range (935 pg/mL) as measured by Cornell Animal Health Diagnostic Center, Endocrinology
Laboratory], and three were PPID positive (plasma levels >35 pg/mL) (Place et al., 2010);
however, no significant differences in inflammatory parameters were found between PPID
and non-PPID horses.
2.2. Sample Collection, PBMC Isolation, and Culture Preparation
Heparinized blood was collected via jugular venipuncture from n=6 senior horses,
and PBMCs were isolated using a Ficoll-Paque Plus™ (Amersham Biosciences,
Piscataway, NJ) density gradient and purified with sterile Phosphate Buffered Saline (PBS)
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). A VICELLTM CounterXR (Beckman Coulter, Miami, FL) counted cells and determined cell viability using
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Trypan blue staining prior to plating. PBMCs were plated at a concentration of 4x106
cells/mL with cRPMI media [RPMI 1640 (Gibco, Grand Island, NY) supplemented with
2.5% fetal equine serum (FES; Sigma-Aldrich, St. Louis, MO), 55 μM 2-mercaptoethanol
(Gibco), and 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/mL streptomycin (HyClone
Pen/Strep/Glutamine solution; Thermo Scientific)] (Adams et al., 2008; Adams et al.,
2009; Breathnach et al., 2006).
2.3. Compound Preparation
The day prior to peripheral blood collection, stock solutions (0.16 M) of
polyphenolic compounds [curcuminoids (Natsol Laboratories Pvt. Ltd., Hyderabad, India),
resveratrol (Biological Prospects® LLC, Lexington, KY), pterostilbene (Biological
Prospects® LLC), 3-hydroxypterostilbene (Natsol Laboratories), and quercetin (Natsol
Laboratories)] and NSAIDs [flunixin meglumine (Phoenix Pharmaceuticals, Inc., St.
Joseph, MO; 50 mg/mL injectable solution) and phenylbutazone paste (Phoenix
Pharmaceutical, Inc.; 0.33 g/mL)] were prepared in dimethyl sulfoxide (DMSO; SigmaAldrich). The stock solution for each of the polyphenols and NSAIDS were diluted with
DMSO to make a total of 6 working solutions (such that an addition of 2 μL/mL media
would yield final concentrations of 320, 160, 80, 40, 20, and 10 μM) for each of the
polyphenolic compounds and NSAIDs (Qureshi et al., 2012). The working solutions were
then frozen at -20oC overnight until use the following day.
The compound concentrations were determined based on previous work (Quereschi
et al 2013) in which resveratrol, pterostilbene, and quercetin at concentrations ranging 32010 µM were shown to significantly inhibit macrophage inflammatory cytokine production.
In vivo these optimal concentrations ranging from 20-160 µM would equate to 76.7-614.0
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µM concentration in plasma, (given that the 20-160 µM was for 4x106 PBMC/mL, old
horses tend to have ~2.5x107 PBMC per 15 mL blood, and previous work showing that
horses have 6.33 L plasma/100 kg BW and 10.31 L blood total/100 kg BW (Marcilese et
al., 1964)).
2.4. Cell Viability after Incubation with Compounds
After plating the PBMCs with c-RPMI, DMSO (2 μL/mL media) was added to two
wells per horse to act as controls, while the polyphenol and NSAID stock solutions (2
μL/mL media) were each added to a well to achieve final concentrations of 320, 160, 80,
40, 20, and 10 μM for each compound. PBMCs were incubated with the compounds 22
hours at 37oC, 5% CO2. At 18 hours, Brefeldin A (10 μg/mL; Sigma) was added to all
wells, and all wells except one of the DMSO controls per horse were stimulated with
phorbol 12-myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 μM; Sigma)
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). Cell counts and viability
for each well were then determined using the Vicell Counter-XR to determine whether
cells treated with the various compounds differed from those treated with DMSO and PMA
(positive control). The highest compound concentration at which viability did not differ
from the positive control was determined to be the optimal concentration.
2.5. IFN-γ and TNF-α Intracellular Staining and Flow Cytometry
Following incubation, aliquots (200 μL each) of cells from each well were placed
into duplicate 96-well V-bottom plates. Both plates were centrifuged, resuspended in 2%
paraformaldehyde (Sigma), and stored at 4oC overnight. Cells were then washed in saponin
buffer [PBS supplemented with 1% fetal bovine serum (FBS), 0.1% saponin, and 0.1%
sodium azide (Sigma)] and IFN-γ FITC mouse anti-bovine antibody (AbD Serotec,
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Raleigh, NC; 0.1 mg) was added at a 1:100 dilution in saponin buffer to one plate, while
TNF-α anti-equine monoclonal antibody (HL801; kindly provided by Dr. Rob MacKay,
University of Florida) at a 1:10 dilution in saponin buffer was added to the other plate
(Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006). Both plates were
incubated 30 minutes on ice and washed in saponin buffer. The cells in the IFN-γ –stained
plate were then resuspended in FACS Flow (Becton Dickinson, San Jose, CA), while those
in the TNF-α plate were stained with secondary antibody FITC-conjugated goat F(ab’)2
anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL) at a 1:1000 dilution in saponin buffer and
incubated an additional 30 minutes on ice (Adams et al., 2008; Adams et al., 2009;
Breathnach et al., 2006). Following incubation, the plate was washed in saponin buffer and
resuspended in FACS Flow. Both plates were transferred to 5-mL round-bottom tubes for
flow cytometric analysis. Using a FACS Calibur flow cytometer (Becton Dickinson) and
Cell Quest® software (Becton Dickinson), samples were analyzed, and lymphocyte
populations were gated on cell size and granularity to determine percent IFN-γ- and percent
TNF-α-positive lymphocytes as well as mean fluorescence intensities (MFI) of
lymphocytes (Adams et al., 2008; Adams et al., 2009; Breathnach et al., 2006).
2.6. Statistical Analysis.
SigmaPlot version 10.0 and SigmaStat version 3.5 (Systat Inc., Richmond, CA)
were used for data analysis. Data not normally distributed was log-transformed first in an
effort to achieve a normal distribution; however, if normality still could not be achieved,
data was analyzed on ranks. Normally distributed data was shown using bar graphs (mean
+/- standard deviation), while data not achieving normal distribution was shown with box
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plots (median, 25th, and 75th percentile). For all analyses performed, data with p<0.05 was
considered statistically significant.
One-way analysis of variance (ANOVA) tests were performed to determine cell
viability using the Holm-Sidak method for normally distributed data, while Kruskal-Wallis
one-way ANOVA on ranks using the Tukey test was implemented for data not normally
distributed. Two-way ANOVA tests using the Holm-Sidak method was employed to
analyze inflammatory cytokine data at the various concentrations for each compound.
For comparisons of the optimal concentrations of each polyphenol and NSAID to
each other, one-way ANOVAs with Holm-Sidak method were used to measure the viability
and the various inflammatory cytokine parameters for normally distributed data, while
Kruskal-Wallis one-way ANOVAs on ranks using Dunn’s method were implemented for
data not normally distributed.
Results
3.1. Cell viability for polyphenols at varying concentrations
Polyphenolic compounds curcuminoids, hydroxypterostilbene, pterostilbene,
quercetin, and resveratrol exhibit anti-inflammatory properties but can also be cytotoxic at
high concentrations, thus Vicell counting was performed to determine cell viability after
the incubation with compounds and stimulation with PMA and ionomycin. Results show
that with increased compound concentrations, cell viability decreased for all compounds,
as expected (Fig. 5.1). Each of the concentrations of compound for all six horses were
compared to the positive control DMSO PMA in an effort to determine the highest noncytotoxic concentration for each compound, designated the optimal concentration. Results
show that the highest non-cytotoxic concentrations for each of the compounds were the
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following: (A) curcuminoids 20 µΜ, (B) hydroxypterostilbene 40 µΜ, (C) pterostilbene
80 µΜ, (D) quercetin 160 µΜ, and (E) resveratrol 160 µΜ (Fig. 5.1).
3.2. Intracellular staining and flow cytometry for polyphenols at varying concentrations
The effect of polyphenols (at concentrations ranging from 320 to 10 µM in twofold dilutions) on percentages of lymphocytes producing IFN-γ and TNF-α when
stimulated with PMA and ionomycin were examined. No significant interactions were
observed between % IFN-γ and % TNF-α for any of the polyphenols except curcuminoids,
thus the asterisks in Figure 5.2B-E are grouped over the bars for % IFN-γ and % TNF-α
for each concentration, as there was an overall comparison of inflammatory cytokines for
each of the compound concentrations to the positive control (DMSO/PMA). Results
indicate that a concentration-dependent effect was present, with higher concentrations of
compounds yielding decreased pro-inflammatory cytokine production, (some of which is
due to the decreased cell viability with increasing concentration exhibited in Figure 5.1).
Significant differences (p<0.05) relative to the positive control for inflammatory cytokines
IFN-γ and TNF-α were found for (A) curcuminoids at all concentrations but 10 µΜ; (B)
hydroxypterostilbene at all concentrations but 10 µΜ; (C) pterostilbene at 320, 160, 80
µΜ; (D) quercetin at 160 µΜ; and (E) resveratrol at 320, 160 µΜ (Fig. 5.2). Data for
curcuminoids (Fig. 5.2A) and hydroxypterostilbene (Fig. 5.2B) were log-transformed to
achieve equal variance and normal distribution, respectively; however, for comparison to
the other compounds, these data are represented graphically without log-transformation.
3.3. Cell viability and intracellular staining for NSAIDs
Since NSAIDs are often used to treat inflammation, the polyphenol compounds
were also compared with the NSAIDs flunixin meglumine and phenylbutazone commonly
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used in the horse. In the same manner as previously described, cell viabilities were
determined and intracellular staining and flow cytometry for IFN-γ and TNF-α production
by lymphocytes was quantified. Parameters for NSAIDs were only measured at
concentrations ranging from 20 to 160 µΜ in two-fold dilutions, since the optimal
concentrations for the various polyphenols had fallen within this range. Results are shown
for n=5 horses, as one horse was excluded as an outlier. Results for flunixin meglumine
showed a significant difference (p<0.05) in cell viability at 80 and 160 µΜ compared to
the positive control (Fig. 5.3A), while phenylbutazone did not exhibit a difference in cell
viability at any of the concentrations tested (Fig. 5.3C). For lymphocyte production of IFNγ and TNF-α, a significant difference (p<0.05) was exhibited for flunixin meglumine at 40,
80, and 160 µΜ compared to the positive control (Fig. 5.3B), while phenylbutazone did
not have any significant differences for the concentrations tested (Fig. 5.3D). Again, no
significant interactions were observed between % IFN-γ and % TNF-α for either of the
NSAIDs, thus the asterisks in Figure 5.3B are grouped over the bars for % IFN-γ and %
TNF-α for each concentration, as there was an overall comparison of inflammatory
cytokines for each of the compound concentrations to the positive control (DMSO/PMA).
3.4. Intracellular staining for optimal concentrations
Optimal concentrations, as determined by the highest concentrations of each
compound at which cell viability did not significantly differ (p>0.05) from the positive
control, were compared among the various compounds to highlight the effects of the
compounds relative to each other. Optimal concentrations for each of the compounds and
NSAIDs were: phenylbutazone – 160 µΜ, flunixin meglumine – 40 µΜ, curcuminoids –
20 µΜ, hydroxypterostilbene – 40 µΜ, pterostilbene – 80 µΜ, quercetin – 160 µΜ, and
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resveratrol – 160 µΜ. All compounds except phenylbutazone significantly reduced
(p<0.05) IFN-γ compared to the positive control, both by decreasing the percent of
lymphocytes producing IFN-γ (Fig. 5.4A) and the amount of IFN-γ produced on average
per cell [mean fluorescence intensity (MFI)] (Fig. 5.4B). The percent of lymphocytes
producing TNF-α was reduced (p<0.05) for hydroxypterostilbene (40 µΜ), pterostilbene
(80 µΜ), quercetin (160 µΜ), and resveratrol (160 µΜ) (Fig. 5.4C). TNF-α MFI was
significantly decreased (p<0.05) for all compounds including both NSAIDs when
compared to the positive control (Fig. 5.4D).
For comparisons among the compounds for percent of lymphocytes producing IFNγ (%IFN- γ), DMSO/PMA (the positive control) and phenylbutazone exhibited similar
levels (p>0.05) (Fig. 5.4A). Phenylbutazone and flunixin meglumine did not differ
statistically (p>0.05), although flunixin did decrease % IFN- γ significantly compared to
the positive control (p<0.05) (Fig. 5.4A). Flunixin meglumine, curcuminoids, and
quercetin performed similarly in reduction of % IFN- γ (Fig. 5.4A). Curcuminoids also
performed statistically similarly to hydroxypterostilbene, pterostilbene, and resveratrol
(p>0.05), which exhibited the greatest reductions in % IFN- γ (Fig. 5.4A).
Among the compounds for IFN-γ MFI, the positive control DMSO/PMA and
phenylbutazone produced similar amounts of IFN- γ on average per cell (p>0.05) (Fig.
5.4B). Phenylbutazone also performed statistically similarly to flunixin meglumine,
curcuminoids, hydroxypterostilbene, and quercetin (p>0.05) (Fig. 5.4B). The latter four
compounds additionally exhibited similar reductions in IFN- γ MFI to pterostilbene and
resveratrol, decreasing IFN- γ MFI most significantly (Fig. 5.4B).
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For comparisons among the compounds for percent of lymphocytes producing
TNF-α (% TNF-α), the positive control (DMSO/PMA), phenylbutazone, flunixin
meglumine, and curcuminoids performed statistically similarly (p>0.05) (Fig. 5.4C).
However, phenylbutazone, flunixin meglumine, curcuminoids, hydroxypterostilbene,
pterostilbene, quercetin, and resveratrol also did not differ significantly (p>0.05) from each
other for % TNF-α (Fig. 5.4C).
Among the compounds for TNF-α MFI, all polyphenols and NSAIDs decreased
TNF-α MFI compared to DMSO/PMA (p<0.05) (Fig 5.4D). Phenylbutazone, flunixin
meglumine, and quercetin similarly decreased TNF-α MFI, while flunixin meglumine also
exhibited similar levels of TNF-α MFI to curcuminoids and hydroxypterostilbene (Fig.
5.4D). Curcuminoids, hydroxypterostilbene, pterostilbene, and resveratrol produced
similar amounts of TNF-α on average per cell, decreasing TNF-α MFI most significantly
compared to the positive control (p<0.05) (Fig. 5.4D).
3.5. Viability of optimal concentrations
Optimal concentrations were determined as the highest concentration within each
compound titration at which the percent viability of PBMC did not differ (p>0.05) from
the control, DMSO/PMA. However, since optimal concentrations were then selectively
analyzed in comparison to the positive control for IFN-γ and TNF-α, PBMC viability for
the chosen optimal concentrations was also evaluated to determine whether they still did
not significantly differ from the positive control when collectively analyzed.
Hydroxypterostilbene (40 µM) and pterostilbene (80 µM) significantly differed (p<0.05)
in viability when compared to the positive control (Fig. 5.5). No other differences in
viability between treatments were found.
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Discussion
Polyphenols and other nutraceuticals have recently gained popularity in many
species including horses for garnering health benefits without many of the side effects
associated with pharmaceuticals (Belcaro et al., 2010a; Horohov, 2012; Paller et al., 2015;
Reed et al., 2006). Polyphenols including curcuminoids, hydroxypterostilbene,
pterostilbene, quercetin, and resveratrol have demonstrated anti-inflammatory activity in
previous studies. Although various in vitro and in vivo studies have been performed in other
species demonstrating the anti-inflammatory effects of polyphenols (Luna et al., 2007;
Qureshi et al., 2012; Vazquez Prieto et al., 2015; Venkatesan and Chandrakasan, 1995),
little research has been performed in the horse despite the common occurrence of
inflammatory-associated conditions (Goodrich and Nixon, 2006). Furthermore, senior
horses, like elderly humans, exhibit inflamm-aging, and thus provide an excellent model
of elevated inflammation in which to test the efficacy of anti-inflammatory compounds.
In the present study, the effects of polyphenols on inflammatory cytokine
production in vitro have been examined. Results indicate that lymphocyte production of
pro-inflammatory cytokines decreased when treated with polyphenols compared to the
positive control of cells stimulated with PMA/ionomycin and treated with DMSO. All
optimal concentrations of compounds (highest concentration at which viability was not
diminished within each compound titration curve when compared to the positive control)
decreased lymphocyte production of inflammatory cytokines (p<0.05). This demonstrates
that curcuminoids, hydroxypterostilbene, pterostilbene, quercetin, and resveratrol can
significantly reduce inflammation in vitro without becoming toxic to PBMCs.
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Other studies have found similar results, with resveratrol, pterostilbene, and
quercetin decreasing TNF-α, IL-1β, IL-6, and iNOS expression as well as TNF-α secretion
upon stimulation of macrophage cell line RAW264.7 with LPS (Qureshi et al., 2012). The
same study found that resveratrol, pterostilbene, and quercetin decreased NF-κΒ activation
of the human kidney line HEK293 cells, as well (Qureshi et al., 2012). This study exhibited
similar findings to our results in that resveratrol and pterostilbene decreased inflammation
similarly to or better than quercetin (Qureshi et al., 2012). Notably, in the present study,
pterostilbene (80 µM) at half the concentration of resveratrol and quercetin (160 µM) still
decreased inflammation significantly. Curcumin and resveratrol have been shown to
decrease inflammation through modulating the NF-κΒ pathway at various stages
(Buhrmann et al., 2011; Duarte et al., 2010; Samsami-Kor et al., 2015). Additionally,
curcumin has exhibited more potent anti-inflammatory activity than resveratrol in equine
neutrophils (Derochette et al., 2013), which supports our results in which curcuminoids (20
µM) reduced inflammation similarly to resveratrol (160 µM). Although little research has
been performed thus far on hydroxypterostilbene, it has been found to decrease production
of pro-inflammatory COX-2, as well as downregulating upstream PI3K/Akt and MAPK,
more effectively than its counterpart pterostilbene (Cheng et al., 2014). This aligned with
our results, showing potent anti-inflammatory action of hydroxypterostilbene (40 µM),
even at half the concentration of pterostilbene (80 µM). The variation observed in optimal
compound concentrations suggests that compounds exhibiting anti-inflammatory effects at
lower concentrations have greater bioactivity in vitro, such as curcuminoids and
hydroxypterostilbene, while those exhibiting anti-inflammatory effects at higher
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concentrations like quercetin and resveratrol may be less bioactive in reducing
inflammation.
Furthermore, these polyphenols reduced inflammation at least as effectively as
common NSAIDs flunixin meglumine and phenylbutazone. In fact, phenylbutazone did
not significantly reduce lymphocyte production of IFN-γ or TNF-α at any of the
concentrations tested, whereas all polyphenols did. Phenylbutazone did, however, reduce
TNF-α MFI when compared to the positive control. Phenylbutazone may not have
performed as well as expected due to the fact that phenylbutazone paste was suspended in
DMSO before addition to PBMCs (since paste is the formulation most commonly used in
the horse). Using an intravenous formulation of phenylbutazone, however, may have
yielded significant decreases in inflammation on more parameters, since the effects of
PBMC incubation with paste may exhibit masked effects when compared to a more pure
form.
Additionally, the mechanisms of action for these polyphenols suppress
inflammation by inhibiting the gene expression of inflammatory cytokines and other
proteins, while NSAIDs primarily work to treat the symptoms of inflammation, inhibiting
the pro-inflammatory COX enzyme (Beretta et al., 2005). Polyphenols particularly
modulate inflammation via NF-κΒ and MAPK signaling (Buhrmann et al., 2011; Busch et
al., 2012; Comalada et al., 2005; Kumar and Sharma, 2010; Vazquez Prieto et al., 2015).
Curcumin, quercetin, and resveratrol have also been shown to activate Sirtuin 1 (SIRT1),
which is involved in deacetylation of histones and transcription factors. (Busch et al., 2012;
Chung et al., 2010). One study compared phenylbutazone with curcumin and resveratrol,
finding that both of the polyphenols decreased NF-kB activation at far smaller
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concentrations than phenylbutazone, thereby suggesting the greater potency of polyphenols
to modulate the source of inflammation when compared to phenylbutazone (Takada et al.,
2004). Another study compared flunixin meglumine and phenylbutazone, determining that
while both NSAIDs inhibited COX-1, flunixin meglumine also decreased NF-kB
activation to some degree, indicating that flunixin meglumine may function to decrease
inflammation by a COX-independent pathway as well (Bryant et al., 2003). This may also
explain why our study found flunixin meglumine to be the more effective NSAID.
Nevertheless negative side effects, particularly gastrointestinal problems, have been
associated with long-term NSAID use (Luna et al., 2007; Reed et al., 2006; Yoon and Baek,
2005). Thus, polyphenol nutraceuticals may provide a more proactive approach to treating
inflammation, without the various side effects, though more research is needed in this area,
particularly in vivo.
Although these results suggest significant anti-inflammatory activity of the
polyphenols examined in vitro, bioavailability and bioactivity of these compounds in the
horse in vivo must also be taken into account. Little research has been performed thus far
in this area, as the use of these naturally-occurring polyphenols as anti-inflammatory
treatments in the horse is novel. From research in other species, oral bioavailability of the
polyphenol compounds are as follows: curcuminoids – 0.47% (Gutierres et al., 2015),
pterostilbene – 35-80% (Azzolini et al., 2014; Kapetanovic et al., 2011), quercetin – 17%
(Ader et al., 2000), resveratrol – 20% (Kapetanovic et al., 2011), and hydroxypterostilbene
– yet to be determined. For NSAIDs phenylbutazone and flunixin meglumine, the common
routes of administration (and the formulations used in this study) were oral paste and i.v.
injectable, respectively; the bioavailability of oral phenylbutazone in the horse is
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approximately 70% (Tobin et al., 1986), while flunixin meglumine was assumed to be
100%, as it is administered intravenously. Upon taking the bioavailability of these
compounds into account, the extrapolated amount of the compounds needing to be
administered orally based on our results would be the following: curcuminoids – 269.36,
pterostilbene – 4.40-10.07, quercetin – 48.89, resveratrol – 31.37, flunixin meglumine (i.v.)
– 3.38, and phenylbutazone – 12.11 mg/kg body weight.

These extrapolated

concentrations, while shown to be anti-inflammatory in vitro, need to be examined in vivo
to determine their anti-inflammatory effects in the horse.
Furthermore, some of these amounts may appear formidable, however it is
necessary to note that studies have been conducted in vivo with much smaller amounts
yielding biologically beneficial effects. Curcumin administered orally (90 mg/kg) to
diabetic rats has improved glucose tolerance and insulin sensitivity (Gutierres et al., 2015),
and curcumin given at a low dose of 8 mg/kg in pigs has been shown to decrease transport
stress in various biological markers (Wei et al., 2010). Pterostilbene (40 mg/kg)
administered orally has yielded powerful antioxidant results in diabetic rats (Amarnath
Satheesh and Pari, 2006), and our results suggest that the dose could potentially be lowered
and still exhibit beneficial effects. Quercetin (20 mg/kg) given to rats has been shown to
decrease adipose inflammation (Vazquez Prieto et al., 2015). Resveratrol administered at
a dose of 20 mg/kg to diabetic rats decreased blood lipid and sugar levels (Balata et al.,
2016). Although hydroxypterostilbene has been researched little thus far, a study in mice
found that hydroxypterostilbene (10 mg/kg, i.p.) exhibited anti-tumor properties including
decreased levels of COX-2 (Cheng et al., 2014). Flunixin meglumine has exhibited
analgesic properties at a dose of only 1.1 mg/kg i.v. (Foreman and Ruemmler, 2011).
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Phenylbutazone at the clinical dose of 4.4 mg/kg has been shown to decrease lameness in
the horse when administered i.v. (Foreman and Ruemmler, 2011) as well as decreasing
clinical signs of osteoarthritis when administered orally (Doucet et al., 2008). Given the
body of literature in other species regarding the biological effects of polyphenols in vivo,
it is anticipated that doses lower than those anticipated by the results of this in vitro study
may be effective biologically, and perhaps reduce chronic inflammation. Some of these
effects may be mediated by polyphenol metabolites not taken into account when studies
have examined bioavailability of these compounds previously. Furthermore, many of these
polyphenols are known to have poor bioavailability, thus research is currently underway to
formulate more bioavailable versions or targeting systems of many of these polyphenolic
compounds (Balata et al., 2016; Belcaro et al., 2010a; Nahar et al., 2015; Swaminathan et
al., 2016).
In vivo research in the horse examining the anti-inflammatory effects of these
polyphenols is clearly warranted. Future research should focus on determining the
pharmacokinetics of these compounds in the horse. This will make possible the
establishment of a recommended dose, which can then be examined for anti-inflammatory
and antioxidant effects in vivo. Safety of the polyphenols should also be monitored in the
horse when establishing dose, although long-term tolerability has already been reportedly
high in other species for some polyphenols, such as curcumin and resveratrol (Belcaro et
al., 2010a; Tome-Carneiro et al., 2012).
In conclusion, our research suggests the polyphenol compounds curcuminoids,
resveratrol, quercetin, pterostilbene, and hydroxypterostilbene show potential as antiinflammatory therapies for chronic inflammation in the horse. More research is warranted
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in vivo in the horse to determine the extent to which these compounds may be effective as
alternatives to the use of NSAIDs when treating long-term inflammatory conditions.
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CHAPTER 6
EFFECTIVENESS OF CURCUMIN IN MODULATING CHRONIC
INFLAMMATION OF THE SENIOR HORSE
Abstract
Senior horses (≥20 years) exhibit inflamm-aging, or systemic, chronic, low-grade
inflammation associated with aging, similarly to senior humans. In humans, inflamm-aging
is associated with morbidity and mortality, with many diseases having underlying
inflammatory components. In addition to inflamm-aging, many horses exhibit chronic
inflammation, but treating these conditions with non-steroidal anti-inflammatory drugs
(NSAIDs) long-term can have negative side effects. As a potential alternative to NSAIDs,
an in vivo study was conducted to examine the effects of dietary polyphenolic compound
curcumin, found in the root of Curcuma longa, on inflammation in horse, particularly the
senior horse experiencing inflamm-aging,. Senior horses (n=30) were supplemented with
either curcumin (5.6 mg/kg BW of Longvida® containing 20% optimized curcumin) or
placebo (4.48 mg/kg BW of background components of Longvida® without curcumin) for
90 days. The effects of curcumin were examined to determine peripheral blood
mononuclear cell (PBMC)-mediated cytokine production & gene expression using flow
cytometry & RT-PCR, respectively. Prostaglandin E2 (PGE2) production was determined
using ELISA to examine the effects of curcumin on the inflammatory cyclooxygenase-2
pathway. Endocrine function was examined as well, specifically basal insulin, basal
adrenocorticotropin hormone (ACTH), and ACTH in response to thyrotropin releasing
hormone stimulation (a test to determine whether horses exhibit pituitary pars intermedia
dysfunction, a common endocrinopathy in older horses). Horses were clinically examined
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pre and post study to examine body temperature, heart rate, respiratory rate, and overall
health status. Horse body weight and body condition score was also monitored monthly
throughout the study. Complete blood count & blood chemistry panels were run pre and
post study to monitor health status, as well. Blood was also collected post study to
determine curcumin and curcumin metabolite concentrations. No significant differences
(p>0.05) were seen between treatment groups over the course of the study for any of the
parameters measured. Curcumin and metabolites were only detected in quantifiable
amounts for 2/15 horses supplemented with curcumin. In this study, horses supplemented
with curcumin did not appear to experience anti-inflammatory effects in relation to the
placebo group. These negative results may be due to any number of factors including low
dosage and/or low bioavailability of curcumin. Further research is needed to determine if
a higher dosage of curcumin can demonstrate bioactive effects in the horse, particularly in
regards to decreasing chronic inflammation.
Introduction
Senior horses comprise a significant percentage of the equine population, with
estimates ranging from 11.4 to 15% in the United States (≥20 years old) (Malinowski et
al., 1997; USDA, 2016) and estimates as large as 29% in the United Kingdom (≥15 years)
(Ireland et al., 2011a). However, like humans, senior horses tend to exhibit both inflammaging (chronic, low-grade systemic inflammation systemically with aging) and
immunosenescence (deterioration of the immune system with aging, particularly adaptive
immunity), leading to a generally immune-compromised state (Adams et al., 2008;
Franceschi et al., 2000; Franceschi et al., 2007). Inflamm-aging has been characterized in
both gene expression and proteins in whole blood as well as specifically being mediated
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by lymphocytes and monocytes (Adams et al., 2008; Adams et al., 2009). Thus far, clearly
established clinical conditions of the horse associated with inflamm-aging have not been
discovered. Based on human studies, however, inflamm-aging is associated with morbidity
and mortality (Adriaensen et al., 2015; Franceschi and Campisi, 2014).
Common treatments for localized and chronic inflammation of the horse include
non-steroidal anti-inflammatory drugs (NSAIDs), such as phenylbutazone and flunixin
meglumine. These NSAIDs are a non-specific cyclooxygenase (COX) inhibitors, meaning
that they inhibit both COX-1 and COX-2; this has specifically been shown in horses
(Brideau et al., 2001; Duz et al., 2015). Inhibition of COX-1 is frequently associated with
secondary problems, most notably gastric ulcers (Carvajal et al., 2004; Monreal et al.,
2004), since COX-1 protects the glandular lining of the stomach. Phenylbutazone
specifically has created oxidative stress in the stomach mucosa of horses (Martinez
Aranzales et al., 2014). Other adverse effects of NSAIDs may include liver and kidney
damage, hypoalbuminemia, and neutropenia (Bessone, 2010; Ingrasciotta et al., 2015;
McConnico et al., 2008; Reed et al., 2006).NSAIDs targeting COX-2 have been developed;
however, even these NSAIDs are not intended for ongoing use. For example, firocoxib
(Equioxx®, Merial), one of the most commonly used COX-specific NSAIDs in horses, has
a maximum of 14 days of intended use and must be prescribed by a veterinarian, according
to the manufacturer.
Despite the benefits of using NSAIDs for treating acute inflammatory conditions,
long-term use of NSAIDs in treating chronic conditions can have detrimental effects. Thus,
the potential of anti-inflammatory phytonutrient curcumin to mitigate chronic
inflammation of the senior horse was examined.
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Curcumin has been used in traditional Asian medicine for treating various
inflammatory diseases (Jeenger et al., 2014; Jurenka, 2009); however, recently curcumin
has gained a scientific reputation as a potent anti-inflammatory, antioxidant, and antitumorigenic compound (Franck et al., 2008; Schaaf et al., 2009; Venkatesan and
Chandrakasan, 1995). This polyphenol comprises 0.3% to 5.4% of raw turmeric, the
cooking spice which is derived from the rhizomes of Curcuma longa (Jeenger et al., 2015;
Khan and Abourashed, Hoboken, New Jersey). In food-grade curcumin, the compound
curcumin itself constitutes 77%, while other curcuminoids demethoxycurcumin (DMC)
and bisdemethoxycurcumin (BDMC) only make up 17% and 6%, respectively (Kumar et
al., 2010).
The number of mechanisms by which curcumin is thought to act is vast (Di Pierro
et al., 2013). However, many anti-inflammatory activities of curcumin are thought to be
orchestrated through down-regulating the nuclear factor–kappa B (NF-κB) and COX
pathways. For the NF-κB pathway: Curcumin has been found to decrease IκB kinase (IKK)
activity, thereby decreasing IκBα phosphorylation, which in turn decreases NF-κB
activation, thus decreasing its gene products, such as IκBα, interleukin(IL)-6, IL-12, tumor
necrosis factor-alpha (TNF-α), and COX-2 (Bharti et al., 2003; Nanji et al., 2003). The
COX pathway may actually be a specific cascade of the NF-κB pathway, as it has been
suggested that NF-κB upregulates COX-2 expression (Kim et al., 2006). COX-2 catalyzes
the conversion of arachidonic acid into pro-inflammatory prostaglandin E2 (PGE2)
(Chizzolini and Brembilla, 2009; Park and Conteas, 2010). COX-1 is constitutively
expressed, while COX-2 is inducible. Curcumin has been shown to selectively inhibit
COX-2, without interfering with COX-1 (Goel et al., 2001).
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The effectiveness of curcumin as an anti-inflammatory agent has been extensively
exemplified in vitro. Since curcumin is a lipophilic molecule, it can easily penetrate the
phospholipid bilayer of cells and may even be capable of mediating some of its actions
through influencing lipid rafts of cell membranes (Derochette et al., 2013; Lin et al., 2014).
Some studies have shown that curcumin decreases inflammation and oxidative stress when
taken orally (Venkatesan and Chandrakasan, 1995). However, curcumin is rapidly
metabolized into curcumin sulfate or curcumin glucuronide after oral administration
(Kumar et al., 2010). Thus, it is often unable to reach immune cells while still in its
bioactive state.
Since this issue of bioavailability is a known hurdle, various studies have been
conducted in an endeavor to generate more bioactive analogs of curcumin. Stabilizing
curcumin by solid lipid curcumin particle (SLCP) ™ technology has met with success in
the formulation of Longvida® optimized curcumin, which employs a lipophilic matrix to
deliver curcumin into the bloodstream and target tissues (Gota et al., 2010). Longvida®
has been shown to improve mood and working memory (Cox et al., 2015) and to decrease
pathophysiology associated with Alzheimer’s disease (decreasing amyloid plaques,
insoluble β-amyloid peptide, and soluble Tau dimers)(Begum et al., 2008; Ma et al., 2013),
while decreasing inflammation [interleukin(IL)-1β, inducible nitric oxide synthase (iNOS),
and upstream c-Jun N-terminal kinase (JNK)](Begum et al., 2008). In vitro studies have
also shown that Longvida® decreases inflammation by decreasing nitric oxide,
prostaglandin E2, and IL-6 via downregulating NF-κB activity(Nahar et al., 2014).
Recently, oral supplementation with Longvida® has also demonstrated anti-inflammatory
effects, decreasing the degree of systemic inflammation (IL-8, TNF-α) associated with
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exercise-induced muscle damage (McFarlin et al., 2016). This body of evidence taken
together asserts that solid lipid particle curcumin has great potential as an antiinflammatory treatment.
In relation to the potential of curcumin use in the horse specifically, a few studies
have been performed examining curcumin as an anti-inflammatory and antioxidant. Most
studies have primarily focused on its in vitro effects, which have yielded favorable results,
suggesting the use of curcumin for its anti-inflammatory and anti-oxidant properties
(Derochette et al., 2013; Franck et al., 2006; Franck et al., 2008). Our lab has found
curcumin to have potent anti-inflammatory effects in vitro specifically in the senior horse
(Siard et al., 2016). One small scale study in vivo has been performed in the horse with
some beneficial effects, showing decreased IL-1β and IL-1RN expression and apparent,
though not statistically significant, reductions in COX-2, TNF-α, and IL-6 expression in
osteoarthritic mares (Farinacci et al., 2009a). However, numerous limitations were present,
including a short study duration of only fifteen days, small sample size (n=7), and no
placebo group to serve as a control (Farinacci et al., 2009a). Moreover, no studies have
been conducted in the senior horse.
Thus, we performed the first large-scale study to determine the effectiveness of
curcumin in the senior horse in vivo, comparing its anti-inflammatory action to a control
placebo group. It was hypothesized that treatment with curcumin would decrease
inflammation at both the gene expression and protein levels in senior horses. Specifically,
this study was performed to determine the effects of curcumin supplementation on PBMCmediated inflammatory cytokine expression and production, COX-1 and COX-2 gene
expression, and PGE2 production in senior horses. It is anticipated that decreasing
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inflamm-aging may be beneficial to healthspan and lifespan. Furthermore, the horse
exhibiting inflamm-aging was used as a model to determine whether polyphenols could
decrease chronic inflammation.
Methods and Materials
2.1. Animals and Supplementation.
Thirty senior horses (mean age = 26.2±3.2 years) of mixed breeds and both sexes
were fed a mixture of 50% alfalfa pellets and 50% oats twice per day (at 0830 and 1400
hours) at maintenance. The horses were housed on pasture (with mixed grass hay
supplemented during early spring) at the University of Kentucky, Department of
Veterinary Science, Woodford Farm. The study was conducted from late March to late
June 2016.
Treatment groups were determined by blocking horses based on body condition
score (BCS), age, inflammatory status as determined by percent of lymphocytes producing
IFN-γ (see Sections 2.3 & 2.4), and pituitary function using a thyrotropin releasing
hormone (TRH) test (see 2.7). BCS was determined using the Henneke scale of 1-9
(Henneke et al., 1983).
The horses daily received 5.6 mg/kg BW of Longvida® supplement (containing
20% of optimized curcumin; Verdure Sciences, Noblesville, IN) (n=15) (Farinacci et al.,
2009a) or 4.48 mg/kg BW of background placebo (n=15) for 90 days. This dose of
Longvida® curcumin was chosen by extrapolating from human Longvida® studies with
biological effects (Cox et al., 2015; McFarlin et al., 2016). Longvida® and placebo were
provided by Verdure Sciences. Longvida® and placebo supplements were suspended in
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soybean oil (approximately 25 mL) and administered orally by syringe once per day with
the morning meal.
A veterinarian who was blinded in regard to treatment groups examined the horses
prior to and post study to determine heart rate, respiratory rate, rectal temperature, and
overall health status. All procedures were in accordance with the University of Kentucky’s
Institute of Animal Care and Usage Committee.
2.2. Sample Collection.
Heparinized blood was collected from horses for PBMC isolation prior to receiving
any treatments (Day 0) and on Days 15, 30, 60, and 90 after receiving treatment. Serum
also collected pre and post study prior to feeding and treatment to determine basal insulin
concentrations. TRH stimulation testing was performed pre and post study, with EDTA
plasma collected pre and 10 minutes post TRH injection to determine ACTH
concentrations. Blood was also collected into citrate tubes post study to determine
curcumin and curcumin metabolite concentrations. All blood sampling (except serum for
basal insulin, as noted) occurred approximately 1.5 hours after being fed (similar to a
previous study in the horse (Farinacci et al., 2009a)). Horse body weights and BCS (by
three assessors) were also recorded pre study and monthly thereafter for the duration of the
study.
2.3. PBMC Isolation & Culture.
Peripheral blood mononuclear cells (PBMC) were isolated and purified from
heparinized blood using a Ficoll-Paque Plus™ (Amersham Biosciences, Piscataway, NJ)
density gradient and Phosphate Buffered Saline (PBS), respectively (Adams et al., 2008;
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Breathnach et al., 2006; Siard et al., 2016). PBMC were counted using a VICELLTM
Counter-XR (Beckman Coulter, Miami, FL) in order to plate cells at a concentration of
4x106 cells/mL media [RPMI 1640 (Gibco, Grand Island, NY) supplemented with 2.5%
fetal equine serum (FES; Sigma-Aldrich, St. Louis, MO), 100 μM 2-mercaptoethanol
(Gibco), and 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/mL streptomycin (HyClone
Pen/Strep/Glutamine solution; Thermo Scientific)] (Adams et al., 2008; Breathnach et al.,
2006; Siard et al., 2016). PBMC were plated in duplicate, with all wells receiving Brefeldin
A (10 μg/mL; Sigma), while only one well per sample was stimulated with phorbol 12myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 μM; Sigma) (Adams et
al., 2008; Breathnach et al., 2006; Siard et al., 2016). The cells were then incubated at 37oC,
5% CO2 for 4 hours prior to intracellular staining and RNA isolation (Adams et al., 2008;
Breathnach et al., 2006; Siard et al., 2016).
2.4. Intracellular Staining and Flow Cytometry.
Following incubation, PBMC were transferred into duplicate 96-well V-bottom
plates, fixed with 2% paraformaldehyde (Sigma), and stored overnight at 4oC. Cells were
then perforated and washed with saponin buffer [PBS supplemented with 1% fetal bovine
serum (FBS), 0.1% saponin, and 0.1% sodium azide (Sigma)). One plate was intracellularly
stained with IFN-γ FITC mouse anti-bovine antibody (AbD Serotec, Raleigh, NC; 0.1 mg).
The second plate was stained with TNF-α anti-equine monoclonal antibody (HL801; kindly
provided by Dr. Rob MacKay, University of Florida) and secondary antibody FITCconjugated goat F(ab’)2 anti-mouse IgG (H + L) (Invitrogen; 2 mg/mL). Following
intracellular staining, cells from both plates were resuspended in FACS Flow and analyzed
using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA) and Cell Quest®
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software (Becton Dickinson). Data were gated on lymphocyte populations to determine
lymphocyte mediated production of IFN-γ and TNF-α.
2.5. RNA Isolation, Reverse Transcription, and Real- Time Polymerase Chain Reaction.
Following the 4 hour incubation, PBMC were resuspended in Trizol® solution and
stored at -80oC until RNA was isolated using phenol-chloroform extraction. Following
quantification with an Epoch microplate spectrophotometer (BioTek, Winooski, VT),
RNA (1 μg) was reverse transcribed in a thermocyler (Bio-Rad, Hercules, CA) after the
addition of master mix (16 μL avian myeloblastosis virus (AMV) buffer 5X, 16 μL MgCl2,
4 μL dNTP, 1 μL RNasin, 1 μL Oligo dT primer, and 0.5 μL AMV Reverse Transciptase
per sample; Promega, Madison, WI) to the samples. The thermocycler incubated samples
at 42oC for 15 minutes and 95oC for 5 minutes. The cDNA samples then underwent RTPCR after the epMotion 5070 (Eppendorf) loaded plates with the samples and 11 equine
specific intron-spanning primers and probes (Applied Biosystems), specifically IFN-γ,
TNF-α, Il-1β, IL-6, IL-12, IL-4, IL-10, Tbet, GATA3, COX-1, and COX-2 in addition to
Beta-glucuronidase (BGUS), the housekeeping gene. During RT-PCR, samples were
incubated at 95oC for 10 minutes, followed by 40 cycles of 95oC for 15s and 60oC for 60s
using the 7900HT Fast RT-PCR System (Applied Biosystems, Foster City, CA). The
ΔΔCT method (Livak and Schmittgen 2001) will be used to determine relative changes in
cytokine gene expression, with data being reported as relative quantity (RQ) values
according to the equation RQ = 2 -ΔΔCT. The average ΔCT of all media alone samples on
Day 0 will serve as the calibrator for each cytokine.
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2.6. PGE2 ELISA.
Serum was collected on Days 0, 30, and 90 to determine prostaglandin E2 content.
Serum was assayed using a Parameter PGE2 competitive ELISA (R&D Systems,
Minneapolis, MN), according to manufacturer protocol (Shah et al., 2010). This PGE2
ELISA has previously been used to analyze equine samples due to the consistency of
arachidonic acid derivative PGE2 among species (de Grauw et al., 2006; de Grauw et al.,
2009; Lucia et al., 2013).
Briefly, calibrator diluent was added to non-specific binding wells (200 µL) and
zero standard wells (150 µL). Standards, controls, and samples (ranging from undiluted
serum to 1:18, with most samples being diluted 1:3) were added to wells in duplicate (150
µL), followed by primary antibody solution (50 µL; in all wells but non-specific binding).
Plates were shaken for 1 hour (500 ± 50 rpm; 0.12” orbit), followed by the addition of
PGE2 conjugate (50 µL) and an additional 2 hour incubation on a shaker. Plates were then
washed four times, and substrate solution (200 µL) was added, with plates being incubated
at room temperature in the dark for 30 minutes. Stop solution (100 µL) was then added,
and absorbance of each sample was measured at 450 nm with a 540 nm correction using a
colorimetric ELISA microplate reader (Bio-Rad Laboratories, Inc., Philadelphia, PA). The
mean intra-assay coefficient of variation was 7.2%.
2.7. Endocrine Function.
The horses were sampled to determine pituitary function, particularly examining
the presence of pituitary pars intermedia dysfunction (PPID), an endocrinopathy caused by
hyperplasia of the pituitary pars intermedia. Thyrotropin releasing hormone (TRH)
stimulation was performed to determine pituitary function by exogenous injection of TRH
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(1 mg/mL saline per horse; i.v.; Sigma-Aldrich) and analyzing EDTA plasma ACTH
concentrations prior to and at 10 minutes post injection with TRH. EDTA plasma was
shipped to the Cornell Animal Health Diagnostic Center (AHDC) for ACTH analysis using
chemiluminescence immunoassay (Immulite® 1000; Siemens, Berlin, Germany)(Place et
al., 2010). TRH stimulation was performed prior to and post study, approximately 1.5 hours
post feeding and supplementation with curcumin or placebo.
The horses were also sampled prior to feeding to determine serum basal insulin pre
and post study, with serum samples being analyzed by Cornell AHDC using a
commercially available radioimmunoassay for human insulin (RIA) (EMD Millipore Corp,
Billerica, MA) that has previously been validated for use in equine samples.
2.8. Plasma Amyloid-β ELISA.
EDTA plasma was collected on Days 0 and 90 and frozen at -80oC until analyzed
for amyloid-β (Aβ) peptide concentrations by Dr. Michael Paul Murphy, Sanders-Brown
Center on Aging, University of Kentucky. A two-site sandwich ELISA was used to
measure Aβx-42 in plasma samples, as previously described (Beckett et al., 2010). (Aβ is
well-conserved among higher mammals (Johnstone et al., 1991), thus a human ELISA was
used.) Briefly, an Immulon 4HBX plate (Dynex-Thermo Fisher) coated with 0.5 µg/well
of 2.1.3 monoclonal (end specific for Aβ42) capture antibody (Das et al., 2001; Kukar et
al., 2005), was incubated at 4° C overnight prior to blocking with Synblock (AbD Serotec,
Raleigh, NC), according to manufacturer protocol. Biotinylated 4G8 (against Aβ17-24;
BioLegend, San Diego, CA) antibody was used for antigen detection, followed by
incubation with 0.1 μg / ml of neutravidin-HRP (Pierce Biotechnologies; Rockford, IL).
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TMB reagent (Kirkegaard & Perry Laboratories, Gaithersburg, MD) and 6% o-phosphoric
acid solution were used to develop and stop the reaction, sequentially. A multi-well plate
reader (Bio Tek, Winooski, VT) read the plates at 450 nm. The Aβ peptide standard curve
samples and plasma samples were run at least in duplicate.
2.9. CBC with Differential & Chemistry Panel.
Lithium heparinized whole blood was collected at Day 0 and Day 90 and sent to
Rood and Riddle Equine Hospital Laboratory to analyze complete blood count with
differential and blood chemistry panel pre and post study to examine overall health of the
horses. This specifically measured hemoglobin (Hgb), packed cell volume (PCV), red
blood cells (RBC), white blood cells (WBC), total protein, mature neutrophils (seg),
immature neutrophils (bands), lymphocytes (lymph), monocytes (mono), eosinophils (eos),
sodium,

potassium,

chloride,

transaminase/aspartate aminotransferase

albumin,

serum

(SGOT/AST),

glutamic

alkaline

oxaloacetic

phosphatase,

total

bilirubin (T. Bili), direct bilirubin (D. bili), creatine kinase (CK), creatinine, glucose,
gamma-glutamyl transferase (GGT), blood urea nitrogen (BUN), phosphorus, calcium,
sorbitol dehydrogenase (SDH), and lactate dehydrogenase (LDH).
2.10. Curcumin and Curcumin Metabolite Measurement.
Plasma, buffy coat, and red blood cells were collected post study approximately 1.5
hours post treatment and feeding using tubes containing acid citrate dextrose additives
(Solution A - 22.0 g/L trisodium citrate, 8.0 g/L citric acid, 24.5 g/L dextrose; BD
Vacutainer®, Franklin Lakes, NJ) and immediately placed on ice. Within 1 hour of
collection, blood was centrifuged at 1500g for 15 minutes at 4oC. Aliquots of plasma, buffy
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coat, and red blood cell samples were then stored at -80oC until shipped to Dr. Navindra
Seeram at the University of Rhode Island for analysis via ultra fast liquid chromatography
tandem mass spectrometry (UFLC-MS/MS). UFLC-MS/MS was used to determine
content of curcumin, demethoxycurcumin (DMC), bisdemethoxycurcumin (BDMC),
curcumin sulfate, curcumin glucuronide, and ferulic acid for n=3 placebo and all n=15
curcumin-receiving horses.
Briefly, UFLC-MS/MS was performed with a modified protocol from analyzing
polyphenol quantities in maple-dervied foods (Liu et al., 2016b) to determine curcumin
and curcumin metabolite concentrations in buffy coat and red blood cells. Prominence
UFLC (SHIMADZU, Marlborough, MA) with a Waters XBridge® BEH C18 column (100
mm × 2.1 mm i.d., 2.5 μm. Milford, MA, USA) were used to perform chromatography,
while mass spectrometry was performed using a QTRAP 4500 system (Applied
Biosystems, Framingham, MA) with electrospray ionization. Samples were analyzed in
Multiple Reaction Monitoring mode using Analyst 1.6.3 software and MultiQuant 3.0.1
software. The calibration curve ranged from 1-1000 ng/mL for curcumin and ferulic acid
and from 0.1-1000 ng/mL for DMC, BDMC, curcumin sulfate, and curcumin glucuronide
and were analyzed using linear regression following x-2 transformation. Urolithin B was
used as the internal standard. Acetonitrile was used to denature proteins. Curcumin
compounds were extracted from 200 µL of sample (buffy coat or RBC). The mobile phase
consisted of 43% acetonitrile with 0.1% formic acid. The flow rate was 0.2 mL/min with a
total run time of 9 min and an injection volume of 10 µL. The assay validation was
performed in a forthcoming publication in regards to specificity, accuracy and precision
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(intra-day and inter-day), recovery and matrix effect, and stability using n=6 horses and all
three blood fractions (plasma, buffy coat, and red blood cells).
2.11. Statistical Analysis.
To determine sample size for treatment groups, SigmaPlot version 10.0 and
SigmaStat version 3.5 were employed using mean difference and standard deviation from
a data set in a previous study in which a group receiving supplement was compared to a
group receiving placebo. The power level was set at 0.8 and alpha was 0.05.
In this study SigmaPlot version 12.0 was used to perform two-way analysis of
variance (ANOVA) tests with repeated measures to compare treatment groups over time
for Aβ, ACTH, insulin, PGE2, flow cytometry, and normally-distributed CBC/Chem data.
SAS 9.4 software was used to analyze body weight, PCR gene expression, and
some CBC/Chem parameters (Bands, Monocytes, Potassium, SGOT/AST, CK,
Phosphorous, SDH, and GGT), as these data were not normally distributed when analyzed
in SigmaPlot. However, SAS is more robust and met skewness and kurtosis requirements
for each of the variables, (although some required log-transformation). Data was analyzed
using a mixed procedure examining time point, treatment group, and time point x treatment
group as fixed effects, with time point as the repeated variable. PGE2 analysis only
included data from n=12 curcumin and n=11 placebo-receiving horses, as some were
excluded due to high coefficients of variation.
For all analyses, data with p<0.05 were considered statistically significant and
p<0.10 were considered trends.
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Results
3.1. Inflammatory cytokine and PGE2 production.
Inflammatory cytokine production by lymphocytes was determined using flow
cytometry. Specifically, percent of lymphocytes producing IFN-γ (Fig. 6.1A) and TNF-α
(Fig. 6.1C) as well as mean fluorescence intensity of lymphocytes for each of each of these
cytokines (Fig. 6.1B&D) was examined. Similar patterns in results for these cytokine
measures were observed. Particularly, no differences between curcumin and placebotreated horses were found (p>0.05). Significant differences over time were observed
(p<0.001) with an overall increase in inflammatory cytokine production over the course of
the study. However, no significant interactions between treatment group and time were
found (p>0.05).
Curcumin and placebo-treated groups were also compared in relation to serum
concentrations of pro-inflammatory prostaglandin E2 (Fig. 6.2) using a commercial ELISA
kit (R&D Systems), and no differences were seen between treatment groups (p=0.509) or
over time (p=0.673), as well as no interaction of treatment group with time (p=0.877).
3.2. Real-Time Polymerase Chain Reaction Gene Expression.
Gene expression mediated by PBMC was determined by RT-PCR (Table 6.1).
Many variables showed significant differences over time, including: Log(COX-1),
GATA3, Log(IFN-γ), IL-1β, IL-4, Log(IL-6), Log(IL-10), Log(IL-12), Log(Tbet), and
Log(TNF-α) (p<0.05) (Table 6.1). Overall, these variables tended to decrease at Day 30
and increase again thereafter. Log(COX-2) and Log(IL-6) also showed differences between
treatment groups (p<0.05) (Fig. 6.3A&B); however, there were no treatment over time
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interactions (p>0.05) (Table 6.1). Additionally, the differences in treatment groups for
Log(COX-2) and Log(IL-6) appeared to largely be present at the beginning of the study,
prior to supplementation (Fig. 6.3A&B).
3.3. Endocrine Parameters.
Endocrine measures were also examined pre and post study to determine any
differences in regards to supplementation with curcumin. Plasma ACTH was analyzed both
basally and 10 minutes post TRH injection (T-10). No differences between curcumin and
placebo treatment groups were found (p>0.05) (Fig. 6.4). Basal ACTH exhibited a trend
over time (p=0.066) (Fig. 6.4A), and T-10 ACTH exhibited significant differences over
time (p=0.020), with both these measures of ACTH increasing during the study (Fig. 6.4B);
however, no interactions between treatment groups over time were observed (p>0.05).
No significant differences in treatment groups were seen for serum insulin
concentrations (p>0.05) (Fig. 6.5). Over time, insulin concentrations significantly
increased (p<0.001), but no interactions between treatment group and time were observed
(p>0.05) (Fig. 6.5).
3.4. Plasma Aβ concentrations.
Plasma Aβ was also examined as it has been associated with Alzheimer’s disease
in humans, and some similarities have been suggested between PPID of the horse and
Alzheimer’s disease in humans, as both are neurodegenerative diseases occurring primarily
in the elderly. Additionally, Longvida® curcumin has helped decrease some
pathophysiology associated with Alzheimer’s disease in a mouse model (Ma et al., 2013).
No differences in plasma Aβ concentrations were seen in treatment groups overall (p>0.05)
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(Fig. 6.6). Significant differences were observed over time (p<0.001), with Aβ
concentrations increasing after 90 days of treatment with curcumin or placebo (Fig. 6.6).
A trend was observed for differences between treatment groups over time (p=0.094) (Fig.
6.6). Plasma Aβ concentrations at baseline of placebo-receiving horses were marginally
less than those for curcumin-treatment horses, while post-study Aβ values were slightly
greater for placebo-treated horses than for curcumin-treated horses, suggesting that
curcumin may decrease the extent to which Aβ values would otherwise increase. However,
this interaction was only a trend with no significant differences between treatment group
either pre or post study and no significant overall treatment effect (p>0.05).
3.5. Complete Blood Count and Blood Chemistry Analysis.
For CBC and blood chemistry panel parameters, no differences were found in
regard to treatment group alone (p>0.05). Many variables among CBC and blood chemistry
significantly differed with time (p<0.05) including: PCV, RBC, WBC, Log(GGT),
phosphorus, total protein, calcium, sodium, albumin, alkaline phosphatase, direct bilirubin,
total bilirubin, glucose, BUN, and LDH. Among these, albumin was the only variable
exhibiting a significant interaction with treatment group over time (p<0.05), with placeboreceiving horses having increased albumin levels over time, while curcumin-receiving
horses did not (Fig. 6.7A). Direct bilirubin also exhibited a trend (p=0.066) for interactions
between treatment groups and time point (Fig. 6.7B). The placebo group appeared to have
elevated direct bilirubin prior to the study, but these concentrations dropped during the
study, while the curcumin-supplemented horses remained at similar levels (Fig. 6.7B).

144

3.6. Body Weight, BCS, TPR, and Overall Health Parameters.
No significant changes were seen in body weight either over time or in regard to
treatment group (p>0.05) (Fig. 6.8A). Average body condition scores differed only in
regard to time (p<0.05) and not treatment group (p>0.05), with BCS increasing over time
(Fig. 6.8B). No adverse side effects were observed for horses supplemented with curcumin
in comparison to the placebo group regarding body temperature, respiratory rate, heart rate,
nasal discharge, or overall health (data not shown).
3.7. Curcumin & Curcumin Metabolite Measurement.
Buffy coat and red blood cell (RBC) fractions of the blood were each analyzed to
determine curcumin, DMC, BDMC, curcumin sulfate, curcumin glucuronide, and ferulic
acid for n=3 placebo and all n=15 curcumin-receiving horses. The placebo horses were
analyzed post study to ensure that they were negative for curcumin and metabolites, and as
expected, the horses were negative for all 6 compounds in both blood fractions.
Additionally, the curcumin-receiving horses were all analyzed post study, and only 2
horses had quantifiable levels of curcumin, DMC, and BDMC (detected in the RBC
fraction from one horse, and both RBC and buffy coat from the other horse).
Discussion
Curcumin has exhibited anti-inflammatory effects in a multitude of studies;
however, very few studies have been performed in the horse examining curcumin as an
anti-inflammatory. Previously our lab has characterized the in vitro anti-inflammatory
effects of curcumin on PBMC from senior horses (≥20 years) experiencing chronic,
systemic inflammation known as inflamm-aging (Siard et al., 2016). However, only two
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small-scale studies (without control groups) have previously explored the antiinflammatory effects of dietary curcumin on the horse in vivo (Farinacci et al., 2009a;
Schell, 2009). Thus, the present study was undertaken to determine the effectiveness of
dietary curcumin as an anti-inflammatory supplement in the senior horse.
No appreciable differences were seen in various inflammatory markers for senior
horses administered curcumin compared to placebo in this study. Specifically, horses
supplemented with curcumin were expected to have decreased lymphocyte-mediated proinflammatory cytokine expression and production compared to horses receiving placebo;
however no differences between groups were found. Anti-inflammatory cytokines were
also expected to potentially increase, as curcumin has many anti-inflammatory
mechanisms of action, but again, no differences in treatment groups were present. Gene
expression of inflammatory cytokine IL-6 exhibited an overall treatment group effect
(p<0.05); however, there was no interaction between treatment group and time (p>0.05).
Additionally, the difference in IL-6 between treatment groups appeared to be present prior
to the beginning of the supplementation study; thus, the overall difference in treatment
group is likely not due to curcumin supplementation, especially since the difference of
means at the culmination of the study on Day 90 is numerically less than at Day 0 (0.06
and 0.11, respectively).
Curcumin is known to selectively inhibit pro-inflammatory COX-2 (Goel et al.,
2001), thus the curcumin-supplemented group was expected to decrease COX-2 gene
expression compared to the placebo group without inhibiting COX-1 expression. As
expected, there were no differences in COX-1 between treatment groups. In regard to
COX-2, overall differences in treatment group were present; however, no interaction effect
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of treatment group over time was present for COX-2. Since there was no treatment by time
point interaction, and since COX-2 in placebo-treated horses was numerically greater
(0.16) prior to the beginning of the study, the overall significant difference in COX-2
between treatment groups is likely not due to treatment with curcumin. Additionally, horses
in the two groups appear to have equalized COX-2 expression by Day 90, (with the placebo
group even having a slightly lower mean of 2.34 as compared to the curcumin group mean
of 2.40). Thus, COX-2 in the curcumin-supplemented group did not decrease in relation to
the placebo group, which was unexpected.
Furthermore, pro-inflammatory PGE2 in serum also did not exhibit significant
differences in regards to treatment group or over time. Again, this was not originally
anticipated, as the horses supplemented with curcumin were expected to have decreased
levels of inflammatory PGE2 when compared to the placebo group. However, since no
appreciable differences were seen in the interaction of treatment group over time for COX2, which is upstream of PGE2 in the pro-inflammatory signaling cascade as a catalyst for
the conversion of arachidonic acid to PGE2 (Chizzolini and Brembilla, 2009; Park and
Conteas, 2010), the lack of a treatment effect for the horses supplemented with curcumin
is not surprising.
In previous studies, many of the anti-inflammatory effects of curcumin were
demonstrated in vitro, where the known hurdle of bioavailability is not an issue. However,
due to the enhanced bioavailability of Longvida® curcumin (Gota et al., 2010), the
effectiveness of curcumin as an in vivo anti-inflammatory was not expected to be impeded
due to bioavailability. Furthermore, several in vivo studies with curcumin-containing
products with enhanced bioavailability including Longvida® have demonstrated biological
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effects (Cox et al., 2015; Ma et al., 2013). However, few dietary Longvida® curcumin
studies have focused on anti-inflammatory effects of curcumin. One study found lower
exercise-induced inflammation (TNF-α and IL-8) in subjects receiving Longvida®
curcumin in comparison to placebo (McFarlin et al., 2016). However, another study found
serum inflammatory cytokine levels were below detection limits for most parameters
analyzed, and C-reactive protein levels did not differ in Longvida® curcumin-receiving
subjects (Cox et al., 2015).
In addition to determining effects of curcumin supplementation on inflammation,
this study examined the effects of curcumin supplementation on endocrine function,
specifically regarding basal insulin, basal ACTH, and ACTH response to TRH stimulation.
Horses experience various endocrine disorders, with two of the most common being equine
metabolic syndrome (EMS) and pituitary pars intermedia dysfunction (PPID). EMS is
similar to metabolic syndrome in humans in that it involves regional adiposity, insulin
resistance (which may include hyperinsulinemia), and sometimes heightened levels of
triglycerides (Frank et al., 2010b). EMS is particularly problematic due to its associated
predisposition to laminitis, an inflammatory condition of the hoof that can be fatal to horses
(Frank et al., 2010b; Johnson et al., 2012). Curcumin has been shown to decrease
triglycerides and insulin resistance (Ghorbani et al., 2014; Panahi et al., 2014; Song et al.,
2015b), thus it was thought that curcumin may be able to mitigate EMS in the horse. PPID
is common in the senior horse, caused by dopaminergic neurodegeneration of the pars
intermedia lobe of the pituitary and frequently resulting in hypertrichosis, polydipsia,
polyuria, hyperhidrosis, laminitis, muscle atrophy, and abnormal fat distribution
(McFarlane, 2011). Endocrinologically, this frequently results in increased levels of basal
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circulating adrenocorticotropin hormone (ACTH), while also resulting in decreased ability
of horses to return to resting levels of ACTH after intravenous injection of thyrotropin
releasing hormone (TRH) (Beech et al., 2007). Curcumin has been shown to exhibit antitumor activity, including in the pituitary (Bangaru et al., 2010; Curic et al., 2013; Schaaf
et al., 2009; Shan et al., 2012), specifically decreasing hormone levels associated with
pituitary tumors (Miller et al., 2008a; Schaaf et al., 2009). Thus, it was expected that senior
horses supplemented with curcumin would have improved endocrine function, both
increasing insulin sensitivity and decreasing excessive production of ACTH in response to
TRH stimulation. However, no differences in endocrine function were found for horses
supplemented with curcumin in comparison to placebo.
In addition to examining endocrine dysfunctions in the horse, plasma Aβ was also
examined. Amyloid-β production and deposition is one of the two primary pathologies
associated with Alzheimer’s disease (Murphy and LeVine, 2010). Since Longvida®
curcumin has previously decreased various Alzheimer’s-associated pathologies (Begum et
al., 2008; Ma et al., 2013), and since both the PPID horse and Alzheimer’s patients
experience age-related neurodegeneration, examining plasma Aβ was of interest. However,
no differences in plasma Aβ were seen between treatment groups in this study. A trend was
present in the interaction between time point and treatment group for Aβ, but no significant
differences between treatment groups occurred. There was, however, a significant overall
time effect. Variations in Aβ with season have not yet been investigated, although in this
study, it appears that season or some other condition experienced by this group of senior
horses in general seems to influence levels of circulating Aβ. Although horses would most
likely be more apt to exhibit seasonal changes than humans due to their outdoor housing,
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it may bear investigation to determine how easily plasma Aβ may be influenced by
conditions aside from the presence of Alzheimer’s disease.
Many inflammatory and metabolic parameters increased over the course of the
study for horses regardless of treatment group, which may be due to seasonal effects.
Insulin has previously been shown to vary seasonally in equids, particularly for those
grazing on pasture, as insulin was correlated with grass carbohydrate composition (BorerWeir et al., 2013; Frank et al., 2010a). Likewise, ACTH has known seasonal rhythms in
the horse as well (Cordero et al., 2012; Frank et al., 2010a). Inflammatory markers have
exhibited seasonal rhythms in other species (Bilbo et al., 2002; Bowden et al., 2007;
McFarlane et al., 2012), though work in the horse regarding seasonal inflammatory
parameters is limited thus far with only a few studies showing seasonal fluctuations in
unhealthy animals (Beadle et al., 2002; Hamza et al., 2007). Although this study was
conducted in spring/summer (from late March to late June) to control for changes in season
as much as possible, the results of this study show an overall increase in many
inflammatory and metabolic parameters, suggesting that similarly to other species,
seasonal variation of inflammatory markers may occur in the healthy horse as well.
Additionally, these increases in inflammatory markers over the course of the study may at
least in part be due to the increased body condition scores, which indicate an increase in
body fat. And, increased body fat in the horse specifically has been associated with
increased PBMC-mediated inflammation (Adams et al., 2009).
Regarding the lack of curcumin and curcumin metabolites in blood fractions for all
but two of the horses supplemented with curcumin, several factors may contribute. First,
the curcumin may truly not have reached the bloodstream, in which case it would be

150

expected that curcumin glucuronide and curcumin sulfonate would be present (Kumar et
al., 2010); however, this does not appear to be the case. Second, the timing of the blood
collection may not have been ideal to detect curcumin and metabolites for most of the
horses despite the fact that quantifiable levels were present for two of the horses. Studies
have shown that some curcumin formulations are rapidly absorbed into tissues and spend
very little time in the bloodstream, yielding bioactive effects even at undetectable plasma
levels (Pawar et al., 2012). This is entirely possible however does not explain the lack of
biological effects seen in this study. Third, the dose and/or formulation of curcumin was
not effective to reach peak levels in the blood for most horses and thereby have biological
effects in the horse.
The dose of curcumin certainly may be the primary reason that supplementation
did not demonstrate biological anti-inflammatory effects. In many previous studies where
oral curcumin has been used to correct pathophysiology, the dose was often larger in
relation to mg/kg body weight (Kumar et al., 2011; Maithilikarpagaselvi et al., 2016;
Venkatesan and Chandrakasan, 1995). Additionally, previous work in our lab showing in
vitro anti-inflammatory effects of curcumin on PBMC from senior horses indicated a much
higher concentration of curcumin (without enhanced bioavailability) needed to achieve
biological effects (Siard et al., 2016). However, the dose used in the current study was
originally thought to be sufficient due to: 1) the enhanced bioavailability of Longvida®
curcumin (Gota et al., 2010), 2) the length of study (90 days, whereas several other studies
were shorter term), and 3) the quantity of curcumin already being given to horses, even at
a lower mg/kg body weight dose.
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Another potential reason anti-inflammatory effects of curcumin were not seen in
this study may be that naturally-occurring basal inflamm-aging alone was not the best
model in which to evaluate the effectiveness of curcumin as an anti-inflammatory
supplement. Perhaps inflamm-aging of the senior horse was not as readily responsive to
anti-inflammatory supplements as experimental models. Most studies showing curcumin
to have effects on inflammation, metabolism, oxidative stress, senescence, etc. involve
induced models in experimental animals (Kinney et al., 2015; Kumar et al., 2011; Ma et
al., 2013; Maithilikarpagaselvi et al., 2016; Nanji et al., 2003; Venkatesan and
Chandrakasan, 1995). For example, D-galactose-induced senescence in mice was
attenuated by oral treatment with curcumin, improving memory dysfunction and oxidative
damage (Kumar et al., 2011). However, perhaps because senescence was induced,
curcumin may not have the same degree of effectiveness in naturally-occurring senescence.
Additionally, some models of inflammation that have shown the effectiveness of curcumin
and particularly Longvida® involve some type of physiological challenge, such as
exercise, in which the degree of inflammation and muscle damage was modulated in
comparison to a group receiving placebo (McFarlin et al., 2016).
While the expected anti-inflammatory effects of curcumin were not exhibited in
this study at the dose given, negative side effects were not present either, which were
monitored by clinical examination and CBC with differential and chemistry panels prior to
and post treatment. This aligns with a multitude of previous work, showing that curcumin
in generally regarded as safe even at much higher dosages than those given in the present
study (Cox et al., 2015; Nanji et al., 2003).
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In conclusion, senior horses (≥20 years) supplemented with curcumin compared to
placebo did not differ in regard to modulation of inflamm-aging. Treatment with curcumin
also did not appear to affect endocrine function. Numerous parameters showed overall time
effects, but these did not appear to be due to treatment. Since a low dose of curcumin
supplementation was unable to mitigate age-associated inflammation, potentially
increasing the dose of curcumin may be able to mediate anti-inflammatory effects.
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Table 6.1. RT-PCR gene expression of horses receiving curcumin and placebo for 90 days.
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COX= Cyclooxygenase; IFN=interferon; IL=interleukin; TNF=tumor necrosis factor; GATA3 and Tbet are transcription factors

Gene expression data are reported as mean RQ values ± SEM for horses in each treatment group (n=15 curcumin and n=15 placebo)
at each time point (Days 0, 15, 30, 60, 90). Mixed procedure p-values are also reported for each PCR variable in regards to overall
treatment effect, time point effect, and interaction between treatment and time point. Data considered statistically significant (p<0.05)
are denoted with an asterisk (*).
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Table 6.1. (cont.) RT-PCR gene expression of horses receiving curcumin and placebo for 90 days.
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Figure 6.1. Peripheral blood mononuclear cell (PBMC)-mediated production of interferon(IFN)γ and tumor necrosis factor(TNF)-α from n=15 curcumin and n=15 placebo-receiving senior horses
(≥20 years). PBMC were stimulated with PMA and analyzed via intracellular staining and flow
cytometry to determine both percent of lymphocytes producing (A) IFN-γ and (C) TNF-α and
mean fluorescence intensity (MFI) for each of these cytokines (B&D). P-values for significant
(p<0.05) data are denoted on the figures. Ptime refers to the p-value for overall effects of time.
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Figure 6.2. Serum Prostaglandin E2 (PGE2) production in curcumin and placebo supplemented
senior horses. Serum from n=12 curcumin and n=11 placebo-receiving horses was analyzed via
ELISA to determine pro-inflammatory PGE2 production.

157

Ptrt <0.001 (A)

Ptrt <0.001 (B)
Ptime =0.001

Curcumin
Placebo

2.5
2.0

Log(IL-6 RQ)

Log(COX-2 RQ)

3

Curcumin
Placebo

2

1

1.5
1.0
0.5

0

0.0
y 0 ay 1 5 ay 3 0 ay 6 0 ay 9 0
Da
D
D
D
D

y
Da

Time point

0

y
Da

15

y
Da

30

y
Da

60

y
Da

90

Time point
Figure 6.3. PBMC-mediated inflammatory gene expression of curcumin (n=15) and placebo
(n=15)-receving senior horses (≥20 years). Gene expression is reported as the log of relative
quantity (RQ) values of (A) cyclooygenase(COX)-2 and (B) interleukin(IL)-6. P-values for
significant (p<0.05) data are denoted on the figures. Ptrt refers to the p-value for treatment group
overall, while Ptime refers to the p-value for overall time effects.
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Figure 6.4. Thyrotropin releasing hormone (TRH) stimulation testing in senior horses (≥20 years)
pre and post 90-day supplementation with curcumin (n=15) or placebo (n=15). Plasma was
analyzed both for (A) basal ACTH and for (B) ACTH 10 minutes post intravenous injection with
TRH, as measures of pituitary function. Data with p<0.05 were considered significant, while those
with p<0.10 were considered trends. P-values for significant and trending data are denoted on the
figures. Ptime refers to the p-value for overall effects of time (pre vs. post study).
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Figure 6.5. Basal insulin pre vs. post study for curcumin (n=15) vs. placebo-receiving (n=15)
horses. P-values for significant (p<0.05) data are denoted on the figure. Ptime refers to the p-value
for overall effects of time (pre vs. post study).
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Figure 6.6. Plasma Aβ pre vs. post study for curcumin (n=15) and placebo-receiving (n=15) senior
horses (≥ 20 yrs). Data with p<0.05 were considered significant, while those with p<0.10 were
considered trends. P-values for significant and trending data are denoted on the figures. Ptime refers
to the p-value for overall effects of time (pre vs. post study), while Ptrt x time refers to the p-value
for the interaction between treatment group and time point. Bars with different lettering
significantly differ (p<0.05) from each other.
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Figure 6.7. Blood chemistry panel parameters with significant (p<0.05) or trending
(p<0.10) interactions between time point and treatment group (n=15 curcumin and n=15
placebo-treated horses). P-values for significant and trending data are denoted on the
figures. Ptime refers to the p-value for overall time effects (pre vs. post study), while Ptrt x
time refers to the p-value for the interaction between treatment group and time point. Bars
with different lettering significantly differ (p<0.05) from each other.
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Figure 6.8. Body weights and body condition scores (BCS) for senior (≥20 yrs) horses
supplemented with curcumin (n=15) or placebo (n=15) for 90 days. Body weights (A) and
BCS (B) were monitored approximately every 30 days throughout the duration of the study.
P-values for significant (p<0.05) data are denoted on the figures. Ptime refers to the p-value
for overall time effects.
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CHAPTER 7
CONCLUSIONS AND FUTURE RESEARCH DIRECTIONS
Inflamm-aging, the chronic low-grade inflammation occurring systemically with
advanced age, is well-characterized in the horse. Lymphocyte-mediated inflamm-aging has
specifically been demonstrated in the horse, which is not surprising given that a vast body
of literature in various species has shown lymphocytes to be particularly affected by
advanced aging. In humans, inflamm-aging is associated with various age-related diseases
as well as morbidity and mortality; however, clearly defined clinical effects in the horse
have not yet been determined. Given that senior horses (≥20 years) comprise a substantial
component of the equine population, with many continuing to be used for competition and
recreation into their senior years, understanding the implications of inflamm-aging for the
horse is key to promote healthspan as well as lifespan.
In this research, senior horses exhibiting inflamm-aging and adult horses exhibited
seasonal variations in inflammatory cytokine production. Specifically, lymphocytemediated production of pro-inflammatory cytokines was decreased in winter and elevated
during spring and summer. Similarly, PBMC-mediated gene expression of TNF-α was
elevated in summer, while IL-6 expression was actually decreased in summer. Some of
these seasonal inflammatory changes appeared to be associated with body weight and may
be associated with temperature and/or photoperiod, but likely a complex array of neuroendocrine-immune signaling pathways is involved. Future research should focus on
understanding what these seasonal changes may mean for the health of the senior horse,
already immune-compromised due to immunosenescence and inflamm-aging.
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Inflamm-aging was also examined in relation to the common age-associated
endocrinopathy, pituitary pars intermedia dysfunction (PPID), which has been associated
with immunosuppression and increased susceptibility to opportunistic infections. Senior
PPID horses and age-matched non-PPID horses do not appear to differentially experience
lymphocyte-mediated inflamm-aging. Specifically, no differences were found between
PPID and non-PPID horses regarding lymphocyte-mediated inflammatory cytokine
production or PBMC-mediated inflammatory cytokine gene expression. Likely, the aspects
of PPID impacting immunity are primarily mediated by neutrophils, as some previous
research has demonstrated, and not lymphocytes. Future research should examine what
stimulates the initiation of the dopaminergic neurodegeneration associated with PPID,
particularly examining any relationships with inflammation and/or the immune system.
Relationships of inflamm-aging with overall health of the senior horse were also
examined,

particularly

in

regard

to

nutrition

status,

body

composition,

hematology/biochemistry, and PPID status. Inflamm-aging appears to be associated with
increased levels of serum docosadienoic acid (C22:2n6c), docosapentaenoic acid
(C22:5n3c), and folate, which may be due to a compensatory effect, given that these
nutrients are generally considered to be anti-inflammatory. No relationships between
inflamm-aging and markers of body composition were found. However, within the group
of senior horses, age itself was inversely associated with multiple markers of body
composition, indicating the incidence of decreased muscle, body condition, and weight
with advanced age. Further research should focus on elucidating implications of the
relationships found, with the goal of promoting the health and longevity of the senior horse.
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The ability of phytonutrient polyphenols to mitigate lymphocyte-mediated
inflamm-aging of the senior horse was also examined in vitro. Curcumin, resveratrol,
quercetin, pterostilbene, and hydroxypterostilbene all significantly reduced lymphocytemediated inflamm-aging of the senior horse in vitro. These anti-inflammatory results were
achieved at concentrations that were not cytotoxic. Additionally, the anti-inflammatory
capacity of polyphenols was compared to common NSAIDs, and polyphenols were found
to significantly reduce inflamm-aging similarly. In fact, curcumin decreased inflammation
at a concentration lower than the NSAIDs or any of the other polyphenols, demonstrating
its potent anti-inflammatory capacity. Thus, polyphenols were found to mitigate inflammaging of the senior horse in vitro.
As a follow-up to our in vitro polyphenol work, curcumin was evaluated in vivo as
a potential anti-inflammatory supplement for the senior horse exhibiting inflamm-aging.
Senior horses receiving enhanced-bioavailability curcumin and placebo did not
significantly differ in regard to degree of inflamm-aging after being supplemented for 90
days. Specifically, no differences were found between curcumin and placebo-receiving
horses in regards to lymphocyte-mediated inflammatory cytokine production or PBMCmediated inflammatory gene expression. This lack of anti-inflammatory response in horses
supplemented with curcumin may be due to an inadequate dose, as only two of the fifteen
horses administered curcumin showed quantifiable levels of curcumin and/or metabolites
in blood, or a poor response of the senior horse to the specific formulation. Future research
should be conducted to determine whether a higher dose or different formulations of
curcumin delivery systems may enable curcumin to function as an effective antiinflammatory agent in the senior horse. Furthermore, some previous research suggests that
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curcumin in combination with other polyphenols may act synergistically, which would be
of interest to test in the inflamm-aging horse in vivo.
As a whole, this body of research demonstrates that various factors are associated
with lymphocyte-mediated inflamm-aging of the senior horse. Furthermore, this inflammaging may potentially be modulated by anti-inflammatory polyphenols; however, further
research is necessarily to determine dosage and formulations effective as antiinflammatory supplements in the horse. Additionally, future research to better understand
the implications of inflamm-aging on overall health of the senior horse should be
undertaken in an effort to promote healthspan in addition to longevity of horse.
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